Integrative psychiatry:Conceptual foundation, implementation and effectiveness by Hoenders, Harm Jan Rogier
  
 University of Groningen
Integrative psychiatry
Hoenders, Harm Jan Rogier
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2014
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Hoenders, H. J. R. (2014). Integrative psychiatry: Conceptual foundation, implementation and
effectiveness. [Groningen]: University of Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the






Integrative Psychiatry  












































Copyright © 2013 Rogier Hoenders, Groningen 
All rights reserved. No part of this thesis may be reproduced, stored or transmitted in 




Cover: picture of Borobudur*, Indonesia, taken by Tiziana Ciasullo 
Layout and editing: Elske Bos, Nina Vollbehr, Karen van der Ploeg and Rogier 
Hoenders 
Printing: Canon business services, Noord Nederland 
Distribution: Grafisch centrum, Lentis 
 
The work in this thesis was performed at the Center for Integrative Psychiatry, Lentis. 
 








* The Borobudur stupa mandala is situated in Central Java, Indonesia. It was 
constructed out of vulcanic stone in the 8th century by three generations of the 
Sailendra Buddhist Dynasty. It is the largest surviving Buddhist mandala in the world 
that displays all three ‘yanas’ of Buddhism: Theravada, Mahayana and Varjayana. 
Due to a large vulcanic eruption in the 9th century it lay covered with volcanic ash and 
mud for over 1000 years. It was completely overgrown by jungle vegetation when, in 
the 19th century it was rediscovered and excavated by Dutch and English colonial 
explorers. Dutchman Theodor van Erp initiated in 1902 the first attempt to restore it. 
Between 1975 and 1982 it was completely rebuilt and renovated by the Indonesian 
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1 Deze afbeelding, getiteld ‘oneindigheid in duplo’, is een Japanse penseelschildering gemaakt in één 
vloeiende beweging met Sumi-E techniek door Jan Pijpker in 1987. Het is het logo van (Centrum) 
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Sarris, J., Glick, R., Hoenders, R., Duffy, J., Lake, J. & The International Network for 
Integrative Mental Health (2013). Integrative mental healthcare White Paper: 
Establishing a new paradigm through research, education, and clinical guidelines. 









Mental illness accounts for about one-third of adult disability globally (Anderson et al., 
2011) causing considerable societal and personal suffering, and high social and 
economic costs. For instance, major depressive disorder affects an estimated 121 
million people worldwide and is one of the leading causes of disability on a global 
scale (Demyttenaere et al., 2004). By 2020, depression is expected to be the second 
leading contributor to all-cause disability worldwide, second only to heart disease 
(World Health Organization (WHO), 2013). 
Despite important progress in psychiatry not all patients respond well to 
available treatments. Studies using data of both published and unpublished clinical 
trials show that the effects of the most common treatments in psychiatry have been 
overestimated. This seems to be true for psychotherapy (Cuijpers et al., 2010; 
Cuijpers et al., 2011) as well as for the pharmacologic treatments of many major 
psychiatric disorders (Herrmann et al., 2011; Kirsch et al., 2008; Turner et al., 2008; 
Thase, 2007; Velligan et al., 2009). In addition to growing concerns about efficacy, 
psychotropic drugs can cause adverse effects, including weight gain, increased risk 
of diabetes and heart disease, metabolic syndrome, neurological disorders, sudden 
cardiac death, and may potentially increase suicide risk (Henderson, 2008).  
There are also other concerns in (mental) health care. The costs are getting 
out of control, now taking 17.6 percent of gross domestic product (GDP) in the USA 
and 12.0 in the Netherlands (OECD, 2012). One possible strategy to cut costs is 
inviting patients to take a more active role in their recovery, for instance by applying 
therapeutic lifestyle changes like exercise, diet and relaxation (Egger et al., 2007; 
Walsh, 2011). The contribution of lifestyle to modern chronic disease has been 
estimated at 80% (Yusuf et al., 2004) and even 95% (Ruiz-Nunez et al., 2013). There 
is growing evidence for the efficacy of lifestyle changes for improving health, but 
besides running therapy, there is only limited experience with applying lifestyle 
changes in (mental) health care (ACPM, 2009; Walsh, 2011; Sarris et al., 2012; Berk 
et al., 2013).  
Another concern is the quality of the therapeutic relationship, which seems 
threatened by managed care, focus on protocols and evidence-based medicine, and 
a tendency to reductionism, narrowing the view to diseases or symptoms and losing 
sight of the whole person in his / her context. The original definition of evidence-
based medicine is ‘(1) the conscientious use of current best evidence in (2) making 
decisions about the care of individual patients or the delivery of health services, (3) 
taking preferences and needs of patients into account’ (Sackett et al., 1996; Sackett 
et al., 2000). However, the last part of this definition is often neglected. This, together 
with a tendency towards uniformity and efficiency (in the form of guidelines, treatment 
protocols and clinical pathways) can lead to a ‘one size fits all approach’. However, 
there is a growing awareness of the need for a more holistic perspective beyond the 
current paradigm that is primarily focused on brainscience and psychopharmacology 
(Bracken et al., 2012), taking the whole person into account (Ahn et al., 2006). This 
can be observed in new concepts like ‘personalized medicine’ (Galas & Hood, 2009; 
Ozomaro et al., 2013; Van der Greef, 2011), ‘shared decision making’ (Elwyn et al., 
2000) and ‘patient-centered care’ (Gill, 2013). The need for a more holistic / 
integrated approach to medicine has been proposed by the Dutch psychiatrist 
Querido in 1955 (Boenink & Huyse, 1997). In 1977 George Engel formulated his 
biopsychosocial model (Engel, 1977). Since then some models for a more integrated 







These models, however, are mostly theoretically acknowledged but still rarely applied 
in patient care (Astin et al., 2003). 
 
 
Integrative medicine: a new paradigm 
 
In response to the before-mentioned concerns a consortium of academic health 
centers in the USA launched a new concept of health care, called integrative 
medicine, in the late nineties of the past century. Integrative medicine is the central 
theme of this thesis with an emphasis on its application to (Dutch) psychiatry. 
Integrative medicine is the practice of medicine that (1) reaffirms the 
importance of the relationship between practitioner and patient, (2) focuses on the 
whole person, (3) is informed by evidence, and makes use of all appropriate 
therapeutic approaches, healthcare professionals and disciplines to (4) achieve 
optimal health and healing (The Consortium, 2004). Today 55 academic health 
centers (e.g. Duke university, Harvard, Stanford) in the USA are active members of 
this consortium. Many research groups, health centers, educational, advocacy and 
policy activities related to integrative medicine now exist in different countries around 
the world (e.g. Australia, UK, Germany). The part of psychiatry / mental health care, 
however, seems undervalued.  
Integrative psychiatry is integrative medicine applied to mental health care (Sarris 
et al., 2013). It is also based on those four pillars. It (1) emphasizes the importance of 
the therapeutic relationship between clinician and patient using shared decision making 
and a personalized approach. It (2) focuses on treating the ‘whole person’ from a holistic 
perspective, considering mind-body and its systems as interrelated, with biological, 
mental, emotional, cultural, ecological and spiritual / religious aspects. It (3) seeks to 
provide the ‘best of both worlds’ combining conventional medicine with non-conventional 
medicine (this includes lifestyle, complementary and alternative medicine; see next 
paragraph ‘definitions’) based on evidence for their safety and efficacy. Its focus (4) is 
on increasing qualities and strengths (salutogenesis) as well as decreasing symptoms 
(pathogenesis) and it aims for increasing general wellbeing and mental health (Lake et 
al., 2012). 
This approach to medicine might provide some solutions to the concerns 
mentioned in the previous paragraph. The first two principles can increase adherence to 
the treatment plan, improve the therapeutic relationship (Stevingson, 2001) and 
enhance treatment outcome (Koenig, 2000; Nikles et al., 2005; Gill, 2013), as treatment 
outcome has been shown to be highly dependent on the quality of the therapeutic 
alliance (Wampold, 2001; Driessen et al., 2010; Baldwin et al., 2007; De Jong, 2011), 
while a personalized approach may also improve outcome (e.g. Ozomaro et al., 2013). 
The third principle might lead to new treatment options and less adverse side 
effects of conventional medicine. Besides possible health gain for individual patients, 
there are also financial reasons for applying this principle. Recent findings from 
economic modeling research suggest that incorporating lifestyle, complementary and 
alternative medicine into conventional treatment may yield cost-effective long-term 
outcomes (Herman et al., 2005; Bornhoft et al., 2006; Pelletier et al., 2010; Kooreman & 
Baars, 2011). Although the evidence base for alternative medicines is generally weak, 
evidence for the effectiveness of lifestyle and complementary medicine is stronger and 
emerging (see next paragraphs). 
Improved outcomes may also be achieved by not only looking at symptoms 







and qualities of patients and finding ways to increase them (health promotion or 
salutogenesis; Lindstrom & Erikkson, 2005). One example is positive psychology 
(Seligman & Csikszentmihalyi, 2000; Fredrickson, 2001). Another is the induction of 
therapeutic lifestyle changes. It is cheap and can increase self-esteem, responsibility 
for one’s own health and more independence from therapists (Walsh, 2011; Sarris, 
2011; Egger et al., 2007; Berk et al., 2013). It may not only reduce psychopathology, 
but it may also enhance (mental) health and wellbeing by fostering positive emotions 
like calmness, empathy and self-actualization (Shapiro & Carlson, 2009; Walsh & 
Shapiro, 2006). In this way therapeutic lifestyle changes can contribute to the fourth 





There is no consensus on definitions of non-conventional (lifestyle, complementary or 
alternative) medicine, which increases confusion (Gaboury et al., 2012). In this thesis we 









Preventing and treating chronic diseases by inducing  
therapeutic lifestyle changes (Egger et al., 2007; ACPM, 2009).  
 
Running therapy,  




Forms of diagnostics, treatments and prevention strategies that  
are based on theories accepted in biomedicine and are 
substantiated by some scientific evidence (two or more RCTs),  
but for different reasons (cultural or practical) do not form part 








Forms of diagnostics, treatments and prevention strategies that 
make use of other than the basic concepts of biomedicine.  
There is little proof for the efficacy of these treatments and / or 








Lifestyle medicine is also called ‘therapeutic lifestyle change’ or ‘preventive medicine’. 
We include it among non-conventional medicines because a majority of integrative 
clinics have a program of lifestyle medicine (Horrigan et al., 2012) including exercise, 
diet, nutrition, relaxation, yoga and meditation, whereas most conventional clinics do not 
provide any of these. Nonetheless, there are some lifestyle changes that are part of 









Evidence, mechanism and acceptance 
 
To clarify the differences between conventional, complementary, lifestyle and 
alternative medicine, we distinguish three main aspects in table 1: mechanism (is the 
proposed working mechanism of the treatment plausible?), efficacy (how much 
evidence is there for its efficacy?) and acceptance (to what degree are these 
treatments accepted and implemented by conventional health care?).  
Conventional medicine’s efficacy and mechanisms are obviously most 
researched and accepted. Hypotheses on mechanisms follow generally accepted 
basic concepts of science / medicine. Most conventional clinicians agree that 
treatments should be evidence-based (e.g. established efficacy in at least two high 
quality randomised clinical trials; RCTs), and many of the conventional treatments 
are, although not all of them. Estimates of the percentage of conventional treatments 
that are actually evidence-based vary from 15% (Smith, 1991) to 38% (Imrie & 
Ramey, 2001) and 53% (Ellis et al., 1995). Pelletier (2003) assessed the percentage 
of decisions in various medical specialties that follow the rules of EBM; his summary 
ranges from 11% to 70%.  
 
 
Table 1: Characteristics of (non-)conventional medicine 
 
                 Non-conventional medicines  Conventional 
Medicine Lifestyle Complementary Alternative 




present present present Absent 






varying levels  varying levels absent or  
conflicting 








Research shows that lifestyle medicine (Egger et al., 2007) is insufficiently 
appreciated, taught and utilized in (mental) health care, even though there is growing 
evidence for its efficacy and there are few side effects (ACPM, 2009; Ornish, 2009). 
A lifestyle program consisting of diet / nutrition, exercise and relaxation has been 
proven effective for reversal of coronary heart disease and early stage prostate 
cancer (Ornish et al., 1990; Ornish et al., 2005). Promoting lifestyle changes is also 
an effective intervention for mental health (Walsh, 2011). Evidence shows 
improvements in overall (mental) health and reduced relapse risk (Angell, 2009; 
Walsh, 2011; Sarris, 2011; Berk et al., 2013). Mindfulness meditation seems effective 
for mood disorders (Piet & Hougaard, 2011), anxiety (Coelho et al., 2007; Kim et al., 
2009), negative symptoms of schizophrenia (Lake, 2007), addiction (Bowen et al., 
2006), sleep disorders (Ong et al., 2008), eating disorders (Kristeller & Hallet, 1999) 







rigorously, but still with promising results. For instance, yoga seems effective for 
depression, anxiety and sleep disorders (Balasubramaniam et al., 2012; Uebelacker 
et al., 2010; Cramer et al., 2013a; Cramer et al., 2013b) and possibly for 
schizophrenia as an adjunct to pharmacological treatment (Vancampfort et al., 2012). 
Most lifestyle medicine is still underutilized in conventional health care settings, 
although acceptance is growing (e.g. mindfulness).  
For some complementary medicines there is a lot of evidence for their 
mechanism and effectiveness, especially for nutrients (such as S-adenosyl 
methionine (SAMe) and folic acid for mood disorders) and herbs (e.g. St. John’s wort 
for depression and Ginkgo biloba for cognitive decline). For other complementary 
medicines the evidence is less convincing but emerging (e.g. omega-3 fatty acids in 
mood disorders and rhodiola for stress and fatigue). An extensive overview of the 
efficacy of complementary medicines in bipolar disorder and schizophrenia is 
presented in chapters 4 and 5.  
Alternative medicine generally lacks convincing evidence for its effectiveness. 
The proposed mechanism is often based on theories that are not part of basic 
concepts in biomedicine. Alternative medicine is therefore generally not accepted 
and not applied in conventional medicine.  
Therapies do not necessarily stay in one category. They can move from 
alternative to complementary and even to conventional (e.g. EMDR and mindfulness) 
when evidence emerges. They can also move into the other direction when evidence 
emerges that these treatments do not work (e.g. vitamin B3 as a stand-alone 
treatment for chronic schizophrenia). Therapies can also move to another category 
when the proposed working mechanism changes. For example acupuncture: a 
review of eight Cochrane reviews found evidence for its effectiveness in nausea and 
pain (Lee & Ernst, 2011), but there is a lot of debate about the mechanism. 
Originally, in China, it was proposed to work through stimulating acupuncture points 
and energy channels, called meridians. With increasing levels of evidence for 
effectiveness, some authors have suggested other mechanisms more familiar to 
conventional medicine (the pain of needles might stimulate endorphins or other 
neurotransmitters; Sun et al., 2008). With emerging evidence and a mechanism more 
plausible (for conventional doctors), acupuncture can now be classified as 
complementary medicine instead of alternative. This is reflected by a growing 
acceptance (many pain centers of conventional hospitals now provide acupuncture). 
 
 
The use of complementary and alternative medicine 
 
Since integrative medicine was introduced, there has been increasing interest from 
the medical and scientific community. This interest has particularly focused on three 
elements; reaffirmation of the therapeutic relationship (first principle of integrative 
psychiatry), the holistic approach (second principle) and the focus on health and 
healing (fourth principle). But there is criticism as well, especially about the use of 
complementary or alternative medicines (part of the third principle), which remains 
controversial and subject to heated debates. Therefore, this thesis is primarily 
focused on this third principle of integrative medicine.  
 There are more reasons to take a critical look at complementary and 
alternative medicines. Complementary and alternative medicines are widely used by 
patients for a range of mental health conditions. Large surveys confirm that 







Survey findings suggest that 43% of patients in developed countries with an anxiety 
disorder (Bystritsky et al., 2012) and 53% with depression (Wu et al., 2007) use 
complementary or alternative medicine. These patients perceive such treatments as 
improving their physical, emotional, cognitive, social, and spiritual functioning, 
reducing symptom severity and promoting recovery and wellness (Russinova et al., 
2009). We replicated these findings in an outpatient clinic in the north of the 
Netherlands and found a similar percentage (42%; Hoenders et al., 2006). In 
developing countries in Africa and Asia 80% of the population depends on 
complementary and alternative medicine for their primary health care (World Health 
Organization, 2006). 
Many seriously mentally ill individuals who use complementary or alternative 
medicine perceive such treatments as improving their physical, emotional, cognitive, 
social, and spiritual functioning, reducing symptom severity and promoting recovery and 
wellness (Sirois, 2008). However, few patients disclose this use to their psychiatrist, 
family physician or other conventional healthcare provider (Thomson et al., 2012) in fear 
of being ridiculed (Vandercreek, 1999). In our study, 61% of psychiatric outpatients did 
not disclose their use of complementary / alternative medicine to their conventional 
doctor / healthcare provider (Hoenders et al., 2006). This may lead to potential health 
risks such as interactions between medicines and herbs, some of which indeed have 
been reported (Ernst, 2003). Only 3% of the user population is aware of this potential 
risk (Walter & Rey, 1999). 
 
 
Lack of uniformity and practice guidelines 
 
At present, the practice of integrative medicine / psychiatry is highly varied and 
idiosyncratic. Such practice depends on the personal philosophies, values and clinical 
perspectives of its practitioners, and the goals of diverse training programs, clinics or 
hospitals where integrative treatment approaches are employed (Horrigan et al., 2012). 
Such wide variety seems undesirable as regards effectiveness, efficiency and scientific 
evaluation. There is a need for treatment guidelines for the judicious use of 
complementary and alternative medicine in conventional care and more uniformity in the 
practice of integrative psychiatry.  
There are additional reasons for the need for guidelines in integrative psychiatry. 
Despite the emerging evidence for the efficacy of complementary medicines, in the 
Netherlands many doctors do not inform their patients about complementary or 
alternative medicine and avoid prescribing it or referring to it, because of the controversy 
surrounding it or because they are not familiar with these medicines and their 
effectiveness. In a written enquiry 65% of psychiatrists and residents state that ‘they 
want to learn more about complementary / alternative medicine’ (Hoenders et al., 2006). 
Others have claimed that these medicines are quackery and that the effects are based 
on placebo and ‘ridiculous principles’ (Renckens, 2004). Such prejudice against new 
developments is undesirable; decisions should be made on empirical evidence instead 
of subjective opinions. A critical evaluation of complementary and alternative medicine is 
needed because of the before-mentioned high usage patterns in the general population 
and safety issues. Moreover, it seems urgent to facilitate the spread of reliable 
information, as the majority of patients get information on these medicines now through 
the Internet, family or social networks. The quality of this information varies greatly, 
leading to potentially harmful and dangerous situations (Crone & Wise, 2000). The 







harm their patients either by applying unsafe therapies or by delaying the start of 
conventional treatment (Klink, 2009). Thus, in the Netherlands patients and doctors are 
informed about what cannot be done concerning complementary and alternative 
medicine, while it remains unclear what could or should be done. Despite calls from the 
World Health Organization (World Health Organization, 2003) and the European 
Parliament (European Parliament, 1997), until now the Dutch government did not 
formulate policy on this subject. 
 
 
Research on integrative psychiatry 
 
Psychiatric research in the past 50 years has focused primarily on neurobiological 
mechanisms, pharmacotherapy, and (to a lesser extent) psychotherapeutic techniques. 
More recent research has also explored the effects of lifestyle medicine and 
complementary and alternative medicine (Horrigan et al., 2012; Sarris, 2011; Walsh, 
2011, Kemper et al., 2008; Ravindran et al., 2009) although this field is still in its infancy.  
For assessing the effects of treatments (conventional, lifestyle, as well as 
complementary and alternative medicine), researchers have almost exclusively relied on 
RCTs. This is because the RCT has strong features that control for bias and 
confounding (e.g. randomization), which results in high internal validity. Therefore, it has 
been considered the gold standard for determining treatment effects. As a corollary, 
however, external or ecological validity is often compromised (Howard et al., 1996; 
Natan et al., 2000). One example of this potential lack of external validity is the 
observation that patient samples of RCTs are often dissimilar from those seen by 
practicing clinicians, because inclusion criteria are stringent (Natan et al., 2000; Persons 
& Silberschatz, 1998). Other examples are the stringent use of standardized treatment 
protocols, leaving no space to adapt the treatment to the individual patient, and the 
randomization procedure that prevents the patient to choose the treatment of 
preference. Today many researchers propose a more balanced position, acknowledging 
the strong features of RCTs but at the same time stressing the need for other types of 
research (Bluhm, 2009; Slade & Priebe, 2001; Van der Lem et al., 2012; Walach et al., 
2006). 
There are some other drawbacks to conventional research methods. Most 
efficacy studies only take a single therapeutic factor into account. But different factors 
may reinforce or counteract each other. Moreover, conventional randomized studies 
generally show treatment effects at the group level, while at the individual level great 
differences in effectiveness exist. Finally, RCTs usually provide little insight into the 
causal mechanisms by which interventions exert their effect. The typical intervention 
study has measurements before and after the intervention, but not in between. As a 
result, little can be concluded about the process of change and how improvements 
are established (Hilliard, 1993). 
This leads to additional research questions, such as questions of effectiveness 
(does this treatment work in daily practice?), questions of individuality (does this 
treatment work for this particular patient?) and questions of mechanism (why does this 
treatment work?). This is especially true for complex interventions such as 
physiotherapy, surgery and complementary and alternative medicine (Walach et al., 
2006). To answer such questions, effectiveness studies are needed, for example 
modifications of the orthodox randomized trial (called ‘real-world’ randomized trials or 
pragmatic trials) or analyses of large administrative databases (Simon et al., 1995). Also 







(Molenaar & Campbell, 2009; Hilliard, 1993; VandenBroucke et al., 2006; Nikles et al., 
2005). At present there is a scarcity of this kind of research approaches in medicine and 
psychiatry (Sarris et al., 2013). Advances in research and the clinical practice of 
psychiatry will take place when formal research methodologies permit the rigorous 
evaluation of complex interventions involving multiple therapeutic modalities (which 
mirrors true clinical practice) to treat real-world clinical populations. Mental health 
research needs to span both the natural and social sciences (Van Os, 2012; De Jong, 
2013). Evidence based on RCTs has an important place, but to adopt only concepts 
from one body of knowledge is to neglect contributions that other well-established 
methodologies can make (Slade & Priebe, 2001). In other words: besides an integrated 
treatment approach, a truly integrative research focus is also needed. While 
methodologically challenging, this approach may potentially elucidate the relative 
contributions of social, psychological, biological and spiritual factors in each unique 





Part I of this thesis is about the conceptual foundation of integrative (mental) health. 
In chapter 1 we argue that the success of integrative medicine is related to the fact 
that integration is not only a current tendency in medicine, but also fitting recent 
changes in psychotherapy, science, religion and philosophy of which integration 
seems to be the most common feature. In chapter 2 we compare conventional and 
complementary / alternative medicine as regards their perspective, paradigm, 
organization, scientific method and procedures. We show that theoretically, 
conventional and alternative medicine are categorically opposed to each other in 
many respects, but in practice they seem to differ merely dimensionally, with the 
exception of the commonly used theoretical models (paradigms), which do seem to 
differ fundamentally. We argue that the difference in paradigms can be bridged using 
an integrative model that accommodates both. 
Part II is about the implementation of integrative medicine in Dutch mental health 
care. In chapter 3 we present a treatment guideline using an algorithm for the judicious 
safety-conscious application of complementary and lifestyle medicine in psychiatry, 
based on the Dutch law, scientific research, jurisprudence and rules of professional 
bodies (e.g. the Royal Dutch Association of Medical Doctors). 
Part III is about the effectiveness of complementary medicine and integrative 
psychiatry. First, we discuss the effectiveness and safety of complementary medicine 
for bipolar disorder (chapter 4) and schizophrenia (chapter 5) based on (systematic) 
reviews. Then, in a single-subject time-series analysis, we investigate the temporal 
dynamics of symptom and treatment variables in a lifestyle-oriented approach to 
anxiety disorder (chapter 6). Finally, in chapter 7 we discuss pitfalls in the 
assessment, analysis, and interpretation of routine outcome monitoring (ROM) data 
using results from our outpatient clinic for integrative mental health.  
In the last part we discuss the results of the research presented in this thesis. We 
respond to criticism on integrative medicine / psychiatry and give recommendations for 
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Complementary and alternative medicine (CAM) are increasingly used by people in 
first world countries, almost always in combination with biomedicine. The 
combination of CAM and biomedicine is now commonly referred to as ‘integrative 
medicine’ (IM). In Groningen, The Netherlands, we founded a center for integrative 
psychiatry, offering conventional and complementary mental health care. Like other 
centers for integrative (mental) health we have mostly received positive reactions 
although there have been negative and even hostile reactions as well, using phrases 
like ‘quackery’ and ‘betrayal’. We will try to illustrate that these polarising 
qualifications, in which ‘the good’ is being positioned against ‘the bad’ in an over-
simplified manner, are unnecessary and not useful. Moreover, it is unlikely that this 
polarisation will stall the growth of IM. It seems that integration is not only a current 
tendency in medicine, but also a trend fitting the contemporary spirit of the age in 
which integration seems to be the most common focus. It can be observed in religion, 
philosophy, spirituality and psychotherapy as well. This article will discuss the 
difference between differentiation and integration and will show that the focus on 
differentiation or integration varies with time, mostly rising as a reaction to each 
other. The transition from one period to the next is often met with resistance and 
criticism. If the integrative movement is to survive, it cannot do without differentiation 
and must find a middle way in which appropriate attention is being paid to keeping 












The Latin word ‘integralis’ means: ‘forming a greater entity’. Integration stands for 
‘fusing or making collaborate different parts into a larger whole’ or ‘including into a 
whole’. The opposite of integration is differentiation; the process whereby a 
homogeneous entity is being divided in parts with different qualities. Integration and 
differentiation are not mutually exclusive. They should rather be understood as 
movements of the same wave, or phenomena taking turns. When there is too much 
integration, the different parts lose their identity or experience a lack of autonomy. 
This provokes differentiation, leading them to profile themselves independently from 
each other. When there is too much differentiation, they lose sight of each other and 
each other’s interests, which increases the risk of polarisation and conflict. This will 
invariably lead to a need for more integration.  
This process can also be observed in medicine. At the end of the 19th and the 
beginning of the 20th century, the need for differentiation led to a change in medical 
laws and regulations in various countries (for instance the Flexner report in 1910 in 
the United States and the Health Care Implementation Act in 1865 in the 
Netherlands). These changes created a strict separation between recognised 
treatments on the one hand (which later became known as biomedicine or 
conventional medicine) and other forms of medicine (which later became known as 
complementary / alternative medicine). Besides the distinction between biomedicine 
and complementary / alternative medicine, a debate also arose between 
professionals who favoured a reductionistic and biomedical approach of medicine 
and colleagues who preferred a more holistic or integrative approach. In the 
seventies and eighties of the 20th century George Engel was an influential physician 
from the last group. In response to the dominant reductionistic view of medicine, he 
formulated a biopsychosocial model. His criticism (Engel, 1992) of the biomedical 
model encompassed among other things: that illness perception can be insufficiently 
explained by biochemical changes (for instance, illness perception varies with 
culturally shared cognitions about diseases, illness-related behaviours and social 
support); that clinicians pay too little attention to personal factors and communication 
skills (for instance with regards to stimulating therapy adherence); and that 
behavioural and social variables can and do influence the course of an illness.  
After more than a century of separation and conflicts between conventional, 
biomedical medicine and alternative, holistic medicine, from 2000 on there is a 
tendency towards integration under the denominator of ‘integrative medicine’ 
(Hollenberg, 2006; Hsiao et al., 2006; Jobst, 1998). Integrative medicine can be 
defined as ‘the practice of medicine that reaffirms the importance of the relationship 
between practitioner and patient, focuses on the whole person, is informed by 
evidence, and makes use of all appropriate therapeutic approaches, health care 
professionals and disciplines to achieve optimal health and healing (Consortium, 
2009). The most controversial part is the use of ‘all appropriate therapeutic 
approaches’ as it includes the use of complementary and alternative medicine (CAM) 
within conventional hospitals/ (care) delivery systems’ (Hoffer & Hoenders, 2010). 
‘Complementary’ stands for forms of diagnostics, treatments and prevention 
strategies that are based on theories accepted in biomedicine. These are usually 
substantiated by scientific argumentation, but for different reasons do not form part 
of biomedicine. Examples are massage therapy and the use of herbs and food 
supplements. Alternative treatments, such as healing and homeopathy, make use of 
other than the basic concepts of biomedicine. There is little proof for the efficacy of 






these treatments or there is considerable controversy about the scientific validation 
(Lake, 2007).  
In integrative medicine the principles of evidence-based medicine are applied 
to conventional, complementary and alternative treatments. This implies that in 
choosing an intervention, one should take into account the highest level of available 
scientific evidence about the different treatment options; the values, preferences and 
frame of reference of the patient; and the professionalism and experience of the 
therapist (Sackett et al., 2000). The number of options in integrated medicine is 
larger than in regular health care (Hoenders et al., 2011; Lake, 2007; Lake & 
Spiegel, 2006), since CAM treatments are not excluded beforehand.  
The European Parliament (1997) and the World Health Organization (2003) 
plead in favour of promoting integrative medicine (Chung et al., 2011). However, this 
call is meeting a lot of resistance. There is an enormous heterogeneity in views and 
behaviour concerning CAM (Hirschkorn & Bourgeault, 2005). The movement is even 
sometimes labelled as ‘quackery’ and the people who practice or promote CAM are 
sometimes disqualified as betrayers. This can be observed when reading the ‘rapid 
responses’ to the editorial introducing this concept in biomedicine (Rees & Weil, 
2001) and more recently in a letter by Ernst (2012). Our center for integrative 
psychiatry also met these kind of criticisms (Kuipers & Gijsman, 2006). In this essay 
we will try to illustrate that these polarising qualifications, in which ‘the good’ is being 
positioned against ‘the bad’ in an over-simplified manner, are unnecessary and not 
useful. The fact is that integration is not only a current tendency in medicine, but also 
a phenomenon that has manifested itself in the history of mankind in all types of 
fields and all sorts of ways. Not as an enemy of differentiation, but as a natural 
reaction to it. 
 
 
Manifestations of a society aimed at integration 
 
‘Integration’ and ‘differentiation’ both play a central role in the dynamics of life. Cells 
merge and split; people marry and separate; companies are fused and subdivided; 
and power blocks are formed and fall apart. The process of merging and separation 
is taking place on each level of life. It forms a returning theme in the history of 
humanity, and takes different forms in different fields, over and over again. In this 
article, we provide several typical examples from different spheres of life, restricting 
ourselves to the themes related to our own field: world view (philosophy, religion and 
spirituality), health care (treatment demand, pathways to care and psychotherapy), 
and scientific research. 
 
Philosophy 
The contemporary philosophy that evolved roughly after the Second World War is 
called 'postmodernism' (Anderson, 1999; Bertens, 1994; Scruton, 2006). The core of 
this trend is the idea that objectivity and the absolute truth do not exist. There are 
many theories, ideologies, religions, convictions and principles, but history teaches 
us that none of these has profiled itself in such a way that it can be rightfully called 
‘leading’, ‘all-encompassing’ or ‘universal’. 
Lyotard (1979) called this ‘the end of the big stories’. There is no winner and 
thus, there is no such thing as the ultimate truth or essential knowledge. As a result, 
postmodernism is not exclusively aimed at acquiring knowledge, but especially 
points at its ignorant, emotional, narrative, theory-bound and thus unstable 






foundation. If there is no absolute criterion, it is also not determined which goals we 
should pursue. According to one of the post-modern philosophies, existentialism, we 
are therefore doomed to freedom (Sartre, 1965). According to another philosophy, 
social constructivism, we are free to choose what we make of our lives, because 
everything changes all the time (Bertens, 1994). This implies fear and insecurity, but 
also provides unrestricted space to numerous equal, parallel ways to deal with 
things. Mainly because of this freedom, post-modern philosophy is offering a 
visionary framework for integrative thinking and acting.  
 
Religion and spirituality 
Even though polarisation and hostilities between the major world religions still exist, 
and even though inter-religious tension is a risk factor for war and armed conflict (De 
Jong, 2010), there is a clear tendency of integration in the field of religion, especially 
in the Western world. This is caused by the secularisation of society, which has led 
to a decrease in popularity of institutionalised forms of religion, such as the Church. 
This has created a need for new forms of spirituality and interpretation, in which 
Eastern and shamanistic traditions and philosophies have played a considerable role 
in the last decennia. The way this new form of spirituality is being created, is 
characterised by diversity and the post-modern lack of claims on one exclusive 
source of the truth. This is accompanied by the freedom to choose how an individual 
would like to fulfil his spiritual needs.  
Research shows that spirituality has a strong positive association with health 
(Koenig, 2000; Koenig, 2001). It also consistently shows that giving meaning to what 
happens to us, is more important for the wellbeing of a person than any particular 
religion. The experience of finding purpose is more important for the wellbeing of 
people than the capacity to clarify or to give a logical explanation for things (Lewis et 
al., 2005; Scannell et al., 2002; Steger & Frazier, 2005).  
 
Demands for care  
Also regarding to health needs and demands for care, a tendency towards 
integration can be observed. The expression ‘supply creates demand’ implies that 
when people are making a choice, they take into account and use all available 
options. A demand for care is therefore determined for the most part by the available 
supply. Especially because of the internet, all health-related knowledge has become 
accessible to everyone. This has had a huge impact on the kind of health care 
demands people make. Nowadays patients want to choose their own treatment 
(Coulter & Willis, 2004) and are increasingly requesting an integrated package of 
regular, complementary and alternative treatment methods (Hök et al., 2007), not 
bothered by the differences in paradigms and working styles of CAM and 
biomedicine (Hoenders et al., 2008) and the ethical and scientific challenges 
resulting from it (Oguamanam, 2006). 
Eisenberg et al. (1998) showed that CAM is being used on a large scale in the 
United States, usually in combination with regular treatments, and that there is an 
increase in use. In 1990, 34% of the Americans used CAM; by 1997 this percentage 
had increased to 42%. 
Even though patients do increasingly express demands for integrative care, 
they seem to anticipate that caregivers still restrict themselves to their own field of 
interest. About 60-75% of patients appear to conceal the use of CAM to their doctor 
because of fear of disapproval or ridicule (VandeCreek et al., 1999). This is in sharp 
contrast with the fact that patients would like to receive information about CAM from  






their conventional providers. It would be advisable if doctors would address this need 
respectfully, since an open attitude towards nonregular treatment methods is 
essential (Hök et al., 2007): It improves the therapeutic relationship (Stevinson, 
2001) and increases the impact of medical interventions (Koenig, 2000). It is also 
important to enquire about the use of CAM for medical-ethical reasons. Uncontrolled 
use of CAM can be dangerous, because of possible side-effects and interactions 
with regular medicines (Ernst, 2002). In a study in Australia less than 3% of the 
population was aware of this (Walter & Rey, 1998). In this regard it is worrisome that 
one in five patients combines herbs or foods supplements with medication 
(Eisenberg et al., 1998). An open conversation about CAM can take away 
misunderstandings and thereby prevent potentially dangerous situations.  
These considerations led to our own research (Hoenders et al., 2006), which 
showed that 42% of almost 600 psychiatric outpatients in the Northern Netherlands 
had used CAM. This figure is similar to older prevalence figures in psychiatric 
patients (53%) (Knaudt et al., 1999). We also studied the prevalence of CAM use 
among patients of General Practitioners (GPs). A survey of 900 patients showed that 
they had used CAM in 62% of cases (Borgemeester et al., 2008). Both groups of 
patients report less than half of the cases of CAM use to their conventional doctor. 
This is also in agreement with prevalence rates offered by other researchers 
(VandeCreek et al., 1999; Wetzel, 1998). Half of the psychiatric patients and 65% of 
the GP patients would like to receive more information about CAM and prefers that 
their conventional therapist would offer this. In contrast, the psychiatrists and GPs 
who were surveyed in this study heavily underestimated the use of CAM among their 
patients, and only one third of them was in favour of offering this information 
themselves. For one quarter of the psychiatrists and one third of the GPs CAM had 
an outspoken negative connotation. So, it seems that despite most patients favour 
CAM and integrative health care, a considerable number of conventional doctors are 
not willing to work in this way, creating a tension between health needs and supply.  
 
Psychotherapy 
Eventually, the struggle between different schools of thought in Western 
psychotherapy had come to an end. It was replaced by a so-called ‘Dodo bird 
verdict: Everybody has won, and all must have prizes’ (Luborsky et al., 2002). This 
was done because empirical evidence had shown that the ‘specific ingredient’ in any 
given therapy – that which theoretically makes it work – adds little to the nonspecific 
elements of psychotherapy (Asay & Lambert, 1999). Moreover, this research has 
shown that clinical success is more a function of differences among therapists than 
among therapies (Wampold, 2001), and the success of therapists is primarily related 
to the quality of their alliance with patients (Baldwin et al., 2007; Luborsky et al., 
2002).  
This revaluation of nonspecific therapy factors is also being stimulated by an 
increasing collaboration between behaviour-oriented sciences such as neurology, 
biology and experimental, social and clinical psychology. The results of this 
interdisciplinary research questions the existence of the free will: the neo-cortex 
appears to be less dominant and therefore has less influence on our behaviour than 
it would like us to believe (Dijksterhuis, 2008; Lamme, 2010). It seems that we are 
predominantly controlled by automatic neural networks. Someone who would like to 
change his behaviour does not benefit much from a wonderful all-encompassing 
theory, but needs the discipline to replace all old automatisms with new ones that fit 
into his own (small, but subjectively significant) story (Appelo, 2011; Brewin, 2006). 






The treatment method that facilitates this type of learning, is no longer forcefully 
dictated by a particular viewpoint or school of thought. In line with the principles of 
evidence-based medicine, this integrative method results from the interaction 
between the (preferences of the) patient, the (expertise and experience of the) 
therapist and the number of effective interventions that are available at that moment. 
This gives psychotherapeutic practice an integrated, eclectic character (Korrelboom 
& Ten Broeke, 2004). 
Another form of integration in psychotherapy is that of East and West. Eastern 
philosophies are increasingly being integrated into Western (psycho-)therapies; 
examples are mindfulness and Acceptance and Commitment Therapy (ACT) (Kabat-
Zinn, 2003). So, it seems that also in psychotherapy there are many developments 
with a tendency towards integration.  
 
Scientific research 
Although there still are well-defined schools of thought in the world of science with 
their own methodological preferences, we also see, especially in health care, a 
growing space for the equal coexistence of different research methods (Plochg et al., 
2007; Walach et al., 2006). This is facilitated by the criticism of the doctrine of the 
randomised controlled trial (RCT) as a ‘sacred’ scientific research method 
(Ottenbacher & Hinderer, 2001). This criticism is predominantly based on the 
difference between internal validity, or efficacy (does a method or intervention work 
as such?) and external validity, or effectiveness (is it beneficial in a certain context?). 
Proven efficacy does not say much about effectiveness, as what works in a large 
group on average does not per se apply to all individuals in various contexts. On the 
other hand, effectiveness does not simply imply efficacy, because what works for a 
person in a particular situation, cannot always be generalised to a group.  
If an intervention with only one mode of action is being studied, as is the case 
with medication, and if a subject does not prefer the experimental condition over the 
control condition (because he cannot know the difference between the two), it is 
indicated to establish the internal validity of the intervention first. In this case, the 
RCT is the research method of choice. If however the expectation of the result and 
the preference of subjects play a role and these are not the same for the 
experimental and the control condition (as is the case with almost all psychological 
and non-placebo-controlled medication research in health care), establishment of the 
external validity is indicated first. Observational, quasi-experimental and mixed-
methods research is the method of choice in this case (Barry, 2006; Plochg et al., 
2007). This offers possibilities for CAM (Barry, 2006) as most CAM users have a 
strong preference and therefore it is difficult to do RCTs for CAM therapies. Although 
in biomedicine it is common to start with randomised trials first, possibly later 
followed with effectiveness studies, in CAM it seems acceptable to work the other 
way around. To start assessing the effectiveness in a certain context and verifying it 
later in a RCT. This also makes sense as in biomedicine new pharmacological 
compounds are only allowed on the market after assessing efficacy and safety in 
RCTs, but most CAM are already being used, even though efficacy has not been 
established yet. So, it seems that it depends entirely on the research question, kind 
of treatment and circumstances, which kind of research design is needed. No design 
(not even RCT) can be considered best in all circumstances (Walach et al., 2006). 
This calls for an integrated research approach. 
 
 








This essay suggests that the integrative movement in health care does not stand on 
itself. It is a phenomenon that is manifesting itself worldwide and in different aspects 
of daily life. It follows a period in which differentiation took central stage but did not 
lead to absolute, unquestionable truths.  
The conclusion that integrative health care fits the spirit of the time therefore 
seems justified. However, there is a chance that, with continuing integration, this 
movement will develop into another direction. The different parts in this case might 
eventually lose their identity, develop a need for autonomy and try to promote more 
differentiation. The dynamics of the processes of differentiation and integration show 
that both poles are connected (similar to the perpetual dynamics and balance 
between yin and yang in Eastern philosophy or the Western theory of dialectics). If 
the integrative movement wants to survive, it will have to make sure that the balance 
is not lost.  
In other words: a continuing integrative movement cannot do without 
differentiation and must find a middle way in which appropriate attention is being 
paid to keeping the integrated parts sufficiently differentiated and allowing them to 
keep their own identity. Then, integrative health care predominantly means a good 
and equal collaboration between parts that are well differentiated. In this regard it 
would be useful if everyone who is involved in the process, critically contributes to 
the debate and raises the alarm once the balance between differentiation and 
integration is getting lost. In the last few years a distorted balance due to a lack of 
criticism or supervision has become visible in various spheres – e.g., the worldwide 
financial crisis and fraud in scientific research. 
Finally, it would be interesting to raise the question why in the process of 
integration and differentiation people may feel the need for polarisation and rowing 
against the flow, instead of contributing to the debate. We think that the main reason 
why people would protest against integration is that they do not consider themselves 
sufficiently profiled and recognised in the process of differentiation. After all, it looks 
like integration works against one’s own identity. Especially when a person’s identity 
has not been satisfactorily established during the process of differentiation, he may 
fear that integration will destroy it. This phenomenon is visible in the viewpoint of 
Kuipers and Gijsman (2006), who present as an argument against the psychiatric 
branch of the integrative movement, that it has taken regular psychiatry already a lot 
of efforts to be seen as a normal part of medicine. The resistance against integration 
is then related to the lack of a clear identity. Developing such an identity is a good 
thing. But fighting against something else is, in our opinion, not an appropriate 
method to reach this goal. It would be better to invest in the profiling of your own 
message and methods. Once we feel that we are being carried away, against our will 
or not, in an integrative movement, we do not have to be afraid that we will lose 
ourselves in it. We can get out of it on our own, or take part in the larger whole and 
help create something that is more than the sum of its parts, all the while making 
sure that we can still recognise ourselves in what we are doing. That will assist in 
finding and keeping the middle road between preservation of one’s own identity and 
integration into a larger whole.
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In the West half the population uses non-conventional medicines (complementary 
and alternative medicine, CAM; also referred to as Traditional Medicine, TM) 
annually (Bodeker & Kronenberg, 2002), almost always in combination with Western 
Medicine (WM) (Astin, 1998). For instance in the Netherlands CAM is used by 42% 
of psychiatric outpatients (Hoenders et al., 2006a). Most of them favour integration of 
CAM and WM (Hoenders et al., 2006a). In the East, traditional medicines like 
Chinese and Tibetan medicine and Ayurveda are increasingly being researched with 
Western research methods (like the RCT; randomized clinical trial) often with 
remarkable results. Of course, these medicines have already proved their value in 
thousands of years. But now in this information era with increasing exchange 
between East and West and an emphasis on scientific research, there seem to be 
great opportunities for collaboration, exchange and even integration of WM and TM; 
the different medicines of the world. 
But although the practical integration of western medicine (WM) and 
complementary and alternative medicine is growing (Hoenders et al., 2008), their 
paradigms and therapeutic methods often differ greatly. At first sight they even 
appear impossible to reconcile. Is theoretical and therapeutic integration of WM and 
CAM really an illusion or is the presumed gap mainly related to our points of view? 




Comparison of CAM and Western Medicine 
 
Many authors compared the Western biomedical paradigm with alternative 
paradigms (McFarlane, 1996; Goldstein, 2003; Kaptchuk & Eisenberg, 1998). Table 
1 shows five factors that in our opinion characterize the differences most clearly, with 
references to the original authors. 
These distinctions are in most cases not categorical but dimensional, for 
example, the ‘procedures’ aspect ‘technology versus natural sources’. A great deal 
of current WM medications is directly derived from herbs and plant extracts, such as 
procaine and digitalis. This obscures the boundary between 'natural' and 'technical'.  
The same counts for the ‘expert’ issue. It is clear that during surgical 
intervention the patient is under anaesthesia and the doctor is the expert. However, 
afterwards the patient himself has to work actively on rehabilitation. The patient's 
contribution varies from minimal to a great deal considering the circumstances.  
With regard to the ‘therapist-patient relationship’, mainstream psychotherapy 
currently strongly recognizes the importance of non-specific factors (Duncan & Miller, 
2006).  






Table 1: General differences between CAM and WM 
 
 
1 Engel, 1980; Van Der Steen, 1991 
2 Goldstein, 2003; Cassidy, 2001; Weil, 2000 
3 Jonas, 2002 
4 Goldstein, 2003; Kaptchuk & Eisenberg, 1998; Micozzi, 2001; Gulmen, 2004 
5 Vickers & Zollman, 1999 
6 Weil, 1996; Gangchen Rinpoche, 1997 
7 Snyderman & Weil, 2002 
8 Astin, 1998 
9 Kaptchuk & Eisenberg, 1998 
10 Sackett et al., 2000 
11 Wilber, 2000; Bensing, 2000; Happle, 1998; McFarlane, 1996 
12 Ho & Van Der Steen, 2005; Kaptchuk, 2001 
13 Barrett et al., 2000 
14 Happle, 1998 
15 Bruce, 2002 
16 Sarnat & Winterstein, 2004; Boon et al., 2004 
 
 
Factor Western Medicine CAM / TM 
Reductionism1   Holism Perspective 
Pathogenesis (focusing on factors 
that cause disease) 
Salutogenesis (focusing on health, well-being, 
and one’s self-healing capacity)2  
Mechanism3 Vitalism4 Paradigm 
Giving antidote (allopathy) Stimulating healing response (homeopathy)5 
Therapist is expert and  
responsible 
Patient is expert and 
responsible6 
Therapeutic relationship 





Technology Natural sources9 






RCT, efficacy10 N of 1, effectiveness12 










Regarding research, in Western medicine it is largely based on positivism, 
reductionism, objectivism and determinism. This is sometimes called ‘outer science’. 
It strives for standardization and generalization. In furnishing scientific proof, the 
RCT is the golden standard. Alternative therapies are particularly based on 
subjective experience, intuition and belief. The assumption is that the truth is found 
by way of personal experience (McFarlane, 1996). This is sometimes called ‘inner 
science’ or ‘first-person science’ (Wilber, 2000). This approach seems particularly 
suitable for observations or 'single-case' studies (n = 1). In research terms, it is 
related to the difference between efficacy (the ideal outcome in controlled 
circumstances) and effectiveness (the clinical outcome in natural circumstances). 
According to Bensing (2000), ‘outer’ and ‘inner science’ are two different worlds. 
Some say ‘inner science’ is by definition irrational and irreconcilable with rational 
science (Happle, 1998). Conversely, the criticism of RCTs is that they artificially 
reflect a complex clinical practice and that the importance of the individual patient 
becomes devaluated by this (Tataryn & Verhoef, 2005). Moreover, the ‘RCT as 
golden standard’ is, to our opinion, culture-bound and is implemented less outside of 
Western culture. After all, for instance various Eastern spiritual philosophies, 
consider the inner experience as the ultimate basis for attaining knowledge about 
reality. Assumptions are tested according to other (inner) research methods 
(McFarlane, 1996).  
Despite these differences, it is clear that in the last decade Eastern 
philosophies have found more acceptance in the Western world and in psychiatry, 
for example, mindfulness and other Buddhist techniques in the (third generation of) 
behaviour therapy (Brewin, 2006). Additionally, the unassailable status of the RCT is 
more frequently put into question, and research methods suitable for ‘inner science’ 
are proposed more often (Ho & Van Der Steen, 2005; Kaptchuk, 2001). So, also 
where it concerns research methods, the differences found are not as absolute as 
they initially seemed to be. The same gradual distinctions seem to be valid for all 
other factors and aspects. Therefore, theoretical and therapeutic integration of WM 
and CAM seems relatively easy. But is it? 
There seems to be an exception. The contrast between ‘mechanism’ (often 
accompanied by reductionism) and ‘vitalism’ (often accompanied by holism) is 
categorical and has been one of the greatest controversies in philosophy. It still 
leads to heated discussions between WM and CAM. This absolute contrast is of a 
meta-theoretical nature and therefore cannot be solved through standard scientific 
logic (Hein, 1971). Supporters of each paradigm and perspective cannot be 
convinced by scientific evidence to the contrary because their points of view concern 
an existential premise, a conviction regarding the question of ‘why’ things are as they 
are (Coulter & Willis, 2004). 
However, looking deeper, this controversy seems also relative. For example, 
a mechanical, work-related frame of mind does not rule out religion and spirituality in 
private life. Furthermore, a vitalistic philosophy as the leading therapeutic principle 
can occasionally imply a mechanical working method.  
 
 








Besides practical integration practised by patients already for a long time, the 
theoretical and therapeutic integration of WM and CAM is also possible. The findings 
of our literature search argue for using the biopsychosocial model as originally 
proposed by Engel (1980; 1992) to facilitate this process. This model fits well 
because it maintains a middle ground between the biomedical approach and the 
holistic-vitalistic approach and because its basis is in biological systems theory. This 
theory attempts to surpass (the opposition between) mechanism and vitalism, partly 
by nuancing both (Hein, 1972). And it is precisely this nuancing that seems important 
in our post-modern, multicultural society.  
In our opinion we should support integration of WM and CAM in a 
professional, critical manner and with an open mind so that we can arrive at a 
complete, efficient, effective integrated healthcare system in which everyone, 
regardless of his or her culture, race, philosophy of life or need, can receive the help 
he or she needs. 
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Complementary and alternative medicine (CAM) is subject to heated debates and 
prejudices. Studies show that CAM is widely used by psychiatric patients, usually 
without the guidance of a therapist and without the use of a solid working method, 
leading to potential health risks. 
 
Aim:  




A search through scientific and legal articles and discussion in focus groups. 
 
Results:  
In the Center for Integrative Psychiatry (CIP) of Lentis in the Netherlands some 
carefully selected CAM are offered under strict conditions, alongside conventional 
treatments. Because of the controversy and the potential health risks, Lentis 
designed a protocol that is presented. 
 








In 2002 Silvia Millecam, a famous Dutch actress, died of breast cancer after refusing 
conventional medical treatment while trusting herself to practitioners treating her with 
CAM. The Dutch Healthcare Inspection did an extensive inquiry into the matter. 
Three doctors were put to trial for malpractice and were convicted by the Medical 
Disciplinary Tribunal. Two of them lost their medical licence. In the years that 
followed there were heated debates on the use of alternative medicine in the 
Netherlands. 
Supporters of CAM claim that conventional treatments have too many side 
effects, lack effectiveness and room for patients’ wishes and needs. On the other 
hand, opponents state that CAM is quackery and that the effects are based on 
placebo and ‘ridiculous principles’ (Renckens, 2004). This reaction reminds us of 
earlier resistance to change in medicine; for instance, in 1911 Herrick was almost 
laughed out of medicine for stating that atherosclerosis causes myocardial infarction 
(Olshansky & Dossey, 2003). 
Previous and current bias against new developments is undesirable because 
both patients and doctors are uncertain about safety and effectiveness of CAM. This 
is all the more important because about half of the population in a variety of western 
countries (Bodeker & Kronenberg, 2002) and almost half of Dutch psychiatric 
outpatients use CAM annually (Hoenders et al., 2006). A majority of patients gets 
information on CAM via internet, friends or family. The quality of this information 
varies greatly, leading to potentially harmful and dangerous situations (Crone & 
Wise, 2000). 
In the Netherlands many doctors do not inform their patients about CAM and 
they certainly avoid prescribing or referring to CAM. Recently the Dutch Minister of 
Health has announced more severe punishment for practitioners who harm their 
patients either by applying unsafe therapies or by delaying the start of conventional 
treatment (NRC Journal, 2009). Therefore, in the Netherlands patients and doctors 
are informed about what cannot be done concerning CAM, while it remains unclear 
what could or should be done. Despite calls from the World Health Organization 
(WHO, 2003) and the European parliament (European Parliament, 1997), until now 
the Dutch government did not formulate a policy on this matter. 
In an effort to fill this gap and inspired by the North American consortium of 55 
academic health centers for integrative medicine (CAHCIM, 2004), Lentis (a 
community mental health facility in the North of the Netherlands) founded a Center 
for Integrative Psychiatry (CIP) in 2006. It consists of an outpatient clinic, a research 
department, an educational department, and organizes an annual conference (with 
approximately 1000 attendees) (Hoenders et al., 2008). Its main purpose is to 
provide safe and effective integrative mental health care. 
 
 
What is Integrative Psychiatry? 
 
Integrative psychiatry is based on the principles of ‘integrative medicine’: reaffirming 
the importance of the relationship between practitioner and patient; focusing on the 
whole person; using all therapeutic approaches (conventional and CAM) based on 
the principles of evidence-based medicine (EBM); and achieving optimal health and 
healing. 






The debate in the Netherlands focuses mainly on the principle of EBM, i.e. the 
use of CAM within conventional treatment centers, and the correct definition of 
evidence-based medicine. In this regard it is noteworthy that Sackett et al. (2000) 
defined EBM as: (1) the best available evidence for effective and safe treatment 
options, (2) the preferences and needs of the patient, and (3) the clinical expertise of 
the professional. These three together should be decisive in making treatment 
choices.  
This definition is in contrast with the present-day more reductionist 
explanation of evidence-based medicine in which the first and third principle are 
emphasised without paying much attention to the patient’s preference (Offringa et 
al., 2003). The original definition therefore accommodates therapies that still lack 
(sufficient) evidence-based proof. It is also important to realize that according to 
some researchers only about one third of culturally and professionally accepted 
interventions in western medicine is proven effective by RCTs (Booth, 2006; Tataryn 





Some reasons why opponents feel doctors should not use CAM seem to be based 
on prejudices. Table 1 compares the most common prejudices against CAM with 
information from scientific studies.  
 
Table 1: Prejudices against CAM  
 
Prejudice Refutation 
1. Only few people use CAM 1. 30-70% of the population uses CAM1 and 42% 
of Dutch psychiatric outpatients2 
2. My patients do not use CAM because they 
never ask or tell me about it 
2. 60-75% of patients using CAM do not tell their 
doctor out of fear of a negative response3 
3. CAM users are less educated and easily 
influenced 
3. CAM users are typically female, highly 
educated, high income with chronic disease4 
4. They use CAM instead of conventional 
medicine 
4. 80-95% combines2 
5. They use CAM because of negative reasons 
(against conventional medicine) 
5. Besides disappointment about side effects and 
limited results, also positive reasons play a part: 
good relationship with therapist and a shared 
belief about health and disease (holism)5 
6. CAM effects are due to placebo 6. Several CAM are more effective than placebo6 
7. CAM and EBM are incompatible 7. CAM can be offered based on the principles of 
EBM7 
8. CAM are not endorsed by influential institutions 8. The CAHCIM8, the WHO9 and the EP10 
endorse the integration of effective CAM in 
conventional clinics 
 
1 Bodeker & Kronenberg, 2002 
2 Hoenders et al., 2006 
3 Van De Creek et al., 1999 
4 Astin, 1998; Eisenberg et al., 1998 
5 Furham, 1996 
6 Ernst, 2006; Lake & Spiegel, 2006; Mischoulon & Rosenbaum, 2008 
7 Wilson & Mills, 2002; Hoenders et al., 2010 
8 CAHCIM, 2004 
9 World Health Organization, 2003 
10 European Parliament, 1997 







Similarly, those in favor of CAM also seem to have prejudices. Those are mentioned 
in table 2. We therefore argue that CAM needs serious attention, both within 
conventional treatment centers and in the alternative field.  
 
 
Table 2: Prejudices for CAM 
 
Prejudice Refutation 
1. If it does not work, at least it will not harm 1. Some supplements or herbs can cause severe 
side effects or interactions1 
2. Natural substances are more healthy than 
chemicals 
2. Nature contains severe toxins, besides natural 
medicines 
3. CAM do not need to be researched; I know it 
works from experience 
3. Experience is not enough; research is needed 
to distinguish from placebo and bias2 
4. CAM are not suitable for research because of 
their specific nature 
4. Science can be applied to all phenomena; it is 
essential to choose the right design3 
 
1 Ernst, 2003 
2 Sackett et al., 2000 
3 Walach et al., 2006 
 
 
The CAM protocol 
 
One of the primary tasks of our center was to formulate a scientific model based on 
the requirements that it would (1) answer patients’ needs and wishes; (2) respect 
their freedom of choice; (3) would offer western medicine and CAM that are safe and 
effective; (4) would protect against quackery and abuse; (5) should be based on 
Dutch law, the jurisprudence of the Medical Disciplinary Tribunal and the rules of the 
Dutch Association of Medical Practitioners (KNMG); and (6) be based on scientific 
evidence.  
The authors reviewed documents, the scientific literature and collected 
information with the help of focus groups (De Jong et al., 2010). This resulted in the 
CAM protocol (Hoenders et al., 2010). In this protocol we distinguish (between) 
complementary and alternative medicine. The first is defined as “approaches based 
on mainstream biomedical theory and supported by research evidence but not part 
of mainstream practice because of social, political or ideological reasons”. Examples 
are St. John’s wort and massage. Alternative medicine is defined as “approaches 
that are based on concepts that are outside mainstream Western medicine”. 
Examples include homeopathy and healing (Lake, 2007). Based on an analysis of 
the results we produced the algorithm shown in figure 1. 






Figure 1: Decision tree  






This is the working method of the Center for Integrative Psychiatry. The first step of 
the algorithm clarifies that CAM can only be used after an extensive and precise 
stepwise process. They can only be started if conventional treatments have been 
applied before or at least advised as suggested by guidelines and protocols. In 
addition, CAM is considered if there is no danger when a patient refused treatment 
(for instance: a manic or psychotic patient with severe symptoms will be strongly 
advised first to accept conventional medication even when asking for CAM).   
After deciding to start CAM, the second step is based on the principles of 
EBM (i.e. alternative treatments with a lower level of evidence can be provided on a 
patient’s request when there is no contraindication). However, these treatments will 
not be offered within the CIP. Patients will be referred to an external network that 
provides these treatments in conjunction with proven treatments provided by CIP 
and not instead of them. In addition, there are the following required conditions:  
 
• The therapists are members of a (para)professional organization with a formal 
procedure for complaints and malpractice.  
• The therapists base their treatments and their way of working on the professional 
guidelines of the organization.  
• The therapists conform themselves to legal demands concerning patient files.  
• The clinic or office where patients are being treated meet privacy and hygiene 
demands, as common in conventional medicine.  
• The therapists have malpractice insurance.  
• There has to be at least monthly contact between the CIP and the alternative 
practitioner.  
• After finishing the alternative treatment there will be at least one contact with the 
CIP to evaluate.  
• The alternative therapists agree to be included in scientific evaluation by routine 
outcome measurement (ROM) of the effect of the treatments and agree with 
publication, regardless the results.  
 
 
Center for Integrative Psychiatry 
 
In the Center for Integrative Psychiatry of Lentis only conventional and 
complementary medicine that have been proven effective and safe are being 
practised. That means that they have to be based on (reviews of) several well-
designed scientific studies. Examples are St. John’s wort for depression (Linde et al., 
2008), valerian for insomnia (Mischoulon & Rosenbaum, 2008), relaxation for anxiety 
(Eppley et al., 1989), mindfulness-based stress reduction (Baer, 2003; Grossman et 
al., 2004) and mindfulness-based cognitive therapy for depression (Teasdale et al., 
2000), massage for stress, anxiety and depression (Moyer et al., 2004), exercise for 
depression, anxiety and sleep disorders (Craft & Landers, 1998), heart-rate 
variability training for anxiety and stress-related and depressive symptoms 
(Karavidas, 2008; McCraty et al., 2001), single vitamins as a supplement to 
medication for depression (like folic acid) (Taylor et al., 2008), food supplements like 
s-adenosylmethionine (SAMe) for depression (DelleChiaie et al., 2002), melatonin 
for sleep disorders (Zhdanova & Friedman et al., 2008), inositol for depression, panic 
and obsessive compulsive disorder (Belmaker & Levine , 2008), and dietary changes 
for depression (Freeman, 2010). These treatments, integrated with conventional 
psychiatry, have been offered since three years to psychiatric outpatients.  






Alternative medicine like homeopathy, reiki or healing are not being offered. 
However patients can be referred to these treatments under strict conditions, which 
are explained above. All treatments are evaluated by routine outcome measurement 
(ROM). In addition, we study the outcome of innovative treatments with individual 
outcome measurements (IOM) such as N-of-1 design, single-subject experimental 
design and time-series analysis. ROM consists of six questionnaires:  
psychopathology, quality of life, resiliency, costs, satisfaction and one self-report 
personalized outcome indicator, chosen by the patient. Patients fill out these forms 
before treatment starts, every half year, at the end of treatment, and half a year after 
their discharge. Patients with IOM fill out diaries concerning items that are most 
relevant to their treatment and symptoms, to assess subjective improvement on core 





Because of the increasing demand of patients for alternative medicine and 
integrative treatments and because of social, political, scientific and ethical reasons, 
and inspired by the CAHCIM, Lentis has founded a CIP. Here it offers selected 
complementary treatments alongside conventional ones under strict conditions. By 
doing so, the CIP responds to a call from the Word Health Organization and 
European Parliament, even though the Dutch government still hasn’t made policy on 
this subject. Because of the controversy surrounding CAM, because of the lack of 
clear information and because we do not only need an open attitude but also a 
critical one, the CIP has formulated the CAM protocol. It believes that in this way 
CAM can be offered in a safe and effective way within conventional treatment 
centers. It hopes in this way to better serve and respect the individual needs and 
preferences of the diversity of patients who need mental healthcare in our Dutch 
multicultural society. It believes the protocol also protects against quackery, abuse 
and false hope.  
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Bipolar Disorder (BD) is a debilitating syndrome that is often undiagnosed and 
under-treated. Population surveys show that persons with BD often self-medicate 
with complementary and alternative medicine (CAM) or integrative therapies in spite 
of limited research evidence supporting their use. To date no review has focused 
specifically on non-conventional treatments of BD.  
 
Objectives:  
To present a comprehensive review of non-conventional (complementary and 
integrative) interventions examined in clinical trials on BD, and to offer provisional 
guidelines for the judicious integrative use of CAM in the management of BD.  
 
Methods: 
PubMed, CINAHL, Web of Science and Cochrane Library databases were searched 
for human clinical trials in English during mid-2010 using Bipolar Disorder and CAM 
therapy and CAM medicine search terms. Effect sizes (Cohen’s d) were also 
calculated where data were available. 
 
Results:  
Several positive high-quality studies on nutrients in combination with conventional 
mood stabilizers and antipsychotic medications in BD depression were identified, 
while branched-chain amino acids and magnesium were effective (small studies) in 
attenuating mania in BD. In the treatment of bipolar depression evidence was mixed 
regarding omega-3, while isolated studies provide provisional support for a multi-
nutrient formula, n-acetylcysteine, and L-tryptophan. In one study acupuncture was 




Current evidence supports the integrative treatment of BD using combinations of 
mood stabilizers and select nutrients. Other CAM or integrative modalities used to 
treat BD have not been adequately explored to date; however, some early findings 
are promising. Select CAM and integrative interventions add to established 
conventional treatment of BD and may be considered when formulating a treatment 
plan. It is hoped that the safety issues and clinical considerations addressed in this 
article may encourage the practice of safety-conscious and evidence-based 
integrative treatment of BD.   
 
 








Bipolar disorder (BD) is a debilitating heritable mental illness that has profound 
personal and socioeconomic effects. Emerging research findings reviewed in this 
paper suggest that non-conventional therapies may have a potentially significant role 
in improving quality of life, reducing side-effects, improving adherence with 
conventional medications, and reducing the severity of bipolar symptoms. 
Complementary and Alternative Medicine (CAM) consists of therapies such as 
acupuncture or naturopathy, and medicinal interventions such as herbal medicines 
or nutrients (Sarris & Wardle, 2010). CAM is commonly used by people diagnosed 
with mood disorders with up to 50% of psychiatric outpatients using one or more 
CAM therapies in a given year (Knaudt et al., 1999; Hoenders et al., 2006). Studies 
reveal especially high CAM use rates in women, the highly educated, the elderly, 
and those with chronic diseases (Keaton et al., 2009; Kessler et al., 2001; Wu et al., 
2007). Aside from specific CAM interventions used in conjunction with 
pharmacotherapies (reviewed in this paper), according to users, CAM may provide 
general beneficial effects on physical and mental health and quality of life (Sirois, 
2008). Furthermore, research has shown that administration of CAM within an 
holistic model can be beneficial for mental health (Cooley et al., 2009). Thus, 
adjuvant use of CAM within an integrated whole-person framework (combined with 
pharmacological and psychosocial interventions) holds the potential to reduce the 
severity of bipolar symptoms and risk of relapse. 
Despite this, few studies have been done on non-conventional treatments of 
BD. Other than a review by Andreescu and colleagues (Andreescu et al., 2008), 
there is a paucity of peer-reviewed publications reporting clinical trial outcomes and 
safety issues associated with non-conventional treatments of BD. While their article 
is significant for providing the first review in this area, its focus is primarily on 
unipolar depression and it does not review nutritional interventions in detail, many of 
which are effective adjunctive interventions when combined with conventional 
pharmacotherapies (Sarris et al., 2009). The Andreescu et al. review is also limited 
by excluding studies published over 10 years ago. In the present paper we critically 
review evidence for CAM and integrative treatments of bipolar depression, mania 





PubMed, CINAHL, Web of Science and Cochrane Library databases were searched 
during mid 2010 firstly for research in the overarching area of bipolar disorder; then 
for human clinical trials using the terms “Bipolar Disorder”, “Bipolar Depression”, 
“Bipolar Mania”, “Mania”, “Hypomania”, “Cyclothymia” together with terms for CAM 
therapies and products (e.g. herbal and nutritional medicine), and dietary and 
lifestyle factors. A forward search of identified papers was subsequently performed 
using Web of Science cited reference search. Reasons for exclusion included: a 
higher level of evidence being available or inadequate methodological rigor. Included 
clinical trials were open or controlled human studies that recruited people diagnosed 
with BD, examined CAM as a monotherapy or as an adjuvant with a conventional 
medication, and measured outcomes using established psychiatric rating scales. The 
term “significant” was used in studies with p values of <0.05. Effect sizes were 
calculated in all RCTs where data were available. From the results of the clinical 






trials we calculated an effect size as Cohen’s d (Cohen, 1988) by firstly subtracting 
the differences between the intervention and placebo scores on the scale used, then 
dividing this by the pooled standard deviation at baseline (clinical effect: 0.2 = small, 
0.5 medium, > 0.8 large). Studies involving exercise and psychological therapies 
were omitted from analysis as, for purposes of this review, they are considered 
mainstream interventions (however they are briefly discussed in the Clinical 
Considerations section). Results are grouped under omega-3 fatty acids, amino 






Bipolar disorder (BD) is a debilitating heritable mental illness that affects 
approximately 1-2% of adults in their lifetime. When milder subclinical presentations 
are included the prevalence rate increases to approximately 4% (Merikangas et al., 
2007). First-degree relatives of bipolar individuals are significantly more likely to 
develop the disorder than the population at large and twins have a 70% risk of 
sharing the disorder (Gurling et al., 1995). Although not yet fully elucidated, BD 
symptoms are probably caused by dysregulation of serotonergic and dopaminergic 
pathways, and diminished activity in the hippocampus and pre-frontal cortex 
(Konradi et al., 2004; Miklowitz & Johnson, 2006). It has been suggested that 
abnormal activity in hypothalamic circuits involved in maintaining normal circadian 
rhythms manifest as the affective and behavioral symptoms of BD (Miklowitz & 
Johnson, 2006).  
 
Diagnosis 
According to current conventional Western psychiatric nosology, BD diagnosis is 
divided into Bipolar Disorder Type I (BD I) and Bipolar Disorder Type II (BD II: see 
table 1), and can be differentiated from unipolar depression (major depressive 
disorder: MDD) by the presence of manic or hypomanic (lesser) episodes (American 
Psychiatric Association, 2000). A manic episode is a complex symptom pattern that 
may encompass disparate affective, behavioral and cognitive symptoms, including 
pressured speech, racing thoughts, euphoric or irritable mood, agitation, inflated self-
esteem, distractibility, excessive or inappropriate involvement in pleasurable 
activities, increased goal-directed activity, diminished need for sleep, and in severe 
cases, psychosis (American Psychiatric Association, 2000).  
 






Table 1. Unipolar depression and bipolar depression: differential diagnoses*  
 
Major Depressive Disorder   Bipolar Disorder I (mania)   Bipolar Disorder II 
(hypomania) 
Two weeks or more of 
persistent low mood and/or  
anhedonia (loss of interest in 
pleasurable activities) 
Episodes of mania or a mixed 
episode lasting 5 or more days. 
Often presents with cycling 
between mania and depression  
Hypomanic episodes that do 
not meet criteria for full mania, 
in addition to cycling to one or 
more episodes of MDD 
Low mood impairs work and/or 
social functioning, may require 
hospitalization for severe 
depression 
Manic episodes impairs work 
and/or social functioning, and 
often requires hospitalization 
Hypomanic episodes not as 
severe as BD I mania, and do 
not significantly impair 
work/social functioning  
 
Changes in body weight, 
digestion, and sleep patterns 
 
Manic phase (euphoric or 
irritable mood, grandiosity or 
psychosis, decreased need for 
sleep)  
 
Hypomanic phase (euphoric or 
irritable mood, decreased 
sleep, increased talkativeness, 
goal planning and sexual focus)  
Psychological changes (e.g. 
suicidal ideation, guilt, self-
worthlessness, agitation) 
 
Depressive phase can present 
with similar psychological and 
somatic changes to MDD 
Depressive phase can present 
with similar psychological and 
somatic changes to MDD (more 
common in BD II than BD I) 
Not due to bereavement, 
medical comorbidity, drugs or 
alcohol, or medication 
 
Not due to medical comorbidity, 
drugs or alcohol, or medication 
Not due to medical comorbidity, 
drugs or alcohol, or medication 
* Adapted from DSM-IV TR (APA, 2000)  
 
 
A history of depressive episodes is not required for a formal diagnosis of BD I 
according to the Diagnostic and Statistical Manual of Mental Disorders version IV 
(DSM-IV-TR) (APA, 2000). In contrast, BD II can be diagnosed only in cases when at 
least one hypomanic episode and at least one depressive episode have been 
documented. In both disorders moderate or severe depressive episodes typically 
alternate with manic symptoms, however in “mixed mania” symptoms of mania and 
depressed mood overlap. Another variant called rapid cycling is diagnosed when at 
least four complete cycles of depressed mood and mania occur during any 12-month 
period. A mild variant of BD, cyclothymic disorder, is diagnosed when several 
hypomanic and depressive episodes take place over a two-year period in the 
absence of severe manic, mixed or depressive episodes (APA, 2000). The emerging 
concept of a “mood spectrum” hypothesis suggests that patterns of depressive and 
manic symptoms occur along a continuum, and that “mood disorders” do not exist as 
discrete diagnostic entities (Benazzi, 2007; Cassano et al., 2002). Evidence supports 
that unipolar depression and bipolar II depression occur across a spectrum, with 
30% of patients diagnosed with major depressive disorder (MDD) experiencing 
various bipolar symptoms (e.g. agitation, racing thoughts, decreased sleep) 
(Benazzi, 2007). While BD I presents as a distinct psychiatric disorder that fulfills 
specific diagnostic criteria, BD II and cyclothymic disorder are more variable in 
presentation. 






It is estimated that two thirds of individuals diagnosed with BD experience 
moderate or severe symptoms in any given year (Suppes et al., 2005). Bipolar 
patients experience depressive symptoms three times more often than mania, and 
five times more often than rapid cycling or mixed episodes (Judd et al., 2002). A 
diagnosis of BD is one of the highest risk factors for suicide (Pompili et al., 2009). BD 
usually presents in a rhythmic manner, oscillating between episodes of mania and 
depression, with several risk factors and triggers contributing to the rate of relapse 
and failed response to treatment (see figure 1). 
 
Conventional treatment 
Conventional pharmacotherapies are an important and often necessary treatment of 
both the depressive and manic phases of BD. First-line treatments of BD include 
mood stabilizers (e.g. lithium carbonate, carbamazepine, and valproate), 
antidepressants, antipsychotics and sedative-hypnotics (Miklowitz & Johnson, 2006; 
Suppes et al., 2005). Antipsychotics are used to treat agitation and psychosis, which 
occur frequently in acute mania, and select antipsychotics have been found to be 
effective mood stabilizers. Sedative-hypnotics are sometimes prescribed for the 
severe insomnia that accompanies mania, as well as for daytime management of 
agitation and anxiety (Cousin & Young, 2007).  
Side effects often occur with these medications, having a mixed record of 
success due to their limited efficacy and high rates of treatment discontinuation 
(Pompili et al., 2009). Fewer than half of patients who take a conventional mood 
stabilizer or other psychotropic medications following an initial manic episode report 
sustained control of their symptoms (Culver et al., 2007). As many as one half of all 
bipolar patients who take mood stabilizers do not experience good control of their 
symptoms or refuse to take medications, and approximately 50% discontinue their 
medications because of serious adverse effects including tremor, weight gain, 
thyroid dysfunction elevated liver enzymes, and many others (Fleck et al., 2005). 
People diagnosed with bipolar disorders should be maintained on a consistent long-
term pharmacotherapeutic regimen to reduce the rate of re-hospitalization and 
increase chances of full remission (Perlick et al., 1999). In patients diagnosed with 
BD, stressors, seasonal change, reduced sleep and stimulants or recreational drug 
use may provoke an episode of hypomania (although sometimes the trigger may 
have no apparent cause (Miklowitz & Johnson, 2006). Regular exercise, good 
nutrition, a strong social support network, and a predictable low-stress environment 
help reduce relapse risk (Suppes et al., 2005; Benjamin, 2007; Miklowitz & Scott, 
2009; Lakhan & Vieira, 2008).  
Psychotherapy and psychosocial interventions in stable bipolar patients may 
potentially reduce relapse risk by providing psychological support, enhancing 
medication adherence, and helping patients address warning signs of recurring 
depressive or manic episodes before more serious symptoms emerge (Miklowitz & 
Scott, 2009). Relapse prevention usually involves use of “lifecharts” and an effective 
stress management plan. An example is the novel BD relapse prevention program 
(called MAPS), which has evidence in reducing relapse of mania and BD depression. 
The Australian developed MAPS program was studied in a clinical trial involving 84 
participants with BD, and was conducted over 12 weeks (Castle et al., 2010). 
Participants were randomized to either the program involving education on BD 
(symptoms, monitoring triggers, and symptom management skills), in addition to goal 
setting, medication management, and relapse prevention planning; or a control 
group consisting of treatment as usual plus telephone calls. Results revealed that 






participants who received the group-based intervention were significantly (p=0.04) 
less likely to have a relapse of mania or depression, and spent less time unwell. 
 
 
Clinical Considerations  
 
When considering recommending CAM or integrative treatments for BD (in concert 
with traditional psychotropic medications), it is essential to first carefully examine the 
evidence for both conventional and nonconventional therapies. In this paper we 
propose an integrative model that incorporates select CAM therapies in combination 
with conventional psychotropic medications. We recommend against the use of CAM 
or integrative therapies whose safety and efficacy is not supported by strong 
research evidence. This caveat applies even more so to the management of severe 
symptoms of bipolar depression or mania. Mental healthcare providers should 
always recommend those therapies supported by the highest level of evidence 
(Hoenders et al., 2010), and in spite of their limited efficacy and unresolved safety 
issues, mood stabilizers and select antipsychotics should always be regarded as the 
first-line treatments of the severe form of bipolar illness (i.e. BD I) (Nivoli, 2011).  
 Prior to diagnosing bipolar mood disorder a period of mania or hypomania 
lasting several days must be established in the context of a broader pattern of 
impairment that may include decreased need for sleep, flight of ideas, grandiosity, 
excessive or unrealistic spending, or hyper-sexual activity. A life chart can help 
establish a pattern of cyclic mood changes and associated impairments in social 
activity, academic performance and work. An important initial consideration when 
prescribing CAM in persons diagnosed with BD, depends upon which phase are they 
in (i.e. mania, depression, or remission). A careful history is needed to establish a 
persisting pattern of mood changes fluctuating between depression and mania or 
hypomania. Conventional laboratory tests and functional brain imaging studies can 
be used to rule out medical disorders that can mimic symptoms of depressed mood 
or mania including, for example, thyroid disease, strokes (especially in the right 
frontal area of the brain), multiple sclerosis, seizure, or other neurologic disorders 
(Kumar & Clark, 2002). Irritability or euphoria alternating with periods of depressed 
mood is sometimes associated with chronic abuse of stimulants, marijuana or other 
drugs. Thus, screening for substance abuse should be done before a formal 
diagnosis of BD is made (Swann, 2010).  
 In persons in the manic phase of BD type I, hospitalization is usually required, 
at which time adjunctive use of magnesium, choline, branched-chain amino acids, or 
L-tryptophan may be appropriate adjuvants in combination with mood stabilizers or 
antipsychotics. When prominent symptoms of anxiety or agitation are present, 
effective integrative strategies should prioritize treatment of those symptoms. In 
addition to sedating pharmacotherapies, the use of botanical or nutritional anxiolytics 
(such as Piper methysticum, magnesium, L-theanine, or L-tryptophan) may be 
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For patients in the depressed phase the treatment approach is different. It is 
important to note that depressed symptoms are often misdiagnosed as major 
depressive disorder when in fact they are the depressive phase of BD. Thus careful 
screening is essential in all patients presenting with depressed mood including 
assessment of the length, frequency and severity of depressive episodes, 
identification of precipitating stressors, and evaluation of suicidality. Assessment 
should include a urine drug and alcohol screen and a review of their sleep pattern 
and level of stress. CAM therapies for bipolar depressed patients include select 
nutrients (S-adenosyl methionine, L-tryptophan, omega-3 fatty acids (mixed 
evidence) (Sarris et al., 2009b), botanicals (Hypericum perforatum, Rhodiola rosea, 
Crocus sativus) (Sarris, 2007), select acupuncture protocols (Wang et al., 2008), 
regular exercise (Barbour et al., 2007), good nutrition (Jacka et al., 2010), and 
psychological interventions (Cuijpers et al., 2008).  
 All bipolar patients being treated for depressed mood are at risk of “switching” 
to mania and should be closely monitored.  A personalized relapse prevention 
program including patient and family education about early warning signs of 
recurring depressed mood or mania, and a well thought-out plan is an essential 













by the use of CAM therapies that have efficacy in major depressive disorder but that 
have not been established as safe in bipolar depressed mood and found to not 
increase the risk of switching to mania. Case reports implicate select natural 
products used to treat major depressive disorder, such as Hypericum perforatum 
(Moses & Mallinger, 2000), Ephedra sinica (Boerth & Caley, 2003), or S-adenosyl 
methionine (Papakostas et al., 2003) as potentially inducing mania. Several case 
reports of serotonin syndrome have been associated with the combined use of 
Hypericum perforatum and SSRIs (Sarris et al., 2009c). In addition it should be noted 
that extracts high in the active constituent hyperforin may induce cytochrome P450 
3A4 enzymes and the P-glycoprotein drug efflux pump resulting in reduced serum 
levels of many drugs including oral contraceptives, anticoagulants, protease 
inhibitors, and anti-seizure medications (Whitten et al., 2006).  
 A significant percentage of individuals diagnosed with BD use non-
pharmacological modalities adjunctively with prescription medications. However, with 
the exception of the nutrient interventions reviewed in this article, there is relatively 
little evidence for the safety and efficacy of the majority of such integrative 
treatments. Finally, while exercise should be encouraged in all BD patients because 
of established benefits to general health and mood, those patients taking lithium 
should consult their physician before starting a rigorous exercise program. Lithium is 
excreted with perspiration and strenuous physical activity that involves significant 
sweating may lower lithium levels in the blood; at least one such case has been 
reported (Waring, 2006).  
 
 
Clinical Evidence of CAM in Bipolar Disorder 
 
Omega-3 fatty acids 
Countries where there is high fish consumption have relatively lower prevalence 
rates of BD (Hibbeln, 1998). Several clinical trials have studied omega-3 fatty acids 
including fish oil and purified eicosapentaenoicacid (EPA) and docosahexaenoicacid 
(DHA), as a mono-therapy or as an adjuvant intervention in BD. An early RCT 
involving 44 participants using a combination of EPA and DHA (9.6 g/day) with 
conventional drug therapies revealed positive results on measures of depressed 
mood in terms of response and remission rates on The Hamilton Depression Rating 
Scale (HAMD) (d = 1.40) (Stoll et al., 1999; Hamilton, 1960). No significant effect on 
mania outcomes occurred. A 26-week open-label adjuvant study by Osher and 
colleagues (2005) in 12 participants with BD I, revealed that eight out of ten 
participants with one month of EPA were responders on HAMD (d=1.23). It should 
be noted that while these open-label studies are positive, confidence in these should 
be tempered as they are not controlled. A 12-week, 3-arm controlled study involving 
75 participants using 1 g or 2 g of EPA combined with any class of psychotropic 
medication revealed a small but significantly greater reduction on the HAMD from 
either dose, compared with placebo (1 g: d = 0.90, 2 g: d = 0.50) (Frangou et al., 
2006). However, no significant effect for mania was achieved on The Young Mania 
Rating Scale (YMRS) (Young et al., 1978). A later RCT conducted by the research 
group (Frangou et al., 2007) using 2 g of EPA versus placebo over 12 weeks in 14 
female participants with BD I revealed positive, but not statistically significant effects 
on depression outcomes. A novel 4-week adjuvant study involving 21 participants 
with BD I by Hirashima and colleagues (2004), revealed no significant differences 
between EPA 5 g plus DHA 3 g and a non-treatment control. Interestingly however, 






brain resonance imaging showed that T2 levels were reduced in the treatment group, 
denoting increased neuronal cell membrane fluidity.  
 A larger study (n = 121) using 6 g of EPA in combination with at least one 
mood stabilizer in patients diagnosed with rapidly cycling bipolar disorder also found 
no benefit over placebo on reducing mania on YMRS (Keck et al., 2006). Further, a 
small RCT with 15 participants, using 4.4 g of EPA and 6.6 g of DHA/day adjuvantly 
with 20 mg/kg/day of valproate also revealed no benefit over placebo for reducing 
mania (Chiu et al., 2005). Two open-label studies have been published on omega-3s 
in pediatric bipolar disorder: an adjuvancy study and a monotherapy study. Clayton 
et al. (2009) conducted a 6-week study involving 18 adolescents with BD I or II using 
omega-3 (DHA 1560 mg and EPA 360 mg per day) and found significantly reduced 
clinician-rated mania and depression from baseline. A study by Wozniak and 
colleagues (2007) also revealed significant reductions on YMRS (d= 0.90) and BPRS 
(d= 0.83) compared to baseline using 1290 mg-4300mg of fish oil in 20 adolescents 
who met DSM-IV-TR criteria for BP and had a YMRS score of >15. 
Current evidence weakly supports use of omega-3 preparations in 
combination with conventional psychotropic medications in the depressive phase of 
BD; however, omega-3s probably have little or no clinical effect in attenuating mania. 
Although considered a very safe intervention, rare cases of increased bleeding 
times, but not increased risk of bleeding, have been reported in patients taking 
aspirin or anti-coagulants together with omega-3s (Sarris et al., 2009b).  
 
Amino acids 
Bipolar patients may be genetically susceptible to mood swings when certain amino 
acids or other micronutrients are lacking in the diet (Kaplan et al., 2007). Findings of 
two small RCTs suggest that certain branched-chain amino acids (BCAA) may 
rapidly improve acute mania by interfering with synthesis of norepinephrine and 
dopamine (Scarna et al., 2003). In one study 25 bipolar patients randomized to a 
blend of the branched-chain amino acids leucine, isoleucine and valine (60 g/day) 
versus placebo experienced significant reductions in the severity of mania within six 
hours (Scarna et al., 2003). Improvements in mania were sustained with repeated 
administration of the amino acid drink. N-acetylcysteine (NAC) is an amino acid with 
strong anti-oxidant properties that has been used to treat a range of inflammatory 
disorders (Dodd et al., 2008). In novel research, Berk and colleagues (2008) 
conducted a 24-week RCT using 1 g of NAC versus placebo in a sample of 75 
participants stable on medication or therapy with DSM-IV-TR diagnosed BD I or BD 
II. Results revealed that NAC significantly reduced bipolar depression on the 
Montgomery Depression Rating Scale (MADRS) (Montgomery & Asberg, 1979) and 
the Bipolar Depression Rating Scale with strong effect sizes respectively of 1.04 and 
0.83. No significant effect was found on mania outcomes, although it should be 
noted that YMRS mania levels were very low, thus significant changes were unlikely 
to occur. 
Restricting or excluding L-tryptophan from the diet may increase the 
susceptibility of bipolar patients to depressive mood swings; however, research 
findings to date are highly inconsistent (Bell et al., 2005). L-tryptophan has 
demonstrated beneficial effects in reducing depressed mood in people with unipolar 
depression (Sarris et al., 2009b). A 1985 2-week study used 12 g of the amino acid 
in 24 participants with mania (Chouinard et al., 1985). In this two-phase trial, 
measures of mania were significantly reduced with L-tryptophan on Clinical Global 






Inventory (d= 1.47) in the initial open phase, and continued but lessened during the 
controlled phase. 
 
Vitamins and minerals 
Magnesium may be an effective adjuvant therapy for treatment of acute mania or 
rapidly cycling BD. In a small open trial oral magnesium supplementation had 
comparable efficacy to lithium in rapid cycling bipolar patients (Chiounard et al., 
1990). In a small case series intravenous magnesium sulfate used as an adjuvant 
with lithium, haloperidol and a benzodiazepine in bipolar patients with severe 
treatment-resistant mania resulted in significant improvement in global functioning 
and reduction in the severity of mania (Heiden et al., 1999). Many patients treated 
with intravenous magnesium sulfate remained stable on lower doses of conventional 
medications. An RCT used 375 mg of magnesium oxide versus glucose placebo 
over 16 weeks in 20 participants with prior DSM-IV diagnosed mania and > 6 months 
on a stable mood stabilizer (verapamil). Results revealed a significant reduction on 
mania compared to control at week 16 (Giannini et al., 2000).  
 Two clinical trials using inositol (12 g and 5-20 g) adjuvantly with maintenance 
doses of mood stabilizers have been conducted. Both RCTs (Chengappa et al., 
2000; Evins et al., 2006) had small samples (n=24 and 26, respectively) and were 
conducted over six weeks. Results in both studies revealed no significant differences 
between inositol or placebo on depression or mania outcome scales. Clinical 
response however was noted in 12/21 participants taking inositol on pooled results of 
both studies on HAMD and MADRS.  
 Folic acid has been studied in one early trial as an adjuvant in BD patients 
stabilized on lithium. A 52-week RCT by Coppen and colleagues (1986) compared 
200 mcg of folic acid versus placebo tablets in 102 participants taking lithium. 
Results revealed that the completers in the folic acid group (n=41) had significantly 
lower BDI scores than the control group, with a strong effect size of 1.07. 
A proprietary 36-ingredient formula of vitamins and minerals may significantly 
reduce symptoms of mania, depressed mood and psychosis in bipolar patients when 
taken alone or used adjunctively with conventional mood stabilizers. Six out of 
eleven completers had clinical response with strong effect sizes (HAMD: 1.70, 
YMRS: 0.83). In one case series 11 bipolar patients who completed a 6-month 
protocol were able to reduce their conventional mood stabilizers by half while 
improving clinically (Kaplan et al., 2001). In another case series, 13 out of 19 bipolar 
patients who continued on the nutrient formula remained stable after discontinuing 
conventional mood stabilizers (Simmons, 2003). Some patients stopped taking the 
formula because of nausea and diarrhea and three patients resumed conventional 
mood stabilizers because of recurring manic symptoms. Researchers believe the 
formula works by correcting metabolic errors that result in bipolar-like symptoms in 
genetically predisposed individuals when certain micronutrients are deficient in the 
diet (Popper et al., 2001; Kaplan et al., 2001).  
Choline is necessary for the biosynthesis of acetylcholine, and abnormal low 
brain levels of acetylcholine may contribute to some cases of mania (Leiva, 1990). 
Findings of a small open study suggest that phosphatidylcholine (15 gm to 30 
gm/day) may reduce the severity of mania and depressed mood in bipolar patients 
(Stoll et al., 1996). It should be noted that two non-responders were also taking 
hypermetabolic doses of thyroid medication. Clinical improvement correlated with 
increased intensity of the basal ganglia choline signal as measured on proton 






magnetic resonance imaging (MRI). The effect of choline on depressive symptoms 
was variable (Stoll et al., 1996).  
Findings of a small open study suggest that patients diagnosed with BD who 
exhibit mania or depressed mood may respond to low doses (50 micrograms with 
each meal) of a natural lithium preparation (Fierro, 1988). Post-treatment serum 
lithium levels were undetectable in patients who responded to trace lithium 
supplementation.  
Findings from animal research and a small open study suggest that bipolar 
patients who take potassium 20 mEq twice daily with their conventional lithium 
therapy experience fewer side effects, including tremor, compared to patients who 
take lithium alone (Tripuraneni, 1990). No changes in serum lithium levels were 
reported in patients taking potassium. Pending confirmation of these findings by a 
larger double-blind trial, potassium supplementation may provide a safe, cost-
effective integrative approach for the management of bipolar patients who are unable 
to tolerate therapeutic doses of lithium due to tremor and other adverse effects 
(patients who have cardiac arrhythmias or are taking anti-arrhythmic medications 




Findings of a large 12-week placebo-controlled trial involving  a sample of 58 BD 
patients suggest that a proprietary Chinese compound herbal formula consisting of 
at least 11 herbs may enhance the effect of conventional mood stabilizers for 
treatment of the depressive phase of BD (Zhang et al., 2005). Bipolar depressed (but 
not manic) patients randomized to the herbal formula plus carbamazepine 
experienced significantly greater reductions in the severity of depressed mood 
compared to matched patients receiving a mood stabilizer only. These findings were 
replicated in a subsequent study, which confirmed that bipolar depressed patients 
treated with the herbal formula improved more than patients treated with a placebo, 
with a strong effect size (d=0.98) between treatments at week 12 (Zhang et al., 
2007).  






Table 2. Adjuvant nutrient interventions in Bipolar Disorder 
Intervention BD (depression)  BD (mania) Level of evidence 
 









































      B            C 
 
         =  Potential use in bipolar mania or bipolar depression    
NK=  Not known    
BCAA= Branched-chain amino acids  
A=  Several repeated clinical trials (with some positive results)    
B=  Unreplicated positive study   
C=  Small study, or inconclusive results  




Early studies suggested that the Ayurvedic plant medicine Rauwolfia serpentina and 
an alkaloid derivative, reserpine, was an effective treatment of BD by augmenting the 
anti-manic efficacy of lithium without risk of toxic interactions (Bacher & Lewis, 1979; 
Berlant, 1986). However, therapeutic use of this plant in various Western countries is 
restricted due to the presence of the alkaloid reserpine, which has potent effects on 
blood pressure and the CNS. A previous review published in JACM (Sarris et al., 
2009d) of placebo-controlled trials comparing Hypericum perforatum to placebo or 
conventional antidepressants concluded that the herbal medicine might be beneficial 
for mild to moderate depressive symptoms. Although this herb may potentially be 
beneficial in the depressive phase of BD, no studies on this have been conducted to 
date. Several case reports of mania induction with St. John’s wort (Moses & 
Mallinger, 2000; Fahmi et al., 2002) and potential serious interactions with many 
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The art of acupuncture has been used for millennia in Eastern cultures for treating a 
range of illnesses including mental disorders. Research in the area of unipolar 
depression has revealed mixed but mainly positive results. A two-part clinical trial has 
been conducted examining the safety, effectiveness, and acceptability of adjunctive 
acupuncture in the treatment of hypomania and depression associated with bipolar 
disorder (Dennehy et al., 2009). In the first study 20 patients experiencing symptoms 
of mood elevation were given targeted acupuncture (points specific to symptoms) 
versus ‘sham’ acupuncture (non-acupoint needling) over 12 weeks, while for 26 
patients experiencing symptoms of depression targeted acupuncture was compared 
to (off the meridian) acupuncture for nonpsychiatric health concerns over 8 weeks. 
While the results revealed that acupuncture treatment reduced symptoms (mood 
elevation in Study I, depression in Study II), a non-significant difference occurred 






Bipolar disorder may potentially be effectively managed using an integrative 
approach. While use of select nutrients combined with medication in BD is supported 
by strong evidence, to date herbal medicines have not been adequately evaluated. 
Surprisingly, other CAM modalities potentially used by bipolar patients are currently 
not supported by clinical trial evidence. Interventions such as manual therapies (e.g. 
acupuncture, massage), dietary modification, meditation, or mind-body practices (e.g. 
tai chi or yoga) are supported by some evidence in psychiatric disorders; however, 
their beneficial effects in patients diagnosed with BD are currently unknown or 
inconclusive. However, while these interventions may not be ‘directly effective’ in the 
treatment of BD, they have general beneficial effects on physical and mental health 
and quality of life, are probably associated with reduced stress and improved 
functioning in general, and thus may potentially reduce the severity of bipolar 
symptoms and risk of relapse. We hope this article illuminates the current evidence of 
CAM for the integrative management of BD, and may encourage further discussion 
and research in this area. 
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Despite progress in treatment options in the last century, the results of 
pharmacological treatment of schizophrenia are frequently unsatisfactory. Therefore 
some patients use natural medicines, although it is unclear whether natural 
medicines are effective and safe. We assessed the evidence for natural medicines 
with and without antipsychotics in treating symptoms or reducing side effects of 
antipsychotics in schizophrenia. 
 
Method: 




105 RCTs were identified. Evidence was found for glycine, sarcosine, NAC, some 
Chinese and ayurvedic herbs, ginkgo biloba, estradiol and vitamin B6 for improving 
symptoms of schizophrenia when added to antipsychotics (glycine not when added to 
clozapine). Inconclusive or no evidence was found for omega-3 fatty acids, D-serine, 
D-alanine, D-cycloserine, B vitamins, vitamin C, dehydroepiandrosteron (DHEA), 
pregnenolone (PREG), inositol, gamma-hydroxybutyrate (GHB) and des-tyr-gamma-
endorphin when added to antipsychotics. Omega-3 fatty acids without antipsychotics 
might be beneficial in the prevention of schizophrenia. In one large study, ayurvedic 
herbs seemed effective without antipsychotics. Other agents without antipsychotics 
(vitamin B3, vitamin C, sarcosine, glycine, Protilerin) were not effective or had only 
been tested in single or small trials. Ginkgo and vitamin B6 seemed to be effective in 
reducing side effects of antipsychotics (tardive dyskinesia and akathisia). The 
evidence for reducing side effects of antipsychotics by omega-3 fatty acids, 
melatonin and DHEA appeared to be inconclusive. All natural agents produced only 
mild or no side effects. 
 
Conclusion: 
High-quality research on natural medicines for schizophrenia is scarce. However, 
there is emerging evidence for improved outcome for glycine, sarcosine, NAC, some 
Chinese and Ayurvedic herbs, ginkgo biloba, estradiol and vitamin B6, all with only 
mild or no side effects. Most study samples are small, the study periods are generally 
short, the studies only cover a modest part of the world’s population and most results 
need replication. 








Despite much progress in treatment options in the last century, the pharmacological 
treatment of schizophrenia and other psychotic disorders is often unsatisfactory as 
expressed in long-lasting positive, negative, cognitive and affective symptoms and 
problems in social and occupational functioning. Psychotic symptoms are often only 
partially resolved (Rummel-Kluge, 2010), and especially cognitive and negative 
symptoms seem refractory to present pharmacological options (Buckley & Stahl, 
2007). Newer (second-generation) antipsychotics are in general equally effective as 
first-generation antipsychotics in treating positive symptoms, the promise of greater 
efficacy against negative symptoms of newer antipsychotics has not been fulfilled 
(Leucht et al., 2012). Many patients continue to suffer persistent symptoms and 
symptom relapses during treatment with antipsychotics, particularly when they fail to 
adhere to prescribed medications (Van Os & Kapur, 2009). Besides, patients often 
experience undesired treatment (side) effects, most commonly weight gain, sexual 
dysfunction, glycaemic and lipid dysfunction, extra-pyramidal symptoms (EPS) and 
sedation (Stahl, 2008). 
As a result, many patients with psychotic disorders use non-conventional 
medicines or treatments in the hope of decreasing undesired treatment effects or in 
search for a more successful recovery. Nonconventional medicine includes lifestyle 
changes, and complementary and alternative medicine (CAM) (Hoenders et al., 
2013). Complementary medicine comprises forms of diagnostics, treatments and 
prevention strategies that are based on theories accepted in biomedicine and are 
substantiated by some scientific evidence (two or more RCTs), but for various 
reasons - cultural or practical - do not form part of biomedicine (Hoenders et al., 
2011). Alternative medicine comprises forms of diagnostics, treatments and 
prevention strategies that make use of other than the basic concepts of biomedicine. 
Sofar, there is little proof for the efficacy of the latter treatments and / or there is 
considerable controversy about the scientific validation (Lake, 2007). Part of 
complementary medicine refers to natural medicine: using only agents that are 
produced by a living organism (plant, tree, seed, vegetable, fruit, animal, human), 
instead of non-natural (i.e. chemical) agents: agents that cannot be found in nature 
and that can only be obtained from laboratory experiments (Porter, 1998). Some 
patients prefer natural medicines as they assume that natural is better than chemical 
and causes fewer side effects. This is obviously not (always) true as the natural 
environment contains agents that can be toxic to humans and it is the molecular 
structure and dosage of a substance rather than its source that determines its effect 
on human health (Topliss et al., 2002). Besides, herbal medicines can cause 
undesired effects including interactions with prescription medication (Ernst, 2003a). 
  Hazra et al. (2010) reported a lifetime and one-year prevalence rate of CAM 
use of 88% and 68% respectively in Canadian psychotic outpatients. A major 
difficulty these patients encounter is the heterogeneity in treatment options with CAM, 
ranging from possibly interesting agents to useless, or even dangerous, ones (Ernst, 
2003a). For instance, the concomitant use of antipsychotics and Chinese herbs has 
been found to induce significantly improved clinical outcomes compared to only 
antipsychotics. However, a small but significant number of patients treated 
concomitantly with Chinese herbs have a greater risk of developing worse outcomes 
(Zhang, 2011).  
In recent years the preferences and views of patients have received more 
attention in making choices in treatment (e.g. shared decision making (Elwyn et al., 






2000) and ‘patient-centered care’ (Gill, 2013)). The introduction of patient’s choice in 
deciding which antipsychotic to choose has been proposed (Morrison et al., 2012). 
However, it is difficult for both patients and doctors to make informed decisions, in the 
absence of reliable information on the emerging evidence for CAM or natural 
medicine. Considering its high usage in psychotic patients, there is an urgent need 
for objective information. 
The aim of this paper is to provide an overview of evidence for the efficacy and 
safety of most used and most studied natural medicines for symptoms of 
schizophrenia or other psychotics disorders, or for side effects of antipsychotics. As 
the majority of psychosis is related to schizophrenia, in this paper we will use 





Literature search and study selection 
Studies were identified by a literature search in Medline, PsycINFO, CINAHL and 
Cochrane, through April 2013. The search terms (MeSH Thesaurus and free search 
terms) used were: schizophrenia, psychosis, psychoses, psychotic (disorder), 
schizophreniform AND (R)CT, review AND complementary medicines, herbs, 
vitamins, supplements (search terms, in alphabetical order: ascorbic acid, Ayurveda, 
brahmyadiyoga, branched-chain amino acids [BCAA], Chinese herbs, D-cycloserine, 
D-serine, dehydroepiandrosterone [DHEA], DHA, EPA, estradiol, fatty acid, fish oil, 
folic acid, ginkgo biloba, glycine, manganese, methylfolate, N-acetylcysteine, N-
methylglycine, niacine, omega-3, rauwolfia serpentina, sarcosine, sarsasapogenin, 
selenium, TCM, vitamin B complex, vitamin B3, vitamin C, vitamin D, vitamin E, zinc). 
We used search terms for the most used and most researched agents. A total of 
1204 hits (abstracts) were retrieved after systematic deduplication (table 1).  
 
 
Table 1. Sources of literature retrieval and included number of studies before and after 
duplicate findings were removed.  
 
Database Trials  Reviews Total 
Medline 432 541 973 
Cinahl 55 16 71 
PsycINFO 200 97 297 
Cochrane 166 15 181 
    
Total 853 669 1522 
Total deduplicated     1204 
 
 
Next, abstracts about the following topics were included: (i) effects of natural 
medicines on schizophrenia and psychotic symptoms, (ii) effects of natural medicines 
for side effects of antipsychotics, (iii) effects of natural medicines in the prevention of 
the development of psychotic disorders. Exclusion criteria were: (i) non-randomized 
(controlled) trials, (ii) studies that explore the effects of natural medicines (i.e. 
mechanism studies), (iii) animal studies, (iv) other disorders or no disorder, (v) 
conference abstracts, (vi) book chapters, (vii) clinical trial registrations, (viii) 
comments, addenda, corrigenda and letters, (ix) papers in non-English languages 
(e.g. Chinese, Japanese, Hebrew, German and Spanish), and (x) duplicate hits which 
had not been removed systematically. Second, two co-authors (HJRH and AABV) 






independently indicated whether papers - based on the abstracts - should (possibly) 
be included or not. Consultation followed about dubious cases and in case of 
discordance. Thereupon, 386 studies remained of which the full papers were 
retrieved and studied. Of these, another 151 were excluded (81 were not a RCT and 
70 for different reasons). A flow chart of the study selection is presented in Fig. 1. We 
found 122 reviews and checked whether we had included the RCTs in their reference 
lists that matched our inclusion criteria. We added 8 RCTs with a Jadad score of 3 or 
higher that were not found through our original search. 16 RCTs were excluded 
because of a Jadad score less than 3. Finally, 105 randomized controlled trials were 
included. The reviews are not shown in our results table, but their conclusions will be 
contrasted to our results in the discussion section. 
 
Risk of bias assessment 
Two assessors (co-authors AABV and NKV) independently rated the methodological 
quality of the RCTs found in our original search and those found by checking the 
reference lists of the reviews. We used the Jadad scale for reporting randomized 
controlled trials (Jadad et al., 1996). This scale consists of three questions about the 
methodological quality: whether the study is described as (i) randomized, (ii) double-
blind, and (iii) whether (non-) completers are adequately described. The first two 
questions are each followed by two sub-questions, for which either one point extra 
may be gained or lost, the total score of the risk of bias assessment thus amounting 
to a maximum of 5 points (see table 2). RCTs scoring 3 points or higher were 
included in the study, under the condition that the three main questions were 
assigned 1 point each. Interrater agreement on the Jadad scores between the 
assessors before consensus discussion amounted to 0.80. Besides, HJRH 
independently rated a random selection of 17 papers (15%) from the selected RCTs. 
Interrater agreement of all three authors was 0.71. Any disagreements between the 
assessors on the Jadad scoring were resolved through consensus discussion 
between these three authors. The 105 RCTs exceeding the consensus Jadad score 
of 3 were included for the current review and are presented in table 3. Based on the 
hypothesized mechanism, they were divided in six groups: omega-3 fatty acids, B 
vitamins, eastern herbs, glutamate agonists, antioxidants, and ‘other substances’. 
For each of the 105 studies that fulfilled the previously mentioned selection 
criteria the following assessments were made: which natural agent was used; was 
this combined with antipsychotics, and if yes, which antipsychotics and what dosage; 
the effect of the natural agent on negative, positive, cognitive, depressive and 
general symptoms and on side effects of antipsychotics; possible adverse side 
effects of the natural agent; number of participants in the study; control group 
characteristics; number of drop-outs; study duration; Jadad score (results are shown 

















Figure 1: flow chart 






Table 2. Jadad scale for assessing the quality of randomized controlled trials as expressed by 
a score from 0 (low quality) to 5 (high quality) (Jadad et al., 1996). 
 
 
Item Description Scoring 
Randomization Was the study described as randomized (this includes the use of 
words such as randomly, random, and randomization)? 
1 point 
 Was the method to generate the sequence of randomization 
described and appropriate (table of random numbers, computer 
generated, etc)? 
+ 1 point 
 Was the method to generate the sequence of randomization 
described inappropriate (patients were allocated alternately, or 
according to date of birth, hospital number, etc.)? 
- 1 point 
Blinding Was the study described as double blind? 1 point 
 Was the method of double blinding described and was it appropriate 
(identical placebo, active placebo, dummy, etc.)?  
+ 1 point 
 Was the study described as double blind but the method of blinding 
was inappropriate (e.g., comparison of tablet vs. injection with no 
double dummy)? 
- 1 point 
An account of all 
patients  






A total of 105 RCTs on the effectiveness of natural medicines for schizophrenia that 
matched our inclusion criteria were identified (see Fig. 1). Based on the hypothesized 
mechanism, these RCTs were divided into six groups (Table 3).  
 
(i) Omega-3 fatty acids 
Polyunsaturated fatty acids (PUFA) are essential for brain functioning (Tsalamanios 
et al., 2006). They have multiple important biological roles, including membrane 
functioning, neurotransmission, signal transduction, and eicosanoid synthesis. A 
growing body of research suggests that PUFA level reduction is related to 
schizophrenia (Berger et al., 2006). Concordant with these findings, omega-3 PUFA 
may have positive effects in the treatment and prevention of schizophrenia (Peet, 
2008; Emsly et al., 2003; Freeman et al., 2006; Amminger et al., 2010). 
Ten RCTs were included (table 3). In studies combining antipsychotics with 
omega-3 PUFA, one (out of seven) studies on negative symptoms in schizophrenia 
found some positive effect (in patients using clozapine), three (out of seven) found 
some positive effect on positive symptoms, one (out of three) on cognitive symptoms, 
none (out of three) on depressive symptoms, and five (out of nine) on general 
functioning. Two (out of two) studies on omega-3 PUFA without antipsychotics 
reported a decrease of positive symptoms, and one of these reported less use of 
antipsychotics in the second phase of the trial compared to the control group. Three 
(out of six) reported less side effects of antipsychotics (EPS and or dyskinesia). Two 
studies reported less use of antipsychotics in the omega-3 PUFA group. Some non-
severe side effects of omega-3 PUFA were reported, such as mild gastrointestinal 
problems and increased bleeding time. 
 
(ii) Glutamate  
Besides dopamine, glutamate is thought to play a role in schizophrenia (Tsai & Lin, 
2010). Based on the hypothesis that the glutamatergic system may be compromised 






in schizophrenia, the use of N-methyl-D-aspartate (NMDA) receptor modulators 
may compensate for alterations in the glutamate system (Singh & Singh, 2011). 
Agents with co-agonistic properties to (glutaminergic) NMDA receptors are: glycine 
(full, endogenous agonist), D-serine (full, endogenous agonist), D-cycloserine 
(partial, exogenous agonist), D-alanine (partial, endogenous agonist) and sarcosine 
(sarcosine = methyl-glycine, acting as a reuptake inhibitor of glycine and source of 
glycine). The glycine transporter-1 (GlyT-1) plays a pivotal role in maintaining the 
concentration of glycine within synapses at a sub-saturating level. Sarcosine is a 
GlyT-1 inhibitor meaning that the presence of sarcosine results in increased glycine 
concentrations. Lower cerebral glycine levels are suggested to be found in patients 
with schizophrenia. The administration of sarcosine is therefore proposed to relief 
symptoms of schizophrenia when added to non-clozapine antipsychotics (Lane et al., 
2006). Whereas the mechanisms of N-acetylcysteine (NAC) are only beginning to be 
understood, it is likely that NAC is exerting benefits beyond being a precursor to the 
antioxidant glutathione, also modulating glutamatergic, neurotropic and inflammatory 
pathways (Dean et al., 2011). 
We included ten RCTs on glycine, six on D-serine, nine on D-cycloserine, one 
on D-alanine, five on sarcosine and two on NAC.  
Glycine improved negative symptoms when combined with antipsychotics in 
six (out of seven) studies, but not when combined with clozapine (two studies). 
Positive symptoms improved in one study, worsened in another (with clozapine) and 
did not change in six (out of eight) studies; cognitive improvement was shown in four, 
and no change in two (out of six) studies; depressive symptoms diminished in five 
(out of five) studies; general improvement was shown in four (out of nine) studies. 
One (out of one) small study (N=8) on glycine suggested improvement of negative as 
well as positive, depressive and general symptoms when provided without 
concomitant antipsychotic drugs. No severe side effects of glycine were reported, 
except some mild gastrointestinal complaints.  
D-serine was shown to improve positive, negative, cognitive and general 
symptoms in two (out of six) studies when added to antipsychotics. The three largest 
- most recent - studies with highest Jadad score did not show a significant effect of D-
serine on any symptom. In five out of six studies D-serine did not improve side effects 
of antipsychotics. Insomnia, weight gain, palpitations and other side effects of D-
serine were reported.  
D-cycloserine showed an improvement of negative symptoms in three (out of 
eight) studies when added to antipsychotics; some improvement of positive 
symptoms in one and worsening in another study (out of seven); little or no effect on 
cognitive, depressive or general symptoms and no improvement of side effects of 
antipsychotics was shown. Five (out of five) studies found no improvement of side 
effects of antipsychotics. No studies were reported on D-cycloserine without 
antipsychotics. No side effects of D-cycloserine were reported.  
The only study on D-alanine reported positive effects when added to 
antipsychotics on negative, positive, cognitive and general symptoms, but no effect 
on depressive symptoms. No effect on side effects of antipsychotics, was found. Side 
effects of D-alanine (insomnia and nausea) were reported. 
All three studies combining sarcosine with antipsychotics (not clozapine) found 
positive effects on almost all symptom domains. When combined with clozapine (two 
studies) no treatment effects were found. Also when given without antipsychotics 
(one study), sarcosine did not improve symptoms. Sarcosine did not improve side 






effects of antipsychotics in four out of four studies. Adverse effects of sarcosine 
included weight gain, insomnia, palpitations, dizziness, and sedation. 
One large study (N=140) on NAC added to antipsychotics reported improved 
positive symptoms but no improvement of negative cognitive or general symptoms 
and no improvement of side effects of antipsychotics, whereas one small study (N=9) 
found some improvement of cognitive symptoms. No adverse effects were reported. 
 
(iii) Eastern (Chinese and Ayurvedic) herbs  
Eastern herbs are provided in the context of treatment with complete systems of 
medicine that evolved over thousands of years, such as traditional Chinese medicine 
(TCM) and Ayurveda. These treatments consist of a treatment including herbal 
compounds, massage, diet, acupuncture and the regulation of lifestyle (Clifford, 
2003; Kaptchuck, 2000). Most clinical studies have been performed on acupuncture 
(outside the scope of this review) and on the herbal compounds of these medical 
systems. 
Many studies on these eastern herbs were found, but only five got a Jadad 
score of 3 or higher. One old study (1956) on resperpine found ‘clinical improvement’ 
after 11 weeks compared to placebo, in 80 patients not treated with antipsychotics, 
but with electroconvulsice therapy (ECT). Several side effects were reported: nasal 
congestion, periorbital edema, diarrhea, epigastric pain, salivating, pseudo-
Parkisonian state, severe headaches, deep pains in limbs. Three (out of four) more 
recent studies found significant effects on general functioning of adding Ayurvedic 
herbs (bacopa monnieri and nardostachys jatamansi; one study) or Chinese herbs 
(mixture of 13 Chinese herbs; 2 studies) to antipsychotics. The Ayurvedic herbs were 
compared to 10 mg of olanzapine in a 76 weeks non-inferiority study including 200 
patients. It found no statistically significant difference between both groups looking at 
improvement of positive, negative and general symptoms. The Ayurvedic group 
developed less weight gain. Two large studies by Chen (2008, N=200; 2009, N=120) 
on a mixture of 13 Chinese herbs found improvement of general functioning (both 
studies) and cognitive and depressive symptoms (in one of two studies) when added 
to risperidone (max 8 mg/day). One study (Xiao et al., 2011) found no effect of 
Chinese herb sarsasapogenin compared to placebo when added to risperidone on 
positive, negative, cognitive or general symptoms in 90 patients during 8 weeks. 
Many different non-severe adverse effects were reported (e.g. gastrointestinal, 
drowsiness and insomnia). 
(iv) B vitamins  
In his paper in Science, Nobel laureate Linus Pauling proposed a way of 
understanding and treating psychiatric disorders by correcting malfunctions in the 
body’s chemistry, calling this approach ‘orthomolecular psychiatry’ (Pauling, 1968). 
His idea was partly built on studies by Osmond (1962) and Hoffer (1963; 1964) 
reporting good results when treating patients with schizophrenia with large doses of 
vitamins, especially vitamin B3. Hoffer published two more positive results with B 
vitamins (Hoffer, 1971; Hoffer, 1972). However, attempts to replicate his findings 
seem to have failed (Wittkopp, 1972; Ban, 1975). The contradicting findings may be 
explained since vitamine B is suggested to be only effective in early psychosis and 
not in chronic schizophrenia (Hoffer, 1965). One of the proposed mechanisms is 
abnormal one-carbon metabolism due to vitamin deficiencies (Hoffer, 2008). Variable 
levels of components of one-carbon metabolism (folic acid and vitamin B12) and 
consequently altered levels of homocysteine and phospholipid docosahexaenoic acid 






(DHA) have been reported, in medicated patients as well as medication-naïve first-
episode psychotic patients (Kale et al., 2009). Folate status in patients with 
schizophrenia correlates inversely with negative symptoms (Goff et al., 2004). 
 We found 20 RCTs on B vitamins added to antipsychotics including one on B3 
without antipsychotics. B1 showed some effect on general functioning in one study 
and on positive and negative symptoms in another. B3 showed improved general 
functioning in three (out of nine) studies. B6 improved general functioning in four (out 
of five) studies. In one study general functioning improved after administration of B9. 
One study reported no effect of B11. Another study showed a positive effect of 
combined B6, B9 and B12 on positive, negative and cognitive symptoms. B6 
improved extra-pyramidal side effects of drugs (tardive dyskinesia (TD) and 
neuroleptic induced akathisia (NIA)) in four (out of four) studies. In one study on B3 in 
57 children without antipsychotics, cognition and general functioning did not improve 
after six months. Most B vitamins induced modest side effects, especially skin 
flushing and abnormal liver function induced by vitamin B3 and B6. 
 
(v) Antioxidants   
Oxygen is essential in life, but it also generates reactive molecules (called free 
radicals) throughout the body. These free radicals are potentially harmful as they can 
damage essential molecules such as DNA and the enzymes necessary for proper 
functioning of cells. Antioxidants may capture these reactive free radicals and convert 
them back to less reactive forms of the molecules (Singh et al., 2010). There is a 
growing body of evidence that oxidative damage (maybe due to defective enzyme 
systems) may contribute to the course and outcome of schizophrenia (Mahadik & 
Mukherjee, 1996; Fendri et al., 2006; Mahadik, Evans & Lal, 2001) and is already 
present in patients with first episode psychosis (Flatow et al., 2013).  
Ascorbic acid (vitamin C) is an antioxidant vitamin and plays an important role 
in protecting free radical-induced damage in the body. It is present in brain tissue and 
dopamine-dominant areas in higher concentrations compared to other organs 
(Harrison & May, 2009). Ginkgo biloba, an extract of the leaves of the ginkgo biloba 
tree) is also suggested to have antioxidant properties (Maclennan et al., 2002) and 
has been found to improve brain circulation at the microvascular level (Kubota et al., 
2001; Sun et al., 2003; Yan et al., 2008), therefore it might improve outcome in 
schizophrenia.  
Long-term treatment with antipsychotics is associated with a variety of 
movement disorders, including tardive dyskinesia (TD). Both dopamine-receptor 
super-sensitivity and oxidative stress-induced neurotoxicity in the nigrostriatal system 
are suggested to be involved in its pathogenesis (Kulkarni & Naidu, 2003). The pineal 
hormone melatonin is a potent antioxidant and attenuates dopaminergic activity in 
the striatum and dopamine release from the hypothalamus (Shamir, 2001). Thus, 
treatment with antioxidative agents may have a beneficial effect for both treatment of 
psychotic symptoms as well as prevention of TD. Vitamin E has been suggested for 
TD because it is a lipid-soluble antioxidant that decreases free radical formation 
(Herrera, 2001). 
 We found 2 RCTs on vitamin C: one found improved general functioning and 
reduced side effects (reduced serum malondialdehyde (MDA); a lipid peroxidation 
product) when added to olanzapine (10 mg), quetiapine (200 mg) or ziprasidone (40 
mg) after 8 weeks. One study without antipsychotics found no effect on cognition or 
motor functioning after 10 days. Both studies reported no side effects of vitamin C. 
Three out of four studies on ginkgo biloba found improved positive symptoms, two of 






three improved general functioning, four out of four no improvement of negative 
symptoms when added to antipsychotics. All four improved side effects of 
antipsychotics (behavioral toxicity, symtoms of nervous system, TD). No side effects 
of ginkgo were reported. One study of melatonin for tardive dyskinesia reported a 
decrease of TD and no side effects. Six (out of twelve) studies on vitamin E for 
reducing extra-pyramidal symptoms, while using antipsychotics, showed a decrease 
of TD (5 studies) and EPS (1 study), those with shorter duration of TD seemed to 
improve more; no side effects of vitamin E were reported, except mild diarrhea in two 
studies. Five (out of five) reported no effect on general functioning. 
 
(vi) Other substances 
Agents that did not fit in the five categories mentioned above were classified in this 
residual category. Sixteen high-quality RCTs have been performed on multivitamins, 
hormones (dehydroepiandrosteron (DHEA), pregnenolone (PREG), estradiol, 
protilerin), inositol, gamma-hydroxybutyrate (GHB) and des-tyr-gamma-endorphin.  
Three (out of five) studies on DHEA added to antipsychotics, showed improvement of 
negative symptoms, one (out of three) on positive symptoms, one (out of two) on 
cognition, two (out of three) on depression and one (out of three) on general 
functioning. Two (out of four) improved side effects of drugs. One (out of one) small 
study (N=12) on protilerin (thyrotropin releasing hormone) found improved general 
functioning. Three (out of three) studies on estradiol found improved general 
functioning, two (out of three) improved positive symptoms, one out of one improved 
cognition and none (out of three) improved negative symptoms. One (out of one) 
small study (N=14) on inositol found no effect on positive or negative symptoms. Two 
(out of two) studies on GHB found no general improvement. One (out of one) very 
small (N=6) study on des-tyr-gamma-endorphin found improvement on general and 






This review suggests emerging evidence for the beneficial effects of various natural 
medicines for schizophrenia. Glycine, sarcosine, NAC, some Chinese and Ayurvedic 
herbs, ginkgo biloba, estradiol and vitamin B6 seem effective for symptoms of 
schizophrenia when added to antipsychotics (glycine not when added to clozapine). 
We found inconclusive or absent evidence for omega-3 fatty acids, D-serine, D-
alanine, D-cycloserine, other B vitamins, vitamin C, DHEA, PREG, inositol, GHB and 
des-tyr-gamma-endorphin when added to antipsychotics. Omega-3 without 
antipsychotics might be beneficial in the prevention of schizophrenia. Reserpine 
without antipsychotics seemed effective in one old study. Ayurvedic herbs were 
reported to be as effective as olanzapine in a recent large study. Other agents as 
monotherapy (vitamin B3, vitamin C, sarcosine, glycine, protilerin) do not seem 
effective or have only been tested in single or small trials. For alleviation of side 
effects, ginkgo and vitamin B6 seem effective for TD and NIA. The evidence for 
diminishing some side effects of antipsychotics by omega-3, melatonin and DHEA is 
(still) inconclusive. With regard to the safety of natural compounds, all those were 
found to produce only mild or no side effects. However, most study samples were 
small, duration was generally short and studies were not designed or powered to 
identify side effects. They only covered a modest part of the globe’s geography and 






most studies need replication. 
There is promising but inconclusive evidence for improved outcome by 
omega-3 fatty acids combined with antipsychotics in schizophrenia, either on 
symptoms or on side effects of antipsychotics. Earlier reviews report similar 
conclusions (Tsalamanios et al., 2006; Irving et al., 2011; Boskovic et al., 2011). Most 
promising evidence for omega-3 is found for preventing transition to first episode 
psychosis in high-risk individuals. Amminger et al. (2010) found a reduction of the 
transition rate from 27.5% to 4.8% by prescribing omega-3 fatty acids in people 
thought to be at risk on developing schizophrenia. However, before conclusions can 
be drawn, replication of these findings are needed. A randomized controlled 
multicenter phase III clinical trial of omega-3 PUFA is now in progress (Amminger & 
McCorry, 2012). 
There is some evidence for glycine and sarcosine combined with 
antipsychotics in reducing negative symptoms, but not when combined with 
clozapine and also not as monotherapy. No evidence was found for D-cycloserine 
and D-serine on clinical improvement. Our results concur with two recent reviews 
(Tsai & Lin, 2010; Singh & Singh, 2011) and are in line with a recently updated 
Cochrane review (Tiihonen & Wahlbeck, 2006). Conflicting results from studies on 
drugs targeting the glutamate/NMDA system may be explained by complicated dose-
effect relationships, as recently found in studies with the Glyt-1 transporter antagonist 
bitopertin (Umbricht et al., 2013). 
By adding Chinese or Ayurvedic herbs to antipsychotics, general functioning 
seems to improve. Reserpine might improve outcome, but many side effects are 
reported. There is controversy concerning the frequently mentioned suggestion that 
resperine can induce depression (which lead to the monoamine hypothesis of 
depression; Baumeister et al., 2003). The Mundewadi (2008) study suggests equal 
effects of Ayurvedic medicine as monotherapy (bacopa monnieri and nardostachys 
jatamansi) compared to olanzapine but this study needs replication. A Cochrane 
review (Rathbone et al., 2007) states that ‘the results suggest that combining 
Chinese herbal medicine with antipsychotics is beneficial’. Another Cochrane review 
(Agarwal, 2010) concludes that ‘Ayurvedic medication may have some effects for 
treatment of schizophrenia, but has been evaluated only in a few small pioneering 
trials’. These results need further exploration and pharmacological differentation as 
Chinese and Ayurvedic herbs include hundreds of species combined in thousands of 
different combinations prescribed in a fundamentally different way than Western 
medicines are (Kaptchuck, 2000; Cliffort, 2003). The combined approach using 
knowledge from conventional medicine as well as Chinese medicine seems 
promising as it can lead to innovation (Van der Greef, 2011) and possibly to 
improved outcomes (Zhang, 2011). 
Inconsistent beneficial outcomes of studies on B vitamins were identified, 
especially when given as a combination of B1, B3, B6, B9 and/or B12 with  
antipsychotics. One review (Kleijnen and Knipschild,1991) concluded that no 
adequate support for efficacy of B vitamins in schizophrenia can be identified. Most 
studies with positive effects in our review, however, were published after 1990. Most 
convincing evidence was found for vitamin B6 added to antipsychotics, that appears 
to be effective in diminishing general psychopathology and TD. 
The findings on the efficacy of vitamin C for schizophrenia in only two RCTs 
were inconsistent, so definite conclusions cannot be drawn. The efficacy of vitamin E 
on TD remains inconclusive as only half of studies in our review found some positive 
result. Even so, a meta-analysis by Boskovic et al (2011) claimed: ’Vitamin E could 






potentially improve TD’. Perhaps this is due to the finding that those with a short 
history of TD tend to improve more than those with a longer history of TD. A 
Cochrane review in 2011 (Soares & McGrath) came to a similar conclusion: ‘small 
trials of limited quality suggest that vitamin E may protect against deterioration of TD. 
There is no evidence that vitamin E improves symptoms of this problematic and 
disfiguring condition once established’.  
Ginkgo biloba is a promising agent that seems to benefit patients with 
schizophrenia in several ways when added to antipsychotics. Several studies in this 
review suggest evidence for improving symptoms in various domains including effect 
on positive symptoms and the reduction of side effects of antipsychotics. Singh et al. 
concludes in another review: ‘ginkgo as add-on therapy ameliorates the symptoms of 
chronic schizophrenia’ (Singh et al., 2010).  
On melatonin, there is preliminary evidence from one study for an effect of 
melatonin to diminish TD. As TD is difficult to investigate with its fluctuating symptom 
severity, this finding needs replication before more definite conclusions can be 
drawn. 
Some inconsistent evidence was found on improved outcomes by several 
hormones (DHEA, PREG and testosterone) in schizophrenia, not allowing final 
conclusions. A Cochrane review on DHEA / testosterone (Elias & Kumar, 2007) 
arrived at a similar conclusion. For estradiol, a Cochrane review (Chua et al., 2005) 
found no convincing evidence over placebo. Since then, two more recent studies 
indicate that estradiol improves positive and general (but not negative) symptoms of 
schizophrenia when added to antipsychotics. Therefore, the use of estradiol in 
schizophrenia warrants further study. 
There is a need for more high-quality efficacy and (cost-) effectiveness 
research on natural medicines for schizophrenia. Especially, more large scale RCTs 
are needed, as most of the studies we included were performed with fewer than 50 
participants. Most obvious candidate agents are glycine, sarcosine, Chinese and 
Ayurvedic herbs, ginkgo biloba, vitamin B6, and omega-3 fatty acids.  
 
Limitations  
This review provides a general overview of the effects of different natural agents in 
treatment of schizophrenia and the treatment of undesired effects of antipsychotics. 
A limitation of this review is its wide scope, allowing only general descriptions of 
included studies in six domains. Second, we have only discussed the most well-
known and most studied natural agents, as identified with our search strategy. There 
may be more natural agents investigated for their effects on schizophrenia or on side 
effects of antipsychotics, that we did not identify. A third limitation is that our search 
excluded papers in other languages than English, although more studies exist, 
mainly in Japanese and Chinese. Presumably this might have led to an 
underestimation of the effects of some natural agents. For instance, Pataracchia 
(2008) reports on six double-blind trials showing positive results of combining vitamin 
B3 and vitamin C in the treatment of schizophrenia, but none were published in 
journals that are included in the databases we assessed. Saku (1991) reports in 
English about 45 studies (published in Chinese) on the efficacy of Chinese herbs for 
schizophrenia and psychosis, with and without modern antipsychotics. Beneficial 
results were reported in studies combining Chinese herbs with low dosage modern 
antipsychotics. Fourth, we do not know to which extent our findings are influenced by 
publication bias, for instance in favor of the publication of studies with positive results. 
Fifth, in the included RCTs there was not much specific information about the kind of 






conventional treatment that was continued during study: no information on frequency 
and type of counselling / therapy and no specific information on dosage and or type 
of antipsychotics (other than: ‘..was kept stable during this study..’). Also the dosage 
of the natural agents and the clinical details on included patients in the study was 
often not clear (e.g. first or chronic psychosis, treating symptoms or preventing 
relapse), limiting firm conclusions. Sixth, we only mentioned whether the effects in 
the studies were significant compared to the control groups. We did not show effect 
sizes, as the data published in many included studies did not allow to calculate effect 
sizes. Therefore, the clinical relevance of the results is debatable. Seventh, we did 
not set a time frame to our search, allowing the inclusion of some rather old studies 
(some dating more than 50 years ago). Older studies provide data in ways not 
always in agreement with more modern conventions, although we did assess the 
quality of all studies. Finally, for this last purpose, we used Jadad, not the Cochrane 
risk of bias assessment. Therefore possible bias may be less easily identified. 
 
Clinical implications 
Clinicians need to be aware of the frequent use of natural medicines without medical 
prescription, while some patients assume that natural is better than chemical and 
causes fewer side effects. Although beneficial effects may occur, this is certainly not 
always the case. Some natural compounds that may be suggested in treatment of 
schizophrenia are toxic to humans (Topliss et al., 2002), and some herbal medicines 
can cause side effects or can interact with medication (Ernst, 2003a). Only 3% of the 
user population is aware of the potential risks of interactions between herbs and 
prescription medication (Walter & Rey, 1999). So, from a medical perspective it is 
important to know what patients buy and try. Another concern is the reports on 
contamination of herbs, for instance from Asia, with heavy metals. However, after 
investigation of 334 samples, Harris et al. (2011) conclude that ’the vast majority 
(95%) of medications in this study contained levels of heavy metals or pesticides that 
would be of negligible concern’. Because of these concerns, patients want their 
medical doctors to advice them on complementary (or natural) medicines (Gray et al., 
1998; Hoenders et al., 2006). The World Health Organization (World Health 
Organization, 2003) and European Parliament (EP, 1997) have advised their 
member states to: ‘formulate national policy and regulation for the proper use of CAM 
and its integration into national health care systems in line with the provisions of the 
WHO strategies on Traditional Medicines; establish regulatory mechanisms to control 
the safety and quality of products and of CAM practice; create awareness about safe 
and effective CAM therapies among the public and consumers.’ Respecting patients’ 
opinions and informing them may also improve the therapeutic relationship 
(Stevingson, 2006) and thus enhance treatment outcome (Koenig, 2000; Nikles et al., 
2005; Gill, 2013), as this has been shown to be dependent on the quality of the 
therapeutic alliance (Wampold, 2001; Driessen et al., 2010; Baldwin et al., 2007).  
 
Further research 
Research in this area is hampered by a lack of funding. Less than 1% of research 
budget is spent on non-conventional medicine (Ernst, 2003b). It is unlikely that 
pharmaceutical companies will provide research grants for natural agents that cannot 
easily be patented. Other obstacles are national and international biodiversity rules 
and regulations and lack of standardization of formulation, production and 
identification of active ingredients from plant products (Ganzera et al., 2001). 
  







This review provides clinicians and patients with an overview of the results of high-
quality scientific studies on the efficacy and safety of natural medicines in 
schizophrenia and related psychoses. Some agents seem effective and safe. From a 
clinical perspective however, many questions remain unanswered: what dosage is 
safe and effective? Are there any interactions with conventional medication? How 
does one relate to the fact that natural agents can be bought anywhere without 
prescription? How to assess questions of quality and insurance? We intend to try to 
answer some of these questions in a subsequent paper focusing on the clinical 





High quality research on natural medicines for schizophrenia and other psychotic 
disorders is scarce. However, there is emerging evidence for glycine, sarcosine, 
NAC, some Chinese and ayurvedic herbs, ginkgo biloba, estradiol and vitamin B6 for 
improving symptoms of schizophrenia when added to antipsychotics. There is 
inconclusive or absent evidence for omega-3, D-serine, D-alanine, D-cycloserine, B 
vitamins, vitamin C, DHEA, PREG, inositol, GHB and des-tyr-gamma-endorphin 
when added to antipsychotics. Omega-3 without antipsychotics might be beneficial in 
the prevention of schizophrenia. Ayurvedic herbs seem as effective as olanzapine in 
one large recent study. Other agents without antipsychotics (vitamin B3, vitamin C, 
sarcosine, glycine, protilerin) do not seem effective or have only been tested in single 
or (very) small trials. Ginkgo and vitamin B6 seem effective for side effects of 
antipsychotics (TD and NIA). The evidence for improved side effects of 
antipsychotics by omega-3, melatonin and DHEA is (still) inconclusive. All agents 
produce only mild or no side effects. However, most study samples are small, 
duration is generally short, they only cover a modest part of the globe’s geography 












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1 Classified per agent, in order of year of publication 
 
2 Scoring of effects: + = positive effect, - = negative effect, 0 = no effect.  
 
A, acetazolamide; AA, arachidonic acid; ABA, Alternative Neliefs Assessment; am, ayurvedic medicine; AP, antipsychotics; ari, 
aripriprazole; ARSNS, Andreasen’s Rating Scale of Negative Symptoms; AT, Ayurvedic treatment; BAS, Barnes Akathisia 
Scale; BDI, Behaviour Disturbance Inventory; BMI, body mass index; BMT, bromocriptine; BSI, Brief Symptom Inventory; 
CANTAB, Cambridge Automated Neuropsychological Test Battery; CAT, catalase; CDSS, Calgary Depression Scale for 
Schizophrenia; CFD, Complex Figure Drawing; CGI, clinical global impression scale; chl hy, chloral hydrate; Cloz, Clozapine; 
CP, Chlorpromazin; CPK, serum creatine phosphokinase; CPRS, Comprehensive Psychopathological Rating Scale; c-o, CPT, 
Continuous Performance Test; c-o, cross-over; contr, control (group); crt, choice reaction time ; ct, completed treatment; d-a, d-
alanine; d-b, double-blind; d-c, d-cycloserine; DHA, docosahexaenoic acid; DIEPSS, Drug-Induced Extrapyramidal Symptoms 
Scale; d-o, drop-out; DS, Digit Span; d-s, d-serine; DTGe, Des-Tyr-Gamma-endorphin; ECT, electroconvulsive therapy; E-E, 
ethyl-eicosapoentaeonate; E-EPA, ethyl-eicosapentaenoic acid; Egb, extract of gingko biloba; EPA, eicosapentaenoic acid; 
EPS. extrapyramidal symptoms; ESRS, Extrapyramidal Rating Scale;  exp, experimental (group); FBS, fasting blood sugar; Flu, 
Fluphenazine; f-u, follow-up; GAS, galactorrhea amenorrhea syndrome; glyc, glycerine; GPX, glutathione peroxidase; gr, group; 
gt, genotype; Hal, Haloperidol; Ham-D, Hamilton Depression Scale; HAM-A, Hamilton Anxiety Scale; HOD, Hoffer-Osmond 
Diagnostic; HOMA-IR, homeostatic model assessment of insulin resistance; inj, injection; LUNSERS, Liverpool University 
Neuroleptic side Effects Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale; MATRICS, Measurement and 
Treatment Research to Improve Cognition in Schizophrenia; MDA, malondiadehyde; mel, melatonine; mian, mianserin; MIBS, 
Inpatient behaviour form; MMN, mismatch negativity; MMPI, Minnesota multiphasic personality inventory; MMSE, mini-mental 
state examination; Mol, molindone; MPQ, multiphasic questionnaire; mts, months; mWAIS, Modifi8ed Chinese version of the 
Wechsler Adult Intelligence Scale; na, nicotinamide; NAC, N-Acetylcysteine; NAD, nicotinamide adenine dinucleotide; NIA, 
neuroleptic induced acathasia; niac, niacinamide; nic, nicotinic acid; NIP, neuroleptic induced Parkinsonism; NOSIE, Nurses 
Observation Scale for Inpatient Evaluation; NPT, neuro psychological test; n.r., not reported; Olan, Olanzapine; p-c, placebo 
controlled; PGD, Peony-Glycyrrhiza Decoction; plac, placebo; pro, protirelin; PRT-BT, Probability Reasoning Task – Bead Task; 
prv, post-randomization visit; PSYRATS, Psychotic Symptom Rating Scales; pyr, pyridoxine; Quet, Quetiapine; QoL. Quality of 
life; RAVLT, Rey Auditory Verbal Learning Test; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; 
Ris, Risperidone; RNRS, Rutgers Nurses’s Rating Scale; RRSP, Rockland’s Rating Scale for Psychotics; RSESE, Rating Scale 
for Extrapyramidal Side Effects; SAE, spiral after effect; SAEs, serious adverse events; SAPS, Scale for the Assessment of 
Positive Symptoms; sar, sarcosine; sars, sarsasapogenin; SAS, Simpson-Angus Scale; s-b, single-blind; SDSS, social disability 
screening schedule;  SFBT, Sequin Form Biard Test; SHRS, St. Hans Rating Scale; SIRP, Sternberg’s item recognition test; 
SOD, superoxide dismutase; SOFAS, Social and Occupational Functioning Assessment Scale; srt, simple reaction time; SOPS, 
Scale of Psychosis-risk Symptoms; SSTMSP, Sternberg Short Term Memory Scanning Paradigm; sx, symptoms; T, thiamine; 
TBARS, thiobarbituric acid reactive substances; TD, tardive dyskinesia; TDRS, Tardive Dyskenesia Rating Scale; tes, 
testosterone; Trif, Trifluperazine; vit, vitamin; vlmr, verbal learning and memory functions; WAIS, Wechsler Adult Intelligence 
Scale; WCST, Wisconsin Card Sorting Test; WISC, Wechsler Intelligense Scale for Children; wks, weeks; WMS, Wechsler 
Memory Scale; wo, washout; WPRS, Wittenborn Psychiatric Rating Scale; YGS, yi-gan san; Zipr, Ziprasidone;  
 
When ‘Also AP?’ is answered with ‘yes’, then the subjects used different types of AP; when 1 AP is mentioned, then all used 
that one. 
 
• Vitamin B3 can be administered in the form of Niacin, Nicotinic acid or Nicotinamide.  
• Full NDMA (N-methyl D-aspartate agonisten): glycine, D-serine; partial: D-cycloserine (D-alanine is endogenous agonist). 
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Although there is increasing evidence for the positive effects of a healthy lifestyle on 
mental health, most studies only take into account a single lifestyle factor, ignore the 
possibility of bidirectional causality, and focus on average group results. 
 
Methods: 
In the present single-subject study we used time-series analysis to unravel the 
dynamic interplay between symptom and treatment variables in a multi-component 
treatment of anxiety disorder. Main treatment variables were two lifestyle factors 
(physical activity and relaxation). 
 
Results:  
The patient in this study recovered completely. Multivariate time-series analysis 
revealed an intricate pattern of dynamic relationships between symptom and 
treatment variables. Relaxation was predictive of symptom reduction but physical 
activity surprisingly worsened the symptoms. Changes in energy predicted changes 
in anxiety. Evidence for bidirectional causality was present as well, with changes in 




This type of research is useful for gaining insight into the causal mechanisms 


























There is increasing interest in, and evidence for, the beneficial effects of a healthy 
lifestyle, including diet, activity and relaxation, on mental health (Walsh, 2011). A 
strong relationship has been found, for example, between physical activity and 
mental health, in population-based as well as intervention studies (Morgan, 1997; 
Biddle et al., 2000; Penedo & Dahn, 2005; Pisinger et al., 2009). Most evidence for 
the beneficial effects of activity has been found in patients with depressive disorder 
(Craft & Landers, 1998; Lawlor & Hopker, 2001; Mead et al., 2009), although some 
effects in anxiety (O’Connor et al., 2000), and other psychiatric disorders 
(Gorczynsky & Faulkner, 2010) have been found as well. Relaxation practices like 
yoga, meditation, guided imagery, breathing, and progressive muscle relaxation have 
also been associated with improved psychological well-being, including reduced 
feelings of anxiety (Eppley et al., 1989; Bindeman et al., 1991; Beck et al., 1994; 
Conrad & Roth 2007; Grossman et al., 2007; Craigie et al., 2008; Lolak et al., 2008; 
Brown & Gerbarg, 2009; Chiesa & Seretti, 2010; Walsh, 2011). 
An important limitation of this research is that different lifestyle behaviors are 
usually studied in isolation. There are to our knowledge no studies on multiple-
component approaches of improving health-related behavior in psychiatric patients, 
and thus no studies that have investigated how different lifestyle behaviors interact in 
producing health gains. This may be important, as different health-related behaviors 
may reinforce or counteract each other. A second problem is that in most studies only 
unidirectional effects have been studied, i.e. how lifestyle behaviors affect mental 
health. The possibility of reverse causality, i.e. that psychological symptoms influence 
the readiness to engage in health-related behaviors, is rarely accounted for. 
Moreover, conventional studies generally show treatment effects at the group level, 
while at the individual level great differences in efficacy or effectiveness exist. Finally, 
little is known about the causal mechanisms by which lifestyle interventions exert 
their effect. The typical intervention study has measurements before and after the 
intervention, but not in between. As a result, little can be concluded about the 
process of change and how improvements are established (Hilliard, 1993; Molenaar 
& Campbell, 2009).  
The present study is an attempt to address the above issues. We investigate 
the temporal relationships between health-related behaviors and symptoms of 
psychological distress in a patient receiving a multi-component treatment for anxiety 
disorder. Our aim is to unravel the dynamic interplay between lifestyle behaviors and 
outcomes using a single-subject time-series approach. In this approach, multiple 
repeated measurements are assessed within a single individual and idiosyncratic 
series are analyzed by means of time-series analysis (Lütkepohl, 2006; Brandt & 
Williams, 2007). Capitalizing on the power of the multitude of repeated 
measurements, such studies can give a detailed and person-tailored account of the 
dynamic relationships between several variables and the temporal order and 
reciprocity of their effects, therewith greatly enhancing the potential to draw causal 

















The participant (called “Alex” in this paper) was a 56-year-old man with a 25-year 
history of recurrent episodes of anxiety, well controlled by 40 mg of paroxetine (a 
selective serotonin reuptake inhibitor; SSRI), at the cost of substantial side effects 
(impotence, 10 kg weight gain and heavy sweating). Because of these side effects, 
Alex had tapered his use of paroxetine successfully in 2006 with the aid of his 
therapist (RH, the first author). In the fall of 2008 he was readmitted to our outpatient 
center1, because of a relapse of anxiety after accepting a job for the first time in many 
years. He had been unemployed for 2 years because of his symptoms and because 
his wife had died of breast cancer, after which he had to take full parental 
responsibility for his 4 daughters aged 10 to 18. Just before his readmission he was 
told that his oldest daughter carries the same breast cancer gene as his wife. He 
experienced a general feeling of anxiety and fear, and mild depressive symptoms but 
no specific phobias or panic attacks. He also had  many physical symptoms like 
fatigue, low energy and nausea. The clinical diagnosis did not fulfill the criteria for 
any specific anxiety disorder. Anxiety Disorder NOS and cluster C personality traits 
(DSM-IV; American Psychiatric Association, 2000) were diagnosed by RH. 
 
Study design 
The study had a naturalistic design; the treatment followed the regular course of 
treatment as given at the center. Alex recorded symptom and treatment variables on 
a daily basis by means of a self-report registration form. These recordings were part 
of the lifestyle intervention. Daily completion of the registration form started as soon 
as the treatment started, on October 23, 2008, after the intake interview. Alex 
continued his recordings until June 15, 2009 resulting in a series of 236 assessment 
points. After termination of the therapy Alex gave his informed consent for the use of 
his data for research and publication. 
 
Treatment 
The treatment was explicitly multifactorial. A biopsychosocial approach was adopted, 
in which lifestyle interventions and psychiatric counseling were combined with 
selected psychotropic medication or nutritional supplements (Hoenders et al., 2010). 
The treatment started with lifestyle interventions targeting relaxation and physical 
activity. After identifying the most prominent symptoms (low energy and anxiety), 
Alex was instructed to score the intensity of these symptoms daily, together with the 
time spent on relaxation practices and physical activity. This was done because 
results of behavioral interventions are known to improve when patients keep track of 
their own behaviors and get feedback on them from their therapist. Daily self-
monitoring enhances self-observation and control, which in turn may foster 
responsibility and motivation for treatment (Quenter et al., 2002). Alex did not want to 
start again with regular medication because of the side effects. Therefore, RH 
suggested inositol, a naturally occurring compound that is a member of the B-vitamin 
family. There is evidence for its effectiveness in anxiety-related disorders and 
depression (Belmaker & Levine, 2008). The effective dosage is 12-18 g (Settle, 
2007). In the second half of the study period Alex switched to paroxetine again, for 
reasons that will be addressed in the Results section. Paroxetine is registered for 
                                                














treating depression and anxiety-related disorders. The recommended dosage of 
paroxetine is 20-60 mg.  
During the entire study period, Alex and RH had regular therapy contacts. 
They had 17 contacts in total, varying in duration from 5 to 50 minutes (mean = 33 
min). During these contacts Alex and RH discussed his registration and RH advised 
and commented on them, reinforcing healthy lifestyle changes. He further employed 
an eclectic supportive psychotherapeutic approach, focusing on unconditional 
positive regard, adjusting to Alex’s needs and preferences and helping him to regain 
a sense of control. RH consistently endorsed Alex’s initiatives and decisions 
regarding his own treatment (for instance his initiative to adjust RH’s general lifestyle 
advice to his personal situation and his wish to be medicated with ‘natural 




The study variables were assessed daily by means of a registration form. The form 
consisted of 7 columns, two in which Alex recorded his daily levels of energy and 
anxiety (range 0-10), two for registering the type of relaxation practices and physical 
activity, and two for the time he spent on it (in minutes). In the seventh column Alex 
could mark special events. The Energy score refers to the patient’s morning energy 
level, because the morning was the time of day Alex could estimate this level most 
accurately. The Anxiety score refers to the average anxiety level experienced during 
the day. The Relaxation score denotes the time spent on relaxation-related 
techniques like yoga and mediation. The Activity score denotes the time spent on 
physical activities including walking, gardening and household activities. 
 
Statistical analysis 
The statistical analyses were done by one of the authors (EB), who was blinded to 
treatment outcomes. Univariate time series were investigated using time-series 
regression analysis, to examine trends over time (Ostrom, 1990). Time-series 
regression accounts for the fact that repeated observations tend to be serially 
correlated (autocorrelation) by fitting autoregressive moving average (ARMA) models 
to the residuals. To investigate the dynamic relationships between the different 
variables, we used Vector Auto Regressive modeling (VAR) (Lütkepohl, 2006; Brandt 
& Williams, 2007). VAR was originally developed by Sims (1980) in econometrics and 
since then has also been used in fields like meteorology, sociology, political science, 
and neuroimaging. In the field of psychiatry, VAR has only been used occasionally 
(e.g., Dugas et al., 2009). An attractive feature of VAR is its ability to investigate 
bidirectional influences between variables without having to make a priori 
assumptions about the direction of the effects. By separating the dynamic part of the 
model (the relationships between the lagged values of the variables) from the 
simultaneous part (the relationships between the contemporaneous values), the 
model allows to make inferences about the temporal order of the effects and thus 
about causality (Brandt & Williams, 2007). A further advantage is that VAR allows for 
feedback effects and for indirect links between variables, i.e. that the effect of one 
variable on another runs via a third variable. This makes the VAR approach very 
suitable for studying mechanisms of change. 
A VAR model is a multivariate autoregressive model that consists of a set of 
unrestricted regression equations for a system of two or more variables (Brandt & 














that they can be both determinant and outcome. Each of the endogenous variables is 
regressed on its own lagged values and the lagged values of the other variables. The 
error terms, called innovations or shocks, should be serially uncorrelated but can be 
contemporaneously correlated. In VAR, the coefficients in the regression equation 
cannot be interpreted individually, because they are part of a system in which all 
elements are dynamically related to each other. Therefore, VAR is usually 
accompanied by the techniques of Granger causality testing, impulse response 
analysis and forecast error variance decomposition, which give an indication of the 
system’s dynamic behavior (Brandt & Williams, 2007).  
In the present study, a 4-variable VAR was used, modeling the temporal 
dynamics of Energy, Anxiety, Relaxation and Activity. To account for the potential 
effects of inositol and paroxetine, we added two control variables denoting the 
dosages of these drugs to the model. These control variables were considered 
exogenous to the system (which means that they may influence the system but 
cannot themselves be influenced by the system). A variable denoting the treatment 
contacts (0/1) was also included as an exogenous variable, but as it did not 
contribute significantly to the model it was removed from the final model. After 
estimation of the VAR, we examined whether the coefficients of some parameters 
could be constrained (set to 0; Lütkepohl, 2006). The VAR was re-estimated after 
placing each constraint. Parameters with the lowest t-values were constraint first. The 
procedure was continued until a p-value of 0.300 was reached. We checked whether 
the final VAR model was correctly specified using diagnostic tests on stability and 
residual autocorrelation (Lütkepohl, 2006). A two-tailed alpha level of 0.05 was used 
to determine statistical significance. Bootstrapped 95% confidence intervals were 
used for the error bands of the impulse response functions (Lütkepohl, 2006). 





Figure 1 shows the time series of daily energy and anxiety levels, and the time spent 
on relaxation practices and physical activity. Alex completed the registration form 
every single day, yielding a unique series of 236 consecutive daily observations with 
no missing values. He engaged in relaxation practices and physical activities almost 
every day (see Figure 1). The relaxation practices he recorded most often were yoga 
and meditation. Occasionally, he recorded massage and singing in a Russian choir. 
The physical activities he recorded were walking, gardening, housekeeping, and 
swimming. Walking was the activity he registered most often. The average daily time 
spent on Relaxation during the study period was 66 minutes (SD = 28, range 0-150). 
The average time spent on Activity was 52 minutes (SD = 30, range 0-150). Energy 
scores ranged from 2 to 7 (mean = 4.72, SD = 1.15). Anxiety scores were between 0 
and 7 (mean = 1.42, SD = 1.36).  
After a baseline phase of 8 days Alex started to use 2 g inositol, increasing the 
dosage to 4 g after another 8 days. After 90 days, he lowered the dosage to 2 g and 
stopped inositol intake two weeks thereafter. Alex did not come near the supposed 
efficacy threshold (10-12 g) for inositol at any moment during the study period. He did 
not suffer from any side effects but decided to stop because he regarded the effect, 
though present, as too slow and too weak, and now felt more confident to try 
paroxetine again because of previous success. The prospect of suffering the side 














had ended their relationship and he did not feel like engaging a new one in the near 
future. Alex started with 10 mg paroxetine 2 days after he stopped using inositol, 
gradually increasing the dosage to 40 mg in 4.5 weeks. He continued to take 40 mg 
paroxetine until the end of the study period.  
 
 
Figure 1. Daily ratings of Energy and Anxiety (range 0-10), and Relaxation and Activity 
(minutes) from October 23, 2008 until June 15, 2009 (236 days). The bar at the top of the graph 







On Christmas Day, Alex started to add alprazolam to his medication, at his own 
initiative. Alprazolam is a benzodiazepine that is used as an anxiolytic. Alex used this 
drug before and had some leftover. He discussed this initiative with his therapist, who 














Moreover, endorsing Alex’s initiatives was in line with the supportive treatment 
approach and the intention to help Alex regaining a sense of self-determination and 
control. During the next 3 months, Alex took 1 to 3 tablets of 0.25 mg alprazolam on 
days he felt the need to do so. He recorded his use of the drug on the registration 
form. He used alprazolam on 38 days in total. Most often he used 1 tablet; 
sometimes he used 2 or 3 tablets. Since an effect on Energy and Anxiety can be 
expected from taking this drug, a variable denoting the number of alprazolam tablets 
was added to the VAR model as a control variable. We also included the first lag of 
this variable to account for possible lagged anxiolitic effects. 
 
Special events 
According to the registration form, the days around Christmas had been very 
burdening, leading to a sharp increase in anxiety symptoms (see Figure 1). Alex told 
his therapist that he had had a major crisis during these days as a result of a 
coincidence of stressful events: getting back to work, worries concerning his 
daughters, and the Christmas period with its many social happenings bringing back 
memories of his deceased wife. To control for possible confounding effects due to 
this unusual time of the year, we included a dummy variable denoting the Christmas 
period (coded ‘1’ for the 10 days around Christmas and ‘0’ otherwise) as an 
exogenous variable to the VAR model. 
 
Course of symptom and treatment variables 
We first examined overall trends in the four time series over the whole study period. 
As can be seen in Figure 1, the Energy scores showed a gradually increasing trend 
over time, while the Anxiety scores gradually decreased, the Christmas period being 
a major exception. We examined whether these trends were significant using time-
series regression analysis, modeling a linear trend. As the Energy and Anxiety series 
showed heteroscedasticity (nonstationary variances), we used the natural logs of 
these variables to stabilize the variances (Brandt & Williams, 2007). The linear trend 
was significant in the models for Energy (B = 0.002, p = 0.005), Anxiety (B = -0.006, 
p = 0.000) and Activity (B = -0.071, p = 0.013). Thus, Alex showed a significant 
increase in Energy and a significant decrease in Anxiety over time, while his Activity 
levels gradually diminished during the study period. This overall pattern of symptom 
relief was in line with RH’s clinical impression and Alex’s own experience of gradual 
recovery. 
 
Estimation of the VAR 
We determined how many time lags were needed in the VAR model (a “lag” denotes 
the time interval between a value and a previous value). In VAR, the optimal lag 
length can be found using lag-length selection criteria2 (Lütkepohl, 2006). Most of 
these criteria suggested an optimum lag length of 2, some suggested including 1 lag. 
We tested both a 1- and a 2-lag VAR, but as the former showed considerable 
residual autocorrelation, we proceeded with the 2-lag model.  
Next, the VAR with 2 lags was estimated. Table 1 presents the final VAR 
model in which the 4 endogenous variables (Energy, Anxiety, Relaxation, Activity) 
were modeled as a function of their own previous values (lags 1 and 2), the previous 
values of the other endogenous variables, and the control variables. As can be seen 
                                                
2 Likelihood Ratio test, Final Prediction Error, Akaike Information Criterion; Hannan-Quinn 














in the table, both the Energy and Anxiety series showed important positive 
autocorrelation: the first and second lags of these variables significantly predicted 
their own current values. Some positive autocorrelation was also detected in the 
Relaxation series. The Activity series did not show significant autocorrelation. 
Besides these autoregressive effects the variables showed some lagged correlations 
with each other. The second lag of Energy was related to current Anxiety scores: 
higher levels of Energy were followed by lower levels of Anxiety two days later. A 
trend for the reverse effect was also present, with increases in Anxiety being related 
to decreases in Energy the next day. Lagged values of Relaxation were positively 
related to Energy and negatively to Anxiety; the more time Alex engaged in 
Relaxation, the higher his Energy and the lower his Anxiety levels the next day. A 
reverse effect from Energy to Relaxation was present as well: higher Energy levels 
were followed by more time spent on Relaxation the next day. Lagged values of 
Activity were also associated with Energy and Anxiety. The nature of these 
relationships, however, was contrary to what we had expected; higher levels of 
Activity were related to lower Energy and higher Anxiety levels the next day.  
 
Table 1. VAR estimates for the 2-lag model  
 
 Dependent Variables 
 
Energy Anxiety Relaxation Activity 
Variable Coefficient Coefficient Coefficient Coefficient 






























































































































R2      0.72         0.85      0.14      0.04 
 
Note. Energy and Anxiety are natural log-transformed variables. Relaxation and Activity are scaled in hours. 
Coefficients denoted with 0 are constraint parameters. Control variables are exogenous to the system. Number of 
observations = 234. ~p < 0.10, *p < 0.05, **p < 0.01, ***p < 0.001. 
 
Inositol and paroxetine were significantly related to Energy and Anxiety as well. 
Higher dosages of inositol and paroxetine were associated with more Energy and 
less Anxiety. Alprazolam was related to all 4 endogenous variables. More alprazolam 
tablets were taken on days with less Energy and more Anxiety, and taking this drug 
went along with reduced levels of Relaxation and Activity. The presumed anxiolitic 
effect of this benzodiazepine could be observed the day after; the first lag of 
alprazolam was negatively related to Anxiety. Finally, a strong relationship was found 


















In time-series analysis, the temporal ordering of events can be used to empirically 
distinguish between leading and lagging variables. This distinction is the basis of a 
definition of causality called ‘Granger causality’ (Granger, 1969). A variable X 
‘Granger causes’ Y if past values of X improve the prediction of Y (beyond past 
values of Y and other variables in the system) (Lütkepohl, 2006). We performed 
Granger tests to investigate whether there was Granger causality present in our 
system. Table 2 shows the results of these tests. The table shows that the 
relationship between Relaxation and Energy was bidirectional: past Relaxation levels 
predicted current Energy scores (p = 0.035), but also the reverse was true (p = 
0.002). Past Relaxation levels also tended to predict current Anxiety scores (p = 
0.062). Past Energy levels predicted current Anxiety scores (p = 0.039), and a trend 
for the reverse effect, from Anxiety to Energy, was present as well (p = 0.072). 
Activity influenced both Energy and Anxiety (p = 0.011 and 0.031), but was not itself 
affected by any of the other variables. Thus, Activity was exogenous to the system. 
 
Table 2. Granger causality tests  
 
Hypothesis χ2 p 
Relaxation → Energy 
Activity → Energy 
Anxiety → Energy 
 
Energy → Anxiety 
Activity → Anxiety 
Relaxation → Anxiety 
 
Energy → Relaxation 
Anxiety → Relaxation 
Activity → Relaxation 
 
Energy → Activity 
Anxiety → Activity 


























Note. Tests denoted with (-) were not performed because the parameters involved were constrained. A significant 
χ2-value implies that the first variable “Granger causes” the second variable. Thus, the first variable is considered 
to have causal impact on the second variable (whether the impact is positive or negative cannot be derived from 




We subsequently calculated the contemporaneous correlations between the 
endogenous variables, using the residuals of the VAR model (Brandt & Williams, 
2007). These correlations represent the immediate relationships between the 
variables, i.e. on the measurement days itself. Table 3 shows that the highest 
contemporaneous correlation was between Energy and Anxiety; these variables were 
negatively correlated with each other (r = -0.338). The other correlations were 



















Table 3. Contemporaneous correlations 
 






















Impulse Response Functions 
The regression coefficients of a VAR can only be interpreted as part of a system of 
variables that are dynamically related to each other. Impulse Response Functions 
(IRFs) allow tracing out the dynamic impacts of changes in each of the endogenous 
variables over time. They do so by visualizing the impact of an isolated shock in one 
of the variables to the other variables, thus showing how these innovations are 
propagated through the system. IRFs only take into account the time-lagged 
relationships between the endogenous variables. Orthogonalized Impulse Response 
Functions (OIRFs) are variants of IRFs that take into account the contemporaneous 
correlations between the variables as well (see Brandt & Williams, 2007). OIRFs 
assume that a specific ordering is chosen for the direction of the contemporaneous  
relationships. If no theory is available guiding this choice, the results of alternative 
orderings can be presented. The critical point in VAR is that the decision about this 
ordering can be made explicit and can be evaluated after accounting for the 
dynamics in the data (Brandt & Williams, 2007). In the present study, we know that 
the Energy scores refer to Alex’s morning energy levels and the Anxiety scores to his 
average anxiety level during the day. We further know that Alex did his relaxation 
practices generally at earlier times of the day than his activities. Thus, a reasonable 
ordering for the innovations in the variables within the same day is that changes in 
Energy precede changes in Anxiety, which precede changes in Relaxation, which 
precede changes in Activity. This is the ordering of our first choice (Order 1: Energy– 
Anxiety–Relaxation–Activity). We investigated alternative orderings as well.  
Figure 2 shows the OIRFs for Order 1. The upper row shows the impact of a 
shock in Energy. The first graph of this row shows the response of Energy to its own 
shock. This response is positive and persists over many days, slowly decaying to 0 
after about 10 days. The same pattern of strong persistence can be seen in the 
response of Anxiety to the Energy shock (2nd graph of 1st row). We see a significant 
direct decrease in Anxiety that slowly diminishes during the following days. The next 
two graphs show that a shock in Energy also results in a direct increase in Relaxation 
and Activity. This effect is not significant for Activity, but becomes significant after 1 
day for Relaxation. The latter effect decays slowly to 0 after 1 week.  
The second row shows the impact of a shock in Anxiety. An increase in 
Anxiety is followed by a decrease in Energy the next day, which becomes significant 
after 3 days and persists over several days. Strong persistence can also be seen in 
the response of Anxiety to a shock to itself. We further see that the Anxiety shock has 
a positive impact on Relaxation and Activity, but this effect is short in duration and 
only significant for Activity. Thus, on anxious days, the participant spent more time 
than average on physical activities.  
The third row shows the impact of a shock in Relaxation. The responses of 
Energy and Anxiety to this shock are initially 0, which is a natural result of the chosen 
ordering in which changes in Relaxation follow after changes in Energy and Anxiety 














day, when an increase in Energy and a decrease in Anxiety can be observed. These 
effects become significant later, as the confidence intervals become smaller. Both 
effects persist during the next days, slowly dying out after about 10 days. The 
response of Relaxation to a shock to itself is short in duration and disappears after 2 
days. The response of Activity to the Relaxation shock is not significant.  
The lowest row shows the impact of a shock in Activity. An innovation in 
Activity leads to a decrease in Energy and an increase in Anxiety the next day. Also 
these effects gradually taper off to 0 after several days. The Activity shock further 
leads to a delayed decrease in Relaxation. This must be an indirect effect, as the 
Activity parameters in the VAR equation for Relaxation were both set to 0 because 
they did not contribute significantly to the model. Presumably, this effect runs via 
reductions in Energy. Finally, there is no persistence in the response of Activity to its 
own shock after the first day. 
 
Figure 2. Orthogonalized Impulse Response Functions for a 4-variable VAR with 95% 
bootstrapped error bands. Responses are considered significant if their error bands do not 
include 0. Energy and Anxiety are natural log-transformed variables. Relaxation and Activity 
are scaled in hours. Order 1: Energy–Anxiety–Relaxation–Activity. Responses are plotted over 



















Cumulative Impulse Response Functions 
The accumulated impact of a shock over time is calculated by computing Cumulative 
Orthogonalized Impulse Response Functions (COIRFs). The results showed that an 
isolated one-time shock of 1 SD in the natural logs of Energy (corresponding to a 
10% increase in Energy) results in a total reduction in Anxiety of 44% over 10 days. 
The same Energy shock leads to a total increase in Relaxation of about ¼ hour over 
that period. The response of Activity to the Energy shock is negligible. A shock of 1 
SD in Relaxation (about ½ an hour) leads to a total increase in Energy of 6% and a 
total decrease in Anxiety of 11% over 10 days. A similar shock in Activity on the other 
hand results in a total decrease in Energy of 7% and a total increase in Anxiety of 
13% over the same period. 
 
Alternative orderings 
We also considered OIRFs for alternative orderings of the contemporaneous 
correlations. The results appeared to be rather robust to different orderings. The main 
differences resulted from converting Energy and Anxiety in the ordering, which is not 
surprising because these two variables showed the largest contemporaneous 






This study aimed to unravel the dynamic relationships between psychological 
symptoms and the health-related behaviors intended to improve these symptoms. 
These relationships turned out to be characterized by bidirectionality, lagged 
influences, indirect effects, and feedback loops, both between symptoms and 
behaviors as well as among them. The present time-series design with its many data 
points enabled us to disentangle these complex effects. These would have gone 
unnoticed in conventional group studies, as the small number of measurements and 
the aggregation of data across individuals in such studies obscures relevant 
information on the dynamic interdependencies between variables (Hilliard, 1993; 
Molenaar & Campbell, 2009; Dugas et al., 2009).  
The results showed that this patient’s symptoms and behavior were 
interrelated in an intricate way. One important finding was that energy and relaxation 
mutually reinforced each other. Changes in relaxation tend to be followed by changes 
in energy, but also the other way around. Furthermore, both energy and relaxation 
were predictive of anxiety. Anxiety in turn was predictive of energy, particularly in the 
longer run. This suggests an intricate system of indirect effects and positive feedback 
loops, which may form a target for initiating a positive spiral. Once initiated, such a 
spiral may bring about a cascade of small but relevant increments in healthy 
behaviors and reductions of symptoms. It is precisely this potential cascade effect 
that makes the results meaningful. Although the isolated effects of changes in 
individual variables may be small, the eventual effects can be large because of the 
way these changes propagate through the system and mutually reinforce each other. 
Moreover, in daily life changes are often not isolated and once only but occur in 
concert and more frequently.  
The effect of relaxation on anxiety seemed to be a delayed one. The present-














day was not yet significant. The OIRF showed a significant favorable effect of 
relaxation on anxiety only after a few days. This suggests that the direct effects of 
relaxation on anxiety are small in this patient, but that the indirect effects, presumably 
via increments in energy, are larger. A more immediate connection seemed to exist 
between energy and anxiety. The contemporaneous correlation between these 
symptoms was moderately large. Furthermore, past energy levels influenced current 
anxiety scores and also a trend for the reverse effect was present. So, energy and 
anxiety seemed to mutually reinforce each other. 
A striking result was that activity seemed to worsen the patient’s symptoms. 
Increases in activity were followed by decreases in energy and increases in anxiety. 
The results further showed that activity had a negative effect on relaxation. These 
findings could possibly have large implications for everyone promoting lifestyle 
behavior for (mental) health and assuming that all ‘healthy behavior’ is healthy for 
anyone. This might not be the case. In this patient exercise was not beneficial, at 
least not in the short run. Maybe Alex did his activities in the wrong way, for example 
by not respecting his limits. That might have stirred up an already overactive stress 
response system. In several mental disorders including anxiety, the stress response 
systems (the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous 
system (SNS)) are hyperactive (Wolkowitz, 2001; Mantella et al., 2008). Prolonged or 
excessive activation of these systems can lead to excessive anxiety and fatigue 
(McEwen, 2000; Wolkowitz, 2001; Heim et al., 2000). Anxiety and fatigue (lack of 
energy) were Alex’s two main problems. Exercise represents a physical stressor that 
activates the stress response systems (McEwen, 2008; Mastorakos, 2005). Whereas 
sustained physical conditioning is associated with a decreased stress response to 
exercise, in untrained individuals or when applied inappropriately the response is 
relatively high (Howlett, 1987; Mastorakos, 2005).  
Interestingly, relaxation practices such as yoga and meditation are known to 
do the opposite. They down-regulate the stress response systems (Astin, 1997; 
Brown & Gerbarg, 2009; Chiesa & Serreti, 2010), stimulate a relaxation response by 
increasing parasympathetic nervous system activity (Hoffman et al., 1982; Innes et 
al., 2005; Benson, 2009), and improve subjective measures of fatigue (Brown & 
Gerbarg, 2009). Possibly, in some circumstances or in some type of individuals, 
relaxation practices are more beneficial than exercise. Similar evidence has been 
reported by some other authors (Ross & Thomas, 2010; Streeter et al., 2010). By 
down-regulating the stress response systems, relaxation practices may create a 
window of opportunity for dynamic interactions to instigate a positive feedback loop 
that advances recovery.  
Inositol as well as paroxetine had positive effects, decreasing anxiety and 
increasing energy. The design, however, did not allow drawing any conclusions 
about the effectiveness of these drugs, as there was no good control (baseline period 
too short, no predefined intake schedule, and too little variation in dose). There are 
some strong experimental designs for testing the effectiveness of treatments in single 
subjects (e.g., Guyatt et al., 1986; Ottenbacher, 2001), but these were not applied 
here.  
According to RH’s clinical impression, another important factor in Alex’s 
recovery was the promotion of his sense of control. Yoga and meditation are thought 
to be beneficial not only because of their relaxing effects, but also because they 
cultivate feelings of self-regulation and control (Astin, 1997; Shapiro et al., 2006). 
Further, during the treatment sessions RH consistently endorsed Alex’s initiatives 














therapeutic relationship and Alex’s self-efficacy. Research has shown that treatment 
is most effective when patients are actively involved in treatment decisions (e.g., 
Nikles et al., 2005; Ryan & Deci, 2008) and when therapists and interventions are 
matched to the patient’s worldview, preferences, and motives (Prochaska et al., 
1992; Rothwell et al., 2007). Also evidence-based medicine (EBM) defines patient 
preference as one of three pillars in decision making (Sackett et al., 2000).  
The most important limitation of this study is that the results cannot be 
generalized to a larger patient population because we used a single-subject design. 
Broader generalization can be established by systematic replication, gradually 
expanding the population to patients with different profiles (Hilliard, 1993; 
Ottenbacher, 2001). It should be noted however that generalization of group-
averaged results to individuals, as is implicitly done in nomothetic research designs, 
is often not justified (Molenaar, 2004). The study has also several strong features, 
including its naturalistic design, the high-intensity data set, and the innovative 
analytic techniques, which allowed us to catch sight of the intricate dynamic 
processes involved in psychophysiology and behavior. We feel this kind of research 
may be useful for improving our understanding of the complex mechanisms 
underlying the effects of a healthy lifestyle on mental health and individual 
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There is considerable debate about routine outcome monitoring (ROM) for scientific 
or benchmarking purposes. We discuss pitfalls associated with the assessment, 
analysis, and interpretation of ROM data, using data of 376 patients. 206 patients 
(55%) completed one or more follow-up measurements. Mixed-model analysis 
showed significant improvement in symptomatology, quality of life, and autonomy, 
and differential improvement for different subgroups. Effect sizes were small to large, 
depending on the outcome measure and subgroup. Subtle variations in analytic 
strategies influenced effect sizes substantially. We illustrate how problems inherent 
to design and analysis of ROM data prevent drawing conclusions about 



















Routine outcome monitoring (ROM) is a method to assess the effectiveness of 
treatments by systematically collecting outcome data in everyday clinical practice. 
ROM was introduced to improve treatment results (Carlier et al., 2012), learn from 
patient experience, and assess treatment quality to justify costs of mental health care 
(Bruinsma et al., 2012; Macdonald, 2009). Scientific interest for ROM grew with an 
increasing awareness that efficacy-focused randomized clinical trials (RCTs) do not 
adequately describe patient care (Gilbody et al., 2002). ROM is on the rise because 
of exploding costs of health care, and -in the Netherlands particularly- because of an 
increasing influence of insurance companies. These companies emphasize more 
transparency regarding cost-effectiveness and patient satisfaction. ROM is 
considered a means to this end, especially because it can be used for benchmarking 
results of all mental health institutions, so that therapies, therapists, departments or 
even facilities can be compared (Nugter & Buwalda, 2012). 
However, ROM does not come without problems. First, ROM data collection 
and analysis is expensive and labour intensive, while (cost-)effectiveness is unclear 
(Carlier et al., 2012; Slade et al., 2006). Further, non-response percentages are 
typically high and seemingly ineradicable. Despite huge efforts and a motivated staff, 
De Beurs et al. (2011) reported a 50% reduction of the sample on each successive 
assessment. In a study by Stiles et al. (2006), post-treatment data were available for 
only 33% of the patients that had provided pre-treatment data. These percentages 
might indicate attrition bias, e.g. when patients who did not improve do not complete 
the ROM measurement; and selection bias, e.g. when therapists (unconsciously) 
include patients that tend to improve easily. 
Another problem is that the use of different outcome measures can lead to 
different results (detection bias), e.g. because some instruments are more responsive 
to change than others (De Beurs et al., 2012). Further, there is the risk of reporter 
bias: therapists may report more favorably about their own patients than an objective 
observer would, and patients may under-report their symptoms because they don’t 
want to disappoint their therapist or over-report them because they want to stay in 
therapy (Bilsker & Goldner, 2002). Not all authors, however, have found these 
suggested biases (e.g. MacDonald & Trauer, 2010).  
In the analysis process a number of problems arise as well. First, different 
statistical techniques can lead to different outcomes (Burgess et al., 2009). Secondly, 
differences in casemix can lead to confounding and make it seemingly impossible to 
compare the effects of different therapists or institutions (Clark et al., 2008; Gilbody et 
al., 2002; Holloway, 2002). Third, because of the lack of a control group it remains 
uncertain whether the observed effects can be attributed to the treatment (Clark et 
al., 2008; Happell, 2008). Thus, there is considerable risk that ROM results are 
misinterpreted and conclusions are drawn that are not warranted (Clark et al., 2008; 
Van Os et al., 2012). 
In view of these problems, there is considerable debate on whether the use of 
ROM is feasible and valid (Bruinsma et al., 2012; Clark et al., 2008; Van Os et al., 
2012). This debate focuses on the use of group-level ROM data for effectiveness 
studies and benchmarking, which should be distinguished from the use of individual-
patient ROM data by patients and clinicians for optimizing the individual treatment 
regimen (Bickman et al., 2011; Hawkins et al., 2004; Hysong, 2009). We will illustrate 
these problems using ROM data from the Center for Integrative Psychiatry (CIP), a 














We present the first results of ROM data collected at the CIP since 2008 and discuss 
the problems and pitfalls in the analysis and interpretation of such data. Specifically, 
we present a regular analysis of the presumed treatment effect and effect sizes, an 
example illustrating the use of ROM data for comparing groups, some examples 
showing consequences of different procedures for data processing and analysis, and 
discuss the implications for interpretation. This paper does not discuss the use of 





Participants and procedure 
The CIP is a small department of Lentis, a publicly funded large community mental 
health care institution. The CIP provides outpatient psychiatric care to about 500 
adult outpatients, suffering from a large variety of psychiatric disorders, although 
mood disorders are most prevalent. Patients with severe addiction disorders, 
neurological problems, mental retardation, or requiring highly specialized psychiatric 
inpatient treatment are not admitted. About 40% of patients are referred to the CIP by 
family doctors and 60% by other outpatient psychiatric treatment centers. Reasons 
for referral are psychiatric disorders that are too complex or severe for family doctors 
or general outpatient treatment centers, or a wish for integrative psychiatric treatment 
(e.g. refusal of chemical drugs, wish for natural medicines, interest in mindfulness-
based cognitive therapy (MBCT)).  
Since September 2008, all patients admitted to the CIP are asked to 
participate in ROM. At that time, implementation of ROM by mental health services in 
our country was still optional, but in recent years it has become mandatory (i.e. 
coupled to funding from insurance companies). Completion by patients is voluntary, 
although ROM is presented as part of the standard intake procedure. An introductory 
letter explaining the goals of ROM is sent together with an invitation for the clinical 
intake. Patients complete the pre-treatment ROM questionnaires at the CIP, just 
before the intake. Reassessments are done every 6 months during treatment, at the 
end of treatment, and 6 months after the end of treatment. The completed 
questionnaires are returned in a postage paid envelope provided by the CIP. Data 
are collected and processed by independent research assistants. Patients are 
informed that ROM is part of the general policy of the CIP to monitor treatment 
outcome and learn from patient experience, that their data are only accessible for 
their therapists, and that anonymous data will be used for research purposes. If 
patients object to such use, their data are removed (this almost never happens). The 
Medical Ethical Committee in the Netherlands has agreed with this policy. Diagnosis 
and classification according to DSM-IV-R criteria is made by clinicians (psychiatrists 
or senior psychologists) during the intake interview. 
 
Treatment 
At the CIP, patients are treated with conventional therapies (medication, cognitive 
behavioral therapy, EMDR, and counselling by specialized nurses), lifestyle training 
(diet, exercise, relaxation, communication, and heart rate variability training), MBCT, 
and a selection of evidence-based complementary medicines such as St. John’s 
wort, omega-3 fatty acids, s-adenosyl methionine (SAMe) and methylfolate. The CIP 
follows the principle of stepped care and uses a protocol with an algorithm to guide 














therapeutic relationship (including shared decision making and emphasis on patient 
preference) is one of its main features (Consortium of Academic Health Centers for 
Integrative Medicine [CAHCIM], 2004). 
 
Measures 
Besides demographic and disease characteristics collected at baseline, ROM 
consists of questionnaires for the assessment of psychological symptoms, quality of 
life, autonomy, social optimism, and client satisfaction. This set of ROM 
questionnaires is the standard for ROM in several mental health institutions in the 
Netherlands (Huijbrechts et al., 2009). 
Psychological Symptoms. Psychological Symptoms are assessed by means of 
the SSL (Short Symptom List; Dutch: Korte Klachten Lijst). The SSL is a self-report 
questionnaire with 13 items about the degree to which respondents suffer from 
common psychological symptoms, such as anxiety, depression, sleeping problems, 
and addiction (Lange & Appelo, 2007; Lange et al., 2000). Scores for each item can 
range from 0 (not at all) to 4 (very much). Total range for the SSL sum score may 
thus vary from 0 to 52. The reliability and validity of the SSL are satisfactory to good 
(Lange et al., 2007; Lange et al., 2000). The SSL is a proper short alternative for the 
SCL-90; total scores on these measures are highly correlated (Lange et al., 2007). 
Quality of Life. The first three questions used for measuring quality of life are 
based on the Sheehan Disability Scale (SDS) (Sheehan et al., 1996). Respondents 
are asked to rate to what extent their psychological problems have a negative effect 
on their social functioning, their ability to work, and their relationship with people 
close to them. The questions are answered on a scale ranging from 0 “no effect” to 
10 “extreme effect”. The fourth question for measuring quality of life is the Happiness 
Index (Abdel-Khalek, 2006; Veenhoven, 2002). Respondents are asked to rate their 
happiness in the previous month on a scale ranging from 0 “very unhappy” to 10 
“very happy”. Both the SDS (Rush et al., 2000) and The Happiness Index (Abdel-
Khalek, 2006; Veenhoven, 2002) have been tested and validated, showing 
satisfactory psychometric features. The summary measure for Quality of Life is 
calculated by reverse-coding the first 3 items and then dividing the sum of all 4 items 
by the number of the available items (Huijbrechts et al., 2009).  
Autonomy and Social Optimism. Autonomy and Social Optimism are assessed 
with the Positive Outcomes List (POL; in Dutch: ‘Positieve Uitkomsten Lijst’). The 
POL is a short Dutch self-report questionnaire consisting of 10 items, that is 
developed to measure resilience based on the perceived level of autonomy and 
social optimism. Items are rated on a 4-point scale, ranging from 1 “not at all” to 4 
“yes, completely”. The Autonomy subscale (7 items) assesses feelings of autonomy, 
control, and independence. The Social Optimism subscale (3 items) measures to 
what extent respondents are satisfied with and have confidence in their social 
relationships. The psychometric properties of the POL are satisfactory (Appelo & 
Harkema-Schouten, 2003). 
Patient satisfaction. At the first measurement patients are asked to rate their 
satisfaction with the CIP on a scale ranging from 1 to 10. At follow-up measurements 
patients answer the same question and also rate their satisfaction with their main 
therapist and the result of the treatment received at the CIP, on a scale ranging from 
1 to 10. The fourth question is whether patients would recommend the CIP to others 
with mental health problems, in five categories, ranging from “yes definitely” to “no 
absolutely not”. These questions are not part of an established questionnaire, but are 














use for ROM since 2008. Internal consistency of these four questions (Cronbach’s 
alpha) is good (.82) (Huijbrechts et al., 2009). 
 
Statistical analysis 
The label of all follow-up measurements (i.e. ‘during treatment’, ‘post-treatment’, and 
‘6-months post-treatment’) was inspected and corrected if necessary, using the date 
of intake and discharge from the center as reference points. Measurements within 3 
months of the discharge date were labelled ‘post-treatment’; measurements outside 
that window were labelled either ‘during treatment’ or ‘6-month post-treatment’, 
depending on the date of completion. This was done to ensure that labels most 
optimally reflected the intended measurement moment1. Such a re-labelling 
procedure is often used in mental health institutions in the Netherlands. At a total of 
357 follow-up measurements, 41 measurements were relabelled (11%).  
Patients included in the analyses were those who completed the pre-treatment 
assessment and at least 1 follow-up assessment (‘completers’). Differences in 
baseline characteristics between completers and non-completers were tested using 
Χ2-tests and independent samples t-tests. Linear mixed models (with intention-to-
treat) were used to examine change over time in the outcome measures. These 
models have the advantage that all available data can be used and time effects can 
be modelled with great flexibility. A categorical variable denoting the specific 
measurement points (pre-treatment; during treatment, post-treatment, and 6-months 
post-treatment) was used as the predictor, with pre-treatment as the reference 
category. All measurements during treatment were collapsed in these analyses. In a 
secondary analysis, we used a model with a continuous variable denoting the real 
time of the measurements (i.e. time since intake) as a predictor. A random intercept 
was used in all linear mixed models to account for the nesting of measurements 
within subjects. A random slope term was modeled as well, but removed from the 
models when not significant. To investigate differences in outcome among different 
subgroups, we focused on the post-treatment measurement, using a covariance 
analysis approach (Vickers & Altman, 2001). We used a linear regression model with 
post-treatment scores as the dependent variable and the subgroup variable as the 
predictor, adjusting for baseline scores. Differences in baseline characteristics 
between the subgroups were tested with Χ2-tests and independent samples t-tests. 
To investigate associations between disease characteristics and outcome, we used 
linear mixed models with the disease characteristic as the predictor and outcome at 
all assessment waves as the dependent variable, adjusting for baseline scores on 
the outcome measures. Distributions of some of the variables showed deviations 
from normality, especially at later measurement waves. For this reason, we used 
bootstrapped confidence intervals in all analyses, and show medians and 
interquartile ranges (IQR) as descriptive statistics for skewed variables. Analyses 
were done using IBM SPSS Statistics 20. A two-tailed alpha level of 0.05 was used to 

















In total, 850 new patients were referred to the CIP between October 2008 and 
September 2011. We excluded patients who received no treatment after the 
diagnostic interview (second opinions, consultations, mismatch; n = 164) from the 
analyses. We also excluded patients who received their main treatment in other 
departments of the Lentis institute and came to the CIP only to receive MBCT (n = 
139). The remaining patients (n = 547) could be divided into 3 subgroups: (1) 
treatment at the CIP only (‘CIP only’, n = 218); (2) treatment at the CIP and other 
Lentis departments concurrently (‘CIP and other treatment’, n = 253); and (3) 
participation in a MBCT group course only (‘MBCT’, n = 76; we distinguished the 
latter subgroup because these patients might be different from those who received 
individual treatment (e.g. drugs, lifestyle training, complementary medicines and or 
psychotherapy) and also the effect of self-help training such as MBCT might be 
different than the effect of individual treatments). Of these 547 patients eligible for 
ROM, 376 patients (69%) completed the baseline measurement; this is the sample 
described in the present study. Of these, 206 (55%) completed one or more follow-up 
measurements (including 87 (23%) at the end of treatment). These 206 patients are 
the subjects included in the mixed-model analyses.  
 
Baseline characteristics  
Demographic and clinical characteristics of the study sample (n = 376) are shown in 
Table 1. The sample consisted of 115 men and 261 women. Mean age was 41.3 
years (SD = 12.8). Fifty percent had a high educational level. Median illness duration 
was 11 years (IQR = 15). Median treatment duration of the patients whose treatment 
was finished at the time of analysis was 288 days (IQR = 356; n = 245). Median 
treatment duration of all patients, including those who were still in treatment, was 388 
days (IQR = 357). The latter group also included a number of patients who receive 
low-intensity maintenance treatment for medication control (e.g., patients with bipolar 
disorder). Baseline scores on the outcome measures are shown at the bottom of 
Table 1. The outcome measures showed moderate correlations among each other in 
the expected direction: Symptoms were negatively related to Quality of Life (r = -
.472), Autonomy (r = -.544) and Social Optimism (r = -.388). Quality of Life was 
positively related to Autonomy (r = .547) and Social Optimism (r = .439). Autonomy 
was positively related to Social Optimism (r = .525) (all p-values < .001). 
Primary DSM-IV diagnoses on axis I and axis II are shown in Table 2 (co-
morbidity as defined by a second or third diagnosis on axis I or II is not shown as 
these data were not available). The sample was highly heterogeneous as regards 
diagnosis. Mood and anxiety disorders were most prevalent on axis I. Most prevalent 
diagnoses on axis II were borderline and type C personality disorders (avoidant, 














Table 1. Demographic and clinical characteristics of the baseline sample (n=376) 
 
Female (n, %) 261  69% 
Age, years (mean, SD) 41.3 12.8 
Having a partner (n, %) 200 55% 
Living situation (n, %)   
 Alone 142 39% 
 With partner and/or children 179 49% 
 Other 43 12% 
Educational level (n, %)   
 Low 62 17% 
 Middle 120 33% 
 High 182 50% 
Illness duration, years (median, IQR) 11 15 
Treatment duration, days (median, IQR)1 288  356 
Medication and supplements (n, %)2   
           Antidepressants 79 35% 
           Sedatives 34 15% 
           Antipsychotics 23 10% 
           Mood stabilizers 10   4% 
           Stimulants 1 0.4% 
           Food supplements 27 12% 
           Complementary medicines 20   9% 
           Somatic medicines 20   9% 
           No medication or supplements 97 43% 
Symptoms (mean, SD) 17.3 7.9 
Quality of Life (mean, SD) 4.6 2.0 
Autonomy (mean, SD) 18.1 3.9 
Social Optimism (mean, SD) 8.7 1.9 
SD = standard deviation, IQR = interquartile range 
1 For those who finished treatment at the time of analysis 
2 Medication use at baseline (before intake). These data were available for only 225 patients as this 










































1 recurrent (77); single episode (13); NAO (3) 
2 panic disorder (13); post-traumatic stress disorder (11); generalized anxiety disorder (10); obsessive-
compulsive disorder (3); phobia NAO (1); social phobia (2); NAO (17) 
3 bipolar I (26); bipolar II (11); NAO (3) 
4 dysthymic disorder (22); attention deficit hyperactivity disorder (13); identity problem (13); 
somatoform disorder (8); psychotic disorder (7); developmental disorder (7); substance abuse (5); 
eating disorder (5); bereavement (5); dissociative disorder (3); sleeping disorder (3); job-related 
problem (3); mood disorder NAO (2); mood disorder based on physical disease (1); psychiatric 
problem based on physical disease (2); separation anxiety (1); religious problem (1); cognitive disorder 
NAO (1) and life stage problem (1) 
5 schizoid (1), schizotypical (1) 
6 borderline (29), narcissistic (4), antisocial (1) 





 n % 
Primary diagnosis   
Axis I only 248 66 
Axis II only 5 1 
Both Axis I and Axis II 123 33 
Diagnosis axis I   
Depressive disorder1 
 93 25 
Adjustment disorder  40 11 
Anxiety disorder2 
 57 15 
Relationship problems 
 38 10 
Bipolar disorder3 
 40 11 
Other4   103 27 
No or deferred diagnosis on Axis I  5 1 
Diagnosis axis II   
(Traits of) personality disorder (total) 
128 34 
Cluster A5  
2 1 
Cluster B6  
34 9 
Cluster C7  68 18 
Not otherwise specified 24 6 















Follow-up measurements were missing or invalid for 170 of the 376 patients with a 
baseline ROM assessment (45%). Drop-out analysis showed that non-completers 
were younger than completers (mean age 38.7 vs. 43.5 years; t = -3.68, df = 374, p < 
0.001); had a lower level of education (Χ2 = 8.81, df = 2, p = 0.012); and a lower 
baseline score on the Social Optimism scale (8.3 vs. 9.0; t = -3.23, df = 347, p = 
0.003). Further, 57 (50.9%) of non-completers used no medication at the start of 
treatment, against 40 (35.4%) of completers (Χ2 = 5.51, df=1, p=0.019). No 
differences in gender, having a partner, living situation, or illness duration were found 
between non-completers and completers.  
 
Patient satisfaction 
Results for patient satisfaction were very similar at the different assessment points, 
so we pooled the results over all follow-up assessments (total observations = 349). 
Patients’ satisfaction with the treatment center was good (median = 8; range 1 to 10). 
Also satisfaction with the main therapist was good (median = 8; range 1 to 10). 
Patients were also rather satisfied with the results of the treatment (median = 7; 
range 1 to 10). The question whether the respondent would recommend the CIP to 
someone who has problems or complaints was answered with “Yes, for sure” in 
52.9% of the cases, with “Yes, probably” in 34.0%, with “I doubt” in 9.3%, and with 
“No, probably not” in 3.5% of the cases. The answer “No, absolutely not” was 
recorded only once (0.3% of the cases). 
 
‘Treatment’ effect 
In ROM studies, the presumed treatment effect is typically assessed by investigating 
change over time. Figure 1 shows the changes in the scores on the outcome 
measures over the different assessment points. All assessments done during 
treatment were pooled in these graphs (‘dur’). The mixed-model analyses showed 
that these changes were significant for all outcomes and all assessments points, 















Figure 1. Change in scores on the outcome measures over the ROM study period.  
pre = pre-treatment;  dur = during treatment; post = post-treatment; fu = 6-months follow-up.  





















Table 3. Results of the mixed-model analyses (n=206) 
 
95% boot-







   Pre-treatment ref    
    During treatment -4.19 -5.33 -3.04 <0.001 
    Post-treatment -5.74 -7.43 -4.05 <0.001 
    6 months post-treatment -5.58 -7.56 -3.59 <0.001 
      
Quality of Life    Pre-treatment ref    
    During treatment 0.58 0.22 0.95 0.002 
    Post-treatment 1.68 1.14 2.21 <0.001 
    6 months post-treatment 1.41 0.78 2.04 <0.001 
      
Autonomy 
   Pre-treatment ref    
    During treatment 0.90 0.28 1.51 0.004 
    Post-treatment 2.49 1.61 3.38 <0.001 
    6 months post-treatment 2.04 0.89 3.19 <0.001 
      
Social Optimism    Pre-treatment ref    
    During treatment -0.08 -0.35 0.20 0.588 
    Post-treatment  0.19 -0.19 0.58 0.322 
    6 months post-treatment -0.01 -0.56 0.53 0.963 
 
      
Effect sizes 
Effect size measures, such as Cohen’s d, are often used in ROM studies, as they 
seem practical for comparison given their standardized nature. We calculated within-
group effect sizes by dividing the estimated mean difference between the pre- and 
post-treatment scores on the outcome measures by the standard deviation of the 
pre-treatment scores. Table 4 shows the effect sizes for the entire ROM sample as 
well as for the three different subgroups in the sample. Effect sizes for the Social 
Optimism subscale were very small, in all groups. Effect sizes for the other outcome 
measures were moderate to large, ranging from 0.62 to 0.86 in the entire sample. 
Effect sizes were highest in the ‘CIP only’ group, somewhat lower in the ‘MBCT’ 




























































































1 Threshold for baseline symptom severity: SSL score > 11. 
Between parentheses the 95% confidence intervals for the effect sizes. 
 
 
The use of ROM data for comparing groups  
When ROM data are used for benchmarking, outcomes of different departments or 
institutions are compared. To illustrate the difficulties arising at this point, we 
compared the results of the ‘CIP only’ group (n=86) and the ‘CIP and other treatment’ 
group (n=89). We tested the differences in improvement from pre- to post-treatment 
between the two groups using a linear regression model with post-treatment scores 
as dependent variable and Group as predictor, adjusting for baseline scores. Post-
treatment measurements were available for 61 of these participants (29 ‘CIP only’; 32 
‘CIP and other treatment’). Although this is only a small group, we do show these 
results, because effect sizes are usually based on post-treatment data and low post-
treatment response percentages are the rule rather than the exception in ROM 
studies. According to these analyses, the difference between the groups was 
significant for Symptoms (B = 5.91, 95% CI = 1.74 to 10.07, p = 0.007). Thus, the 
‘CIP only’ group had significantly fewer symptoms at post-treatment than the ‘CIP 
and other treatment’ group when differences in baseline severity were adjusted for. 
For the other outcome measures, the difference between the groups was not 
significant (Quality of Life: B = -1.14, 95% CI = -2.50 to 0.16, p = 0.100; Autonomy: B 
= -1.38, 95% CI = -3.67 to 0.53, p = 0.193; Social Optimism: B = -0.39, 95% CI = -
1.26 to 0.54, p = 0.406). 
A critical problem in the comparison of groups is that differences in outcome 
can be confounded by differences in baseline characteristics and/or treatment 
duration. Commonly, researchers try to account for such differences by statistical 
adjustment for such confounders, if these are available. In our example, the ‘CIP 














group (Χ2 = 9.97, df = 2, p = 0.007), and was living less often together with partner 
and children (Χ2 = 6.60, df = 2, p = 0.037). When we adjusted for these two variables 
in the mixed models, the baseline-adjusted group difference on the post-treatment 
Symptom scores remained significant and the estimated difference became 
somewhat larger (B = 6.85, 95% CI = 2.55 to 11.30, p = 0.006). Obviously, we could 
only adjust for the patient and treatment characteristics that we measured. These are 
usually limited in ROM studies. We thus remain ignorant as regards the influence of 
other potential confounders (Brookhart et al., 2010). 
A related problem associated with the use of ROM data for benchmarking 
purposes is that patients treated in different health care settings may differ in the 
complexity of their problems. One aspect of this complexity may be illness duration; 
the literature shows that a recent disease onset is often related to a better outcome 
(Carter et al., 2003; Clark et al., 2008; Mynors-Wallis & Gath, 1997). We therefore 
examined whether illness duration was related to outcome in our sample, using a 
mixed model with illness duration as the predictor, adjusting for baseline scores. 
Illness duration was significantly predictive of a worse outcome for all outcome 
measures: Symptoms, B = 0.12, 95% CI = 0.06 to 0.17, p < 0.001; Quality of Life, B = 
-0.033, 95% CI = -0.052 to -0.015, p = 0.002; Autonomy, B = -0.046, 95% CI = -0.076 
to -0.016, p < 0.001; Social Optimism, B = -0.012, 95% CI = -0.026 to -0.001, p = 
0.049. Another aspect of disease complexity is the presence of a comorbid 
personality disorder (Grilo et al., 2010; Massion et al., 2002; Van Noorden et al., 
2012). We investigated whether patients having a diagnosis at both axis I and II had 
a worse outcome than patients who had a disorder at only one axis (most often axis 
I). This appeared to be true for all outcome measures: having a disorder at both axis I 
and II was related to higher baseline-adjusted follow-up scores for Symptoms (B = 
2.55, 95% CI = 1.32 to 3.83, p < 0.001) and lower scores for Quality of Life (B = -
1.06, 95% CI = -1.51 to -0.63, p < 0.001); Autonomy (B = -1.32, 95% CI = -2.00 to -
0.65, p < 0.001); and Social Optimism (B = -0.60, 95% CI = -0.87 to -0.27, p < 0.001). 
So, disease complexity as indexed by longer illness duration and/or a diagnosis at 
both axis I and II was indeed related to a worse outcome in our sample. 
  
Differences in procedures for data processing and analysis 
Because several choices are made during pre-processing and analysis of ROM data, 
we examined the consequences of some of these choices. First, we compared what 
the results would look like when no pre-processing was done at all (e.g., no 
adjustment of assessment labels, no exclusion of patients not eligible for ROM, et 
cetera). So, we repeated our mixed-model analyses on treatment outcome, but now 
in the raw data set. The only pre-processing step performed in this data set was a 
data entry check, in which data entry errors were corrected. The resulting file was 
similar to the one we sent to the “Stichting Benchmark Geestelijke Gezondheidszorg 
(SBG)”, the overarching association involved in benchmarking activities in Dutch 
mental health care. The information required for most preprocessing steps is not 
available for the SBG, since it is stored in a different database than the ROM data 
(e.g. information on actual discharge date, second opinions, concurrent treatment at 
other centers). We spent many days to retrieve this information and to perform the 
required preprocessing steps. So it is unlikely that all these steps will be done when 
analyses are done by a nation-wide benchmark institution. The sixth column of Table 
4 shows the results from the non-pre-processed data set. The effect sizes were 














Quality of Life and Social Optimism: higher effect sizes were found when no pre-
processing was done.  
Next, we examined the results when patients with low baseline symptom 
severity were excluded from the analyses. We did this because we observed this 
practice in studies from leading ROM authors in the Netherlands (Van der Lem et al., 
2012; Van Noorden et al., 2012). We used a threshold of >11 on the SSL, excluding 
all patients with ‘low’ and ‘very low’ symptom severity according to norm scores 
(Huijbrechts et al., 2009). As could be expected, this resulted in higher effect sizes on 
all outcome measures. The last column of Table 4 shows these results. 
We also examined changes in symptoms over time by means of a model with 
‘real time’ as independent variable, i.e., the time passed since the intake date. Using 
this model, we found a change of -3.61 points on the Symptoms scale per year 
(95%CI -4.48 to -2.90, p = 0.001). This analysis shows a discrepancy with the results 
from the original model. In the original model, the estimated change from pre- to post-
treatment on the Symptoms scale was -5.74 (Table 3). Mean time since intake for the 
post-treatment assessment was 0.95 years for this sample, which is almost a year. 
The model with real time, however, showed a rate of change of -3.61 per year, which 
is thus substantially lower than the estimate from the original model. This discrepancy 
can partly be explained by the fact that outcomes assessed at post-treatment are 
generally low ‘by definition’, since patients are usually discharged from the center 
only when they show sufficient symptom reduction. This also points to the potential 
problem of circularity when outcome measures are used simultaneously for scientific 





We analyzed the data of three years ROM in our outpatient clinic for integrative 
mental health care. Patients were highly heterogeneous in diagnosis and many of 
them had a co-morbid personality disorder. The median illness duration was more 
than 11 years. Long illness duration and the presence of a co-morbid personality 
disorder were related to worse outcome. Follow-up data were missing for 45% of the 
baseline sample. The results showed a significant decrease in symptoms and a 
significant increase in quality of life and perceived autonomy. No significant 
improvement was observed in social optimism. Patient satisfaction was high, which 
seems in accordance with Integrative Medicine’s aim of reaffirming the importance of 
the therapeutic relationship (CAHCIM, 2004). Patients treated only at the CIP did 
better than those who were also treated in other Lentis departments. Although the 
effects of treatment at the CIP seem positive in this sample we have concerns about 
the numerous ways in which the data can be confounded, biased, or misinterpreted. 
Below we discuss some of the pitfalls and challenges in the assessment, analysis, 
and interpretation of ROM data, based on our own results.  
 
‘Treatment’ effect 
For a number of reasons, we do not know whether the observed changes really 
reflect the effect of the treatment at the CIP. First, many patients also received other 
treatments in other departments, before, after, or during the CIP treatment. Some for 
a long time, some shortly, some stopped CIP treatment completely, others stopped 
for a while and continued again. The most consistent feature we encountered when 














up was high. This is often the case in ROM studies, and it presents a problem as it 
may distort results substantially (Bilsker & Goldner, 2002; Clark et al., 2008; De 
Beurs et al., 2011; Stiles et al., 2006). If non-completers are the ones who benefit 
least from treatment or the ones who are most dissatisfied, then the results will be 
overly optimistic. A number of studies have shown that this is often the case (Clark et 
al., 2008; Stiles et al., 2003). However, Young et al. (2000) found that non-
completers performed better on some outcome scales. In the present study non-
completers also differed from completers in many respects. Thus, probably our (and 
most) ROM results do not reflect the real effects of treatment. We doubt whether 
response percentages will increase to acceptable levels in the future, given the fact 
that early ROM countries like the United States of America and the United Kingdom 
are still confronted with this problem (Clark et al., 2008; Stiles et al., 2003; Stiles et 
al., 2006). Australia seems to be an exception, showing an increase in response 
percentages in recent years (Burgess et al., 2012). One reason for this may be the 
huge investments from the Australian government in the implementation of ROM. 
Another important difference is that the core ROM instruments in Australia are 
collected and rated by clinicians. The ROM instruments used by the CIP are self-
report measures rated by the patients, and also the data collection itself is not 
performed by clinicians. This is done to avoid reporter and selection bias, and to 
reduce administrative burden for those whose job is to provide care. Of note, 
response percentages in Australia are high especially for clinican-rated instruments, 
but actually rather low for consumer-rated instruments (AMHOCN, 2013).  
Another concern is that ROM measures are usually very general, because 
they have to be used in a broad range of settings. Therefore, they may not be equally 
fit to detect symptoms or improvements in all patient populations, or fail to capture 
the subtlety of a multifaceted outcome (Ashworth et al., 2009; Gilbody et al., 2002; 
Happell, 2008; Lakeman, 2004). For example, relationship problems are a frequent 
reason for referral to the CIP, but the SSL only has 1 item to assess such problems. 
Patients with these problems may thus score very low on this questionnaire at 
baseline, despite having serious mental problems. A related concern is that some 
questionnaires are more sensitive to detect change than others (Ashworth et al., 
2009; De Beurs et al., 2012). The SSL for instance has been found to have only 
moderate sensitivity to change compared to other symptom measures (De Beurs et 
al., 2012). Further, some patients in our sample with severe mental disorders (bipolar 
disorder, schizophrenia) remain in treatment for a very long time, for relapse 
prevention. Even when this approach is successful, it will not show in ROM data, 
because the outcome measures are not designed to measure such results. Finally, a 
more general problem is the lack of a control group, as a results of which the effects 
may also be caused by spontaneous recovery, regression to the mean, positive 
expectancy, or external events. The above described problems do not exclusively 
apply to the present study, but are encountered in most ROM studies, and are 
inherent to the design. 
 
Effect sizes 
The effect sizes in our study were moderate to large, especially in the ‘CIP only’ 
group. Effect sizes are standardized measures of effects, allowing for comparison of 
results from different measurement instruments. Therefore, they will be attractive for 
policy makers and insurance companies that want to compare institutions in an easy 
way for cutting costs. But the results may be misleading. One reason is that 














treatment quality. Differential sensitivity of questionnaires can be one such 
difference; in a ROM study of Dutch psychiatric outpatients that used the same 
symptom scale as we did (SSL), an effect size of 0.52 was found (De Beurs et al., 
2012), while the effect size on the symptoms scale of the OQ-45 in the same study 
was 0.63. Also, differences in casemix may play a role; for example, patients visiting 
integrative health care centers may be different from patients visiting conventional 
centers. We found four other ROM studies done in centers for integrative medicine 
(Greenson et al., 2008; Myklebust et al., 2008; Scherwitz et al., 2004; Smeeding et 
al., 2010), with effect sizes ranging from 0.00 to 1.20 depending on the outcome 
measure. However, a proper comparison is still not possible because of differences 
in outcome measures, medical conditions (mental, somatic, or both), demographic 
and disease characteristics (e.g. illness duration and baseline severity), alternative 
treatment (e.g. some centers used alternative therapies like homeopathy, 
acupuncture and anthroposophical medicine whereas we did not), time of 
assessment (e.g. 3 months vs 6 or 12 months), type of assessment (e.g. self-report 
vs. telephone interview), type of referral (self-referred or not), and reason for 
admission (e.g. improving health vs. treatment of a disorder). 
Another problem with the use of effect sizes is that they may suggest 
substantial differences that in fact are not statistically significant. Presenting 
confidence intervals around the effect sizes may alleviate this problem to some 
degree, but still the figures may be misleading. For instance, we found a large 
difference in effect size between the ‘CIP only’ group and the ‘CIP and other 
treatment’ group in quality of life (effect sizes 1.42 vs. 0.61). However, this difference 
was not significant when analyzed properly using covariance analysis. Effect sizes 
are based on difference scores and disregard the absolute level of the scores at 
baseline. The underlying assumption is that a drop on a certain scale from 30 to 20 is 
as relevant as a drop from 20 to 10. This is not necessarily true (Delespaul, 2010; 
Iezzoni, 1996): for example, how to compare a decrease from 20 to 15 on a symptom 
scale in a group of patients with a long history of severe psychopathology 
accomplished in 3 years by medication and cognitive behavioral therapy, versus a 
decrease from 18 to 14 in a group of young patients with no history of mental health 
problems accomplished in 2 months by participating in a MBCT course? For the 
same reason, effect sizes do not adjust for regression to the mean, while a proper 
covariance analysis does (Vickers, 2001). Another way of assessing effects is to 
calculate figures on reliable and/or significant change, which can be especially useful 
to show individual differences in effects. However, these are subject to the same 
problems as mentioned above, as they are also based on difference scores. 
 
The use of ROM data for comparing groups  
The main problem with the use of ROM data for benchmarking purposes is ‘pitting 
apples against oranges’; different departments / institutions may differ in many 
respects, including patient characteristics, baseline severity, type of treatments, 
length and intensity of treatments, co-morbidity, additional treatments, ROM 
instruments and procedures, and so on. These potential differences are too many to 
adequately control for, making comparisons between departments / institutions 
meaningless (Clark et al., 2008; Gilbody et al., 2002; Holloway, 2002; Van Os et al., 
2012). For instance, when looking superficially at our results one could think that it is 
better for patients to receive treatment at the CIP only, because these patients 
improved more than patients who received treatment at other departments as well. 














patients in many respects (that might be the very reason why they are still being 
treated in another department as well). They might be more complex, more 
vulnerable, have a lower socio-economic status, a smaller social network, a longer 
illness history, more co-morbid disorders, et cetera (confounding by casemix). To be 
able to adjust for all these differences would imply having access to all (medical) data 
files, if these parameters have been measured at all, which is usually not the case in 
ROM (Brookhart et al., 2010; Höfler, 2005). Even if one is able to adjust for all 
baseline differences, the problem is not solved, because adjusting for one variable 
can introduce an imbalance in other variables (Bosco et al., 2010; Brookhart et al., 
2010; Shrier & Platt, 2008). For these reasons, if patients of some department show 
only modest improvement in comparison with another department, this does not 
necessarily imply that this department is inferior. In one of the first large ROM 
assessments in the USA, patients who were treated appeared to be worse off than 
those not treated (Gilbody et al., 2002). In one subgroup it was possible to correct for 
a lot of baseline differences. In that analysis patients who were treated were better 
off. A similar reversal of outcome results has been found in other studies as well 
(Brookhart et al., 2010).  
 
Differences in procedures for data processing and analysis 
Choices in how to analyze the data can have a large influence on the results. For 
example, some authors exclude patients for which the time between baseline and 
next measurement was too short or too long; e.g. Van der Lem et al. (2012) excluded 
169 patients because of these reasons. Some authors also exclude all patients with 
too low baseline severity (Van der Lem et al., 2012; Van Noorden et al., 2012). Our 
study showed that this procedure leads to much higher effect sizes. Further, we (and 
many others) did a number of pre-processing steps to prepare our data for analysis. 
What are the effects of all these actions? We chose to use a linear mixed-model to 
analyze our data, others may use different models. Some authors focus on pre- to 
post-treatment differences, others may use another end point or real time in their 
analysis. Our study showed that such choices can lead to substantial differences in 
results. Also Burgess et al. (2009) showed that choices in the way data are analyzed 
can lead to considerable differences in results (e.g. significant improvement in 38% 
versus 67% or even 73% of inpatient treatments). 
 
Other concerns 
Some institutions (not the CIP) ask their clinicians to check whether patients have 
completed ROM, and if not, to have them do it during their visit. This may lead to 
socially desirable responses in patients and selection and attrition bias due to 
clinicians (e.g., one might be tempted to show more effort in getting ROM data from 
patients that improve a lot). Another problem is confounding by indication; this may 
obscure the influence of disease complexity because complex patients are often 
referred to the most experienced clinicians / institutions (Bosco et al., 2010). There 
are also ethical concerns. The present ROM system functions in a way that 
inaccurate data collection could be rewarded as it increasingly guides funding and 
decision making (Bilsker & Goldner, 2002). This could lead to ‘gaming’ effects, like 
avoiding to include complex patients who will probably not improve easily (selection 
bias), putting more effort in obtaining follow-up data of patients with positive 
outcomes (attrition bias), and reporting higher than justified scores at referral and 
lower than justified at discharge (reporter bias/provider bias) (Bevan & Hood, 2006; 














and are inherent to provider-based outcome measurement (cf. butchers inspecting 
their own meat). 
 
Practical challenges 
ROM requires a lot of time, effort and money. Moreover, patients may get burdened 
by too many assessments, some of which are only for administrative reasons. For 
instance, in the Netherlands response percentages for ROM are not calculated on 
the basis of the number of patients but on the number of treatments as indexed by 
the financial system (DTC; diagnosis treatment combination; in Dutch DBC), which 
has a maximum treatment duration of one year. Therefore, patients have to fill out an 
‘end of treatment’ ROM every year, even when the treatment continues or when they 
just had had a ROM assessment. This seems odd and in contrast with common 
sense and daily practice. Moreover, when a patient is treated in different departments 
he or she will be asked to complete ROM questionnaires every 6 months for each 
department. This places an unreasonable burden on patients and may also 

















ROM of treatments at the CIP showed that, on average, patients’ symptoms 
decreased and their quality of life and autonomy improved significantly during 
treatment. It is, however, not at all clear what conclusions can be drawn from these 
results as regards the effectiveness of treatments provided by the CIP. The lack of a 
control group and potential selection, attrition, and detection biases preclude 
conclusions about the real treatment effect, while confounding by casemix, 
differences in type, number, length, and intensity of treatments, and differences in 
measurement instruments and procedures for collecting and analyzing the data 
preclude proper comparisons between different departments or institutions. ROM 
may be useful as a clinical tool for individual-patient feedback, and for assessing 
unmet needs and improving communication between patient and practitioner. We 
think, however, it is less suitable for scientific and benchmarking purposes. As an 
alternative we suggest the use of selective well-designed effectiveness studies 
performed by an independent research facility, undertaken at random instead of 
routinely (Bilsker & Goldner, 2002). This would reduce costs, ensure independency, 
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1 In practice ROM measurements are not always completed at the intended moment; 
for example because the discharge of a patient is not reported timely to the ROM 
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This thesis is about the conceptual foundation, implementation and effectiveness of 
integrative psychiatry. We will now discuss these three parts separately. After that we 
discuss and respond to criticism on integrative psychiatry, make a plea for an 
integrative research focus and do suggestions for future research. 
 
 
Part I: conceptual foundation 
 
As integrative medicine is a new concept in health care, we explored its conceptual 
foundation in the first part of this thesis and identified the main concerns in 
conventional medicine for which integrative medicine may provide some solutions (cf. 
Introduction). We argued that integration is not only a current tendency in medicine, 
but also a trend fitting the contemporary spirit of the age, in which integration seems 
to be the most common focus. It can be observed in religion, philosophy, spirituality 
and psychotherapy as well (chapter 1). We then compared conventional and 
alternative medicine as regards their perspective, paradigm, organization, scientific 
method and procedures. We showed that theoretically, conventional and 
complementary / alternative medicine are categorically opposed to each other in 
many respects. In practice, they seem to differ only gradually. However, in one 
aspect they seem to differ categorically both in theory and practice, namely in the 
commonly used theoretical models (mechanism / reductionism versus vitalism / 
holism). This aspect is therefore the main reason for heated debates. We 
nevertheless think these differences can be bridged using an integrative model that 
accommodates both (chapter 2). These two studies provide a conceptual basis for 
integrative medicine and the integration of non-conventional medicines in mental 
health care. Although these studies were based on literature searches, they were not 
performed in a systematic way, so they can be subject to bias.  
There are different views on the integration of conventional and 
complementary / alternative medicine: if and how it could or should take place. 
Parker (2007) concludes that integration should only take place in an integrated 
evidence-based model, not in a multicultural pluralistic model. Pluralism refers to an 
organizational model in which different parts exist next to each other without being 
integrated. Kaptchuck et al. (2005), however, express a rather different view. They 
argue that pluralism is the most ethical and desirable option, as there are 
unbridgeable epistemological differences between the medicines. Koutouvides 
(2004) acknowledges these epistemological differences, but does not regard them as 
obstacles to collaboration or even convergence. He argues that collaboration is the 
way forward, instead of confrontation. Bell et al. (2002) state that integrative medicine 
provides a bridge between these theoretical models / paradigms, because it 
accommodates both conventional treatments and CAM, emphasizing wellness and 
healing of the entire person (bio-psycho-socio-spiritual dimensions) in the context of 
a supportive and effective physician-patient relationship. Tataryn and Verhoef (2001) 
argue that integration can take place at different levels (patient, practitioner, 
department, hospital). In the Netherlands some authors feel integration is not at all an 







conventional medicine (Renckens, 2004; Van den Berg & Hengeveld, 2010; see 
paragraph ‘criticism’).  
We agree with Koutouvides (2004) and Bell et al. (2002); although there are 
epistemological differences in theoretical models (chapter 2), we think these 
differences can be bridged using a model based on the principles of evidence-based 
medicine and integrative medicine (chapter 3). Our model facilitates integration at the 
patient and practitioner level. It helps practitioners to provide safe and effective 
conventional, lifestyle and complementary medicine. Further, patients are informed 
and advised to be able to make responsible and healthy choices when using 
alternative medicine (Part II / chapter 3). 
 
 
Part II: implementation 
 
In the second part of this thesis we outlined our position on the integration of 
medicines and presented a working model / guideline for the judicious use of 
complementary and alternative medicine in conventional psychiatry (chapter 3). 
There were four reasons for formulating and implementing a working model of 
integrative psychiatry. First, the practice of integrative medicine / psychiatry is highly 
varied and idiosyncratic. There is a clear need for more consensus and clinical 
guidelines to optimize effectiveness, efficiency and scientific evaluation. Second, the 
concept of integrative medicine was formulated in the United States of America, but 
in the Netherlands different laws concerning alternative medicine apply. So there is a 
need to adjust the concept of integrative medicine to Dutch law. Third, the World 
Health Organization (2003) and the European Parliament (1997) have asked their 
member states to do research on complementary and alternative medicine, to 
integrate those therapies that have been proven effective and safe, to provide the 
public with reliable information, and to formulate policy. Fourth, in the Netherlands we 
witness heated debates on complementary / alternative medicine in which opponents 
and proponents frequently express prejudices. These prejudices hinder the 
development of a balanced policy.  
We assessed the main prejudices for and against complementary and 
alternative medicine, and refuted them with founded arguments. We then formulated 
a clinical guideline on the judicious use of complementary and alternative medicine in 
conventional psychiatry. Until now in the Netherlands patients and doctors are 
informed about what cannot be done concerning complementary and alternative 
medicine, while it remains unclear what could or should be done. This is a first 
attempt to guide patients and professionals in what they can or should do concerning 
unconventional medicines in the Netherlands. To our opinion, it guards patients 
against malpractice and harm, while simultaneously maximizing treatment options 
based on the needs and preferences of patients.  
This paper has been criticized for being called a ‘protocol’ although ‘it is not 
based on best practice determined by psychiatrists as protocols should’ (Van den 
Berg & Hengeveld, 2010). But there does not seem to be any consensus on 
definitions of protocols, guidelines and decision trees. These terms are used 
interchangeably. Our intention was to make clear that one should act judiciously, 
based on law and scientific evidence. To emphasize that, we used ‘protocol’ to 
emphasize that the steps as described in the decision tree are not merely 








Part III: effectiveness 
 
In the third part we presented four studies to answer some of the questions on the 
effectiveness of integrative psychiatry. We did a comprehensive review on the 
efficacy and safety of complementary medicines for bipolar disorder (chapter 4). We 
found high-quality evidence for the effectiveness of select nutrients. We concluded 
that current evidence supports the integrative treatment of bipolar disorder using 
combinations of mood stabilizers and select nutrients. As this review was not 
performed in a systematic way, it could be subject to bias. Still, it offers a meta-view 
on the evidence base of complementary medicine for bipolar disorder. We also did a 
systematic review of natural medicines for schizophrenia (chapter 5). We found 105 
high-quality RCTs (with a Jadad score of 3 or higher) that show emerging evidence 
for improved outcome by adding herbs or nutrients to antipsychotics. However, most 
study samples are small, duration is generally short, they only cover a modest part of 
the globe’s geography, and most results need replication. Even systematic reviews 
can be subject to bias (Tricco et al., 2008). For that reason protocols to perform 
systematic reviews have been developed (www.cochrane.org), but these were not 
applied here. Although we did use Jadad scores to assess the quality of RCTs, some 
unintended bias cannot be ruled out.  
The above-mentioned reviews have focused on RCTs because these are 
regarded the ‘gold standard’ in medical research. This is because the RCT has strong 
features that control for bias and confounding (e.g. randomization), which results in high 
internal validity. As a corollary, however, external or ecological validity is often 
compromised (Howard et al., 1996; Natan et al., 2000). Today many researchers 
propose a more balanced position, acknowledging the strong features of RCTs but at 
the same time stressing the need for other types of research (Bluhm, 2009; Slade & 
Priebe, 2001; Van der Lem et al., 2012; Walach et al., 2006) to answer additional 
research questions, such as questions of effectiveness (does this treatment work in daily 
practice?), questions of individuality (does this treatment work for this particular patient?) 
or questions of mechanism (why does this treatment work?). To answer such questions, 
effectiveness studies are needed, for example modifications of the orthodox randomized 
trial (called ‘real-world’ randomized trials or pragmatic trials) or analyses of large 
administrative databases (Simon et al., 1995). Also single-subject studies with time-
series analysis or experience sampling can be useful to answer these questions 
(Molenaar & Cambell, 2009; Hilliard, 1993; VandenBroucke et al., 2006; Nikles et al., 
2004; Aan het Rot et al., 2012). Therefore, we did a single-subject study using time-
series analysis to unravel the dynamic interplay between symptom and treatment 
variables in a multi-component treatment of anxiety disorder (chapter 6). We found that 
relaxation practice increased this patient’s energy levels, and - via these - reduced his 
anxiety levels. Physical activity appeared to have the opposite effect, worsening the 
symptoms. Further, a feedback effect from energy to relaxation was found; increases in 
energy increased the patient’s tendency to do his relaxation practices, indicating a 
positive spiral. Although the effects found in this paper were significant, they only 
applied to one patient, so the generalizability to the population was low. More studies 
are needed to confirm or refute our findings. The study did show the potential of high-
intensity time-series designs to disentangle complex interactions in systems of multiple 
interconnected variables. 
The overall outcome of integrative (mental) health care systems has hardly 
been investigated thus far (Verhoef, 2004). Since 2004 only a few routine outcome 







mental health have been published (Greeson et al., 2008; Mykleburst et al., 2008). 
So, we decided to evaluate the outcome of treatment at the Center for Integrative 
Psychiatry, using routine outcome measurement (ROM) (chapter 7). We discussed 
pitfalls associated with the assessment, analysis, and interpretation of ROM data, 
using data of 376 patients. 206 patients (55%) completed one or more follow-up 
measurements. Mixed-model analysis showed significant improvement in 
symptomatology, quality of life, and autonomy, and differential improvement for 
different subgroups. Effect sizes were small to large, depending on the outcome 
measure and subgroup. Subtle variations in analytic strategies influenced effect sizes 
substantially. Because of many problems inherent to the design and analysis of ROM 
data we could not draw conclusions about (comparative) treatment effectiveness. 
Still, this paper yielded some insights into the characteristics of patients visiting 






During these years of research and practice of integrative psychiatry we sometimes 
encountered strong opposition and criticism (Kuipers & Gijsman, 2006; Van den Berg 
& Hengeveld, 2010; Renckens, 2013). Some criticism has been described and 
answered at the end of previous paragraphs. Others are discussed here.  
Most of the critics state that we should not get involved in non-conventional 
medicines in any way, as they are ‘unscientific’. Medicine that is based on ‘ridiculous 
principles’ should not be investigated, so they say (e.g. Renckens, 2004). They think it is 
a waste of money and time. However, we feel that science should not be limited to 
conventional medicine, but can be applied to any medicine, as the scientific method is a 
way of relating to phenomena following certain rules and principles. In other words, it is 
not the subject that determines if it is scientific or not, it is the way in which the 
investigation and analysis are done. If we would decide by ourselves which phenomena 
should and should not be investigated in medicine, based on our subjective ideas, that 
would not be beneficial for the progress of medicine. Also, what seems ridiculous to one 
person may be convincing to another. Many patients use these medicines and pay for it; 
they seem to find them convincing. Who are we to decide that this is nonsense? 
Moreover, many findings in medicine seemed ridiculous and were rejected when they 
were first proposed (e.g. arteriosclerosis causes heart disease, vitamins prevent 
disease, microbes cause disease; Olshansky & Dossey, 2003). Therefore, we argue for 
an open and critical attitude. 
Kuipers and Gijsman (2006) argued that ‘it has taken psychiatry many years to 
become a medical specialty. We have been working hard to get rid of vagueness, 
irrationality and unsubstantiated claims. We are now a scientific discipline. We need 
to armor ourselves against modern trends, magic and exotic religion’. We do agree 
that science should be differentiated from magic or religion. However, we think that 
showing an interest and respect for the opinion and preferences of patients, and 
trying to investigate therapies by means of proper scientific methods is not the same 
as being vague, irrational or magical. There is a need to be open to different 
perspectives on health and disease. Moreover it is an illusion to think that 
conventional psychiatry is scientific in all respects (Dobbs, 2013). Recently, the very 
basis of psychiatric diagnosis and classification, the Diagnostic and Statistical Manual 







Health for being based on consensus rather than scientific evidence (Insel, 2013). 
The institute has already started to redirect its research focus away from DSM 
categories to research across categories or research on subdivisions of categories. 
When we are open to other perspectives, new opportunities might emerge. For 
instance, Van der Greef (2011) reported in Nature how systems biology applied to 
traditional Chinese medicine (TCM) yields promising results and opens possible new 
ways in conventional medicine. Reviews have shown positive outcome of Chinese 
herbal medicine (Rathbone et al., 2007), Ayurvedic medicine (Agarwal, 2010) and 
other complementary medicine (Hoenders et al., in preparation; chapter 5) when 
combined with antipsychotic drugs. 
Renckens (2013) expressed strong criticism on our paper on wind direction 
and mental health (Bos et al., 2012; not part of this thesis). In this paper we used 
time-series analysis to study the relationship between weather parameters and 
symptomatology in a patient suffering from recurrent anxiety. Wind direction was 
related to the patient’s energy levels; these were significantly lower when the wind 
blew from the southeast. The effects could not be explained by other weather 
parameters. Renckens (2013) asked whether we had lost our mind, doing research 
on the influence of weather on mental states. He invited readers to comment on our 
level of insanity in categories (‘fool, damn fool, bloody fool, fucking fool’). While we 
acknowledge that the influence of wind on mental health is an unusual one, there is 
reason to assume it might exist, based on local reports (e.g. on ‘ill winds’ like Foehn, 
Mistral and Sirocco), other research (e.g. ecopsychology) and our data. Moreover, 
we used sound scientific methods to investigate this relationship. But that is not the 
point. What is most intriguing is the question: why do critics feel the need to 
devaluate, even offend us, for engaging in research on complementary / alternative 
medicine? Milders (2006) suggested it is out of fear. Whether or not it was out of fear, 
it seems reasonable to assume that the controversy between mechanism / 
reductionism and holism / vitalism, as described in chapter 2, is involved in these 
heated debates, because a challenge of strongly held convictions can provoke a 
strong emotional response. 
Some psychiatrists argue that when patients ask doctors for advice on 
complementary or alternative medicine, they should refuse to give it or even discourage 
them to try it. But if we do not advice patients on (lack of) evidence for effectiveness and 
safety of these medicines, they will be more vulnerable to unsubstantiated claims made 
on the Internet. Also there is a risk for interactions between drugs and herbs (Ernst, 
2003a). Only 3% of the user population is aware of this potential risk (Walter & Gray, 
1999). So, even from a medical perspective it is important to know what patients buy 
and try. But beyond that, patients do want their medical doctors to advice them on 
complementary medicines (Gray et al., 1998; Hoenders et al., 2006). The World Health 
Organization (WHO, 2003) and European Parliament (EP, 1997) have also advised their 
member states to do so. Respecting patients’ opinions and informing them can also 
improve the therapeutic relationship (Stevingson, 2001) and therewith enhance 
treatment outcome (Koenig, 2000; Nikles et al., 2005; Gill, 2013), as treatment outcome 
has been shown to be highly dependent on the quality of the thereapeutic alliance 
(Wampold, 2001; Driessen et al., 2010; Baldwin et al., 2007; De Jong, 2011). 
There is also criticism on applying lifestyle medicine. Some psychiatrists say: ‘I 
am not trained to prescribe herbs, nutrients or lifestyle changes, that should not be 
work for doctors’. But we feel that any therapy that has been proven effective and 
safe in clinical trials for mental health problems should be known to and possibly 







continuous medical education points did not agree to give points for a three day 
training in compassion (a training that builds on mindfulness with a focus on mildness 
and empathy), stating: ‘systematic training of compassion is for now not relevant for 
doctors’. However, we feel that compassion and empathy are essential for doctors 
and all those involved in healthcare. It is critical for establishing and maintaining a 
good therapeutic relationship, which is one of the most powerful predictors of 
success in (psycho-)therapy (Wampold, 2001; Driessen et al., 2010; Baldwin et al., 
2007; De Jong & Colijn 2010). Moreover, there is emerging scientific evidence for the 
positive effects of compassion training for psychiatric disorders (Gilbert & Proctor, 
2006; Mayhew & Gilbert, 2008; Laithwaite et al., 2009). 
 
 
Integrative research focus 
 
Mental health research needs to span both the natural and social sciences (Van Os, 
2012; De Jong, 2013). Evidence based on RCTs has an important place, but to adopt 
only concepts from one body of knowledge is to neglect contributions that other well-
established methodologies can make (Slade & Priebe, 2001). In other words: besides 
an integrated treatment approach, a truly integrative research focus is also needed.  
In this thesis we used different research methods in an effort to answer some 
of the research questions related to integrative medicine / psychiatry. Based on 
literature searches, we wrote essays on the conceptual foundation. Taking into 
account the Dutch law, scientific research, jurisprudence and rules of professional 
bodies, we wrote a treatment protocol for the judicious application of complementary 
medicine in conventional mental health care. We assessed the quality and results of 
RCTs on complementary medicine in two reviews. Then we used a single-subject 
study to unravel the interrelatedness of symptoms and treatment variables using 
time-series analysis. Finally, we provided some insights into the characteristics of 
patients visiting centers for integrative mental health, their diagnoses and their 





Research into integrative (mental) health is still in its infancy. Far less than 1% of the 
research budget in the United Kingdom and the United States of America is spent on 
complementary / alternative medicine (Ernst, 2003b). The rest is spent on 
conventional medicine. In the Netherlands the situation is probably not much 
different, although exact figures are lacking. This thesis is a small step towards a 
more evidence-based integrative psychiatry. 
Future research in integrative psychiatry should be integrative in methodology 
and include: 1) pragmatic trials comparing integrative treatment approaches to 
conventional treatments to examine (cost-)effectiveness and safety aspects; 2) 
clinical trials that study patient-tailored multiple-component interventions with both 
quantitative outcome measures (e.g. laboratory tests and validated psychometric 
scales) and qualitative experiences (e.g. subjective perceptions of improved 
functioning, placebo and nocebo effects), in RCTs as well as single-subject time-
series designs; 3) use of pharmacogenomic, epigenetic, and neuroimaging 
technologies to elucidate mechanisms of action; 4) exploration of the impact of 







both preventatives and treatments; 5) studies of the interactions between specific 
pharmaceuticals and complementary or alternative therapies and medicines 
(potentially beneficial synergistic and potentially dangerous adverse or toxic effects) 
(Sarris et al., 2013); and last but not least 6) qualitative studies with epistemological 
consideration of the paradigms of widely used Eastern medicine such as TCM, 
Tibetan medicine and Ayurveda. These paradigms contain insights which fit well with 
an immunological view of health that is often at the basis of lifestyle interventions. 
This is an area where more of a systems approach is warranted than an approach 
that looks simply at the individual therapies of whole systems (e.g. acupuncture, 
herbal medicines, massage, etc) rather than at their underlying diagnostic and 
explanatory models. The latter, in the long run, holds the potential to yield important 
new insights for expanding the biomedical paradigm – with major implications for 





In this thesis we differentiated integrative medicine, as a new concept of health care, 
from conventional medicine / psychiatry, arguing that it may provide some solutions 
to current challenges in health care. Looking closer one might argue that most 
aspects of integrative psychiatry should just be part of conventional psychiatry. Most 
conventional doctors agree that the therapeutic relationship is central, that we should 
not only look at diseases but at the whole patient, and that focusing on health is as 
important as trying to eradicate symptoms. Only the third principle, the use of non-
conventional medicines, remains controversial. So, is integrative psychiatry really 
different from conventional psychiatry? Is it really necessary to distinguish them? The 
answer is yes and no.  
Yes, because even though these three principles should be part of 
conventional medicine, they usually are not. Concepts like the biopsychosocial model 
are acknowledged in theory, but rarely practiced fully. Moreover, the third principle 
often provokes strong emotional responses and prejudice, which are not evidence-
based and hinder progress. That is why we discussed those responses extensively.  
No, because most clinicians agree that these principles should be part of 
medicine. So, after differentiating at the start of this thesis we now arrive at 
integration once again, hoping that soon most aspects of integrative medicine are 
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Integrative medicine (IM) is a new concept of health care that was launched by a 
consortium of eight academic health centers in the USA in the late nineties of the 
past century. It has been defined as (1) the practice of medicine that reaffirms the 
importance of the relationship between practitioner and patient, (2) focuses on the 
whole person, is (3) informed by evidence, and makes use of all appropriate 
therapeutic approaches, healthcare professionals and disciplines to (4) achieve 
optimal health and healing (The Consortium, 2004). Since its start there has been 
great interest from the medical and scientific community and a steady growth. Today 
fifty-five academic health centers in North America are active members of this 
consortium. Also in Europe (United Kingdom and Germany) Asia and Australia, IM 
initiatives regarding clincs and research have been undertaken. 
Many research groups, health centers, educational, advocacy and policy 
activities related to IM exist, but the part of psychiatry / mental health care seems 
undervalued, especially as regards research. Because of that, we collaborated with 
researchers and clinicians from Australia and the United States of America to assess 
the need for IM in mental health care and to propose solutions to current challenges 
(Saris et al., 2013).  
Mental illness now accounts for about one-third of adult disability globally, 
reflecting marked societal and personal suffering, and enormous social and 
economic costs. However, the most common treatments in psychiatry (medication 
and psychotherapy) have turned out to be not as effective as previously thought 
(Kirsch et al., 2008; Turner et al., 2008; Cuijpers et al., 2010; Cuijpers et al., 2011). 
So, it seems there is a need for change in the paradigm and practices of mental 
healthcare (Bracken et al., 2012). Integrative medicine in mental health care 
(Integrative Mental Health; IMH) may offer some answers to these challenges. It 
adopts the biopsychosociospiritual model, utilizing evidence-based treatments from 
different medical traditions. Besides mainstream interventions (e.g. 
psychopharmacology, psychosocial therapies) IMH incorporates the judicious use of 
evidence-based complementary and alternative (CAM) medicines and therapies in 
addition to health-promoting lifestyle changes (Sarris et al., 2013). 
 
 
Part I: Conceptual foundation 
 
As the use of complementary and alternative medicine (CAM) in conventional health 
care (implicit in part 3 of the definition) is the most controversial part of IM and 
because this subject led to heated debates in the Netherlands, we decided to focus 
our research on this part of IM. The heated debates seem to indicate that CAM 
provokes strong emotions. This can be explained by strong adherence to (opposing) 
paradigms: those in favor of CAM (the vitalism / holism paradigm) and those against 
(the mechanism / reductionism paradigm; Hoenders et al., 2008).   
IM provides a bridge between these paradigms, because it accommodates 
both conventional treatments and CAM, emphasizing wellness and healing of the 
entire person (biopsychosociospiritual dimensions) in the context of a supportive and 
effective physician-patient relationship (Bell et al., 2002). Its success seems related 
to the fact that integration is not only a current tendency in medicine, but also a trend 







common focus. It can be observed in religion, philosophy, spirituality and 
psychotherapy as well. It follows a period in which differentiation took central stage 
but did not lead to absolute, unquestionable truths (Hoenders et al., 2012). 
 
 
Part II: Implementation 
 
We did an inquiry into the use of CAM by psychiatric outpatients and found that 42% 
of nearly 600 participants had used CAM in the previous year, most of them with 
perceived good results, but mostly without telling their conventional doctor about this 
use. This may explain why we found, when asking their doctors, that they 
underestimated this use (Hoenders et al., 2006). Others have reported similar 
findings: 43% of patients with anxiety disorder (Bystritsky et al., 2012), and 53% of 
patients with depression (Wu et al., 2007) use complementary or alternative medicine 
(CAM). These patients perceived such treatments as improving their physical, 
emotional, cognitive, social, and spiritual functioning, reducing symptom severity and 
promoting recovery and wellness (Russinova et al., 2009).  
Most patients in our study also reported that they want their conventional 
doctors to inform them about CAM and assist them in making health care choices 
(Hoenders et al., 2006). This is also what the European Parliament (1997) and World 
Health Organization (2003) have advised their membership states to do. Because of 
that, we felt there was a need to formulate a protocol to assist patients and doctors in 
using CAM in a judicious way. We felt it should answer patients’ needs and wishes; 
respect their freedom of choice; offer western medicine and CAM that are safe and 
effective; protect against quackery and abuse; be based on Dutch law, the 
jurisprudence of the Medical Disciplinary Tribunal and the rules of the Dutch 
Association of Medical Practitioners (KNMG); and be based on scientific evidence. 
This resulted in the CAM protocol (Hoenders et al., 2011). 
 
 
Part III: Effectiveness 
 
The CAM protocol emphasizes the need for an evidence-based approach. To assess 
the evidence base for CAM we did reviews on complementary medicines for severe 
mental illness.  
In a comprehensive review on bipolar disorder we found several positive 
controlled studies of nutrients (such as folic acid) and Chinese herbs in combination 
with conventional mood stabilizers and antipsychotic medications in bipolar 
depression, while branched-chain amino acids and magnesium seem effective (in 
small studies) in attenuating mania. In the treatment of bipolar depression evidence 
was mixed regarding to omega-3 fatty acids, while isolated studies provide 
provisional support for a multi-nutrient formula, n-acetylcysteine (NAC), and for L-
tryptophan. We concluded that current evidence supports the integrative treatment of 
BD using combinations of mood stabilizers and select nutrients or herbs (Sarris et al., 
2011).  
In a systematic review on schizophrenia we found that high-quality research 
on natural medicines for schizophrenia and other psychotic disorders is scarce. 
However, there is emerging evidence for glycine, sarcosine, NAC, some Chinese and 
Ayurvedic herbs, ginkgo biloba and vitamin B6 in improving symptoms of 







There is inconclusive or absent evidence for omega-3, D-serine, D-alanine, D-
cycloserine, B vitamins, vitamin C, dehydroepiandrosteron (DHEA), pregnenolone 
(PREG), estradiol, inositol, gamma-hydroxybutyrate (GHB) and des-tyr-gamma-
endorphin when added to antipsychotics. Omega-3 without antipsychotics might be 
beneficial in the prevention of schizophrenia. Ayurvedic herbs seem effective without 
antipsychotics in one large study. Other agents without antipsychotics (vitamin B3, 
vitamin C, sarcosine, glycine, protilerin) do not seem effective or have only been 
tested in single or small trials. Ginkgo biloba and vitamin B6 seem effective for 
diminishing side effects of antipsychotics (tardive dyskinesia and akathisia). The 
evidence for diminishing side effects of antipsychotics by omega-3, melatonin and 
DHEA is inconclusive. All identified agents produce only mild or no side effects. Most 
study samples are small, study and treatment duration is generally short, studies only 
cover a modest part of the globe’s geography, and most results need replication 
(Hoenders et al., in preparation). 
 The next step was to assess the effectiveness of the integrative psychiatry 
approach in daily practice. Psychiatric research in the past 50 years has focused 
primarily on neurobiological mechanisms and psychotherapeutic techniques. More 
recent research has explored lifestyle moderators of mental health, mind-body 
therapies, and natural products (Sarris, 2011). At present there is a scarcity of real-
practice research on integrative approaches in medicine and psychiatry (i.e. 
approaches that combine multiple interventions in a personalized manner), with most 
studies employing randomized control trial (RCT) designs to examine single 
interventions at a group level, thereby ignoring individual differences (Slade & Priebe, 
2011; Molenaar & Campbell, 2009). Advances in research and clinical practice of 
psychiatry will take place when research methodologies permit the rigorous 
evaluation of complex interventions involving multiple therapeutic modalities 
(mirroring true clinical practice) to treat real-world clinical populations. So a truly 
integrative research focus is needed. While methodologically challenging, this 
approach may have the potential to elucidate the relative contributions of social, 
psychological, biological and spiritual factors in each unique patient’s response to 
combined treatment modalities (Sarris et al., 2013).  
Along these lines we did a single-subject study using time-series analysis to 
unravel the dynamic interplay between symptom and treatment variables in a multi-
component treatment of anxiety disorder. We found that relaxation practice increased 
this patient’s energy levels, and - via these - reduced his anxiety levels. Physical activity 
appeared to have the opposite effect, worsening the symptoms. Further, a feedback 
effect from energy to relaxation was found; increases in energy increased the patient’s 
tendency to do his relaxation practices, indicating a positive spiral. Although the effects 
found in this paper were significant, they only applied to one patient, so the 
generalizability to the population was low. More studies are needed to confirm or refute 
our findings. The study did show the potential of high-intensity time-series designs to 
disentangle complex interactions in systems of multiple interconnected variables 
(Hoenders et al., 2012). 
 Also routinely assessed outcomes can be used to assess real-life 
effectiveness of treatments. We evaluated the outcome of treatment at the Center for 
Integrative Psychiatry, using routine outcome measurement (ROM). We discussed 
pitfalls associated with the assessment, analysis, and interpretation of ROM data, 
using data of 376 patients. The sample consisted of 115 men and 261 women. Mean 
age was 41.3 years (SD = 12.8). Fifty percent had a high educational level. Median 







(IQR = 356). The sample was highly heterogeneous as regards diagnosis. Mood 
(36%) and anxiety disorders (15%) (axis I of DSM IV) and borderline (8%) and type C 
personality disorders (18%; axis II) were most prevalent. Patients’ satisfaction with 
the treatment center was good (median = 8; range 1 to 10). 206 patients (55%) 
completed one or more follow-up measurements. Mixed-model analysis showed 
significant improvement in symptomatology, quality of life, and autonomy, and 
differential improvement for different subgroups. Effect sizes were small to large, 
depending on the outcome measure and subgroup. Subtle variations in analytic 
strategies influenced effect sizes substantially. Because of many problems inherent 
to the design and analysis of ROM data we could not draw conclusions about 
(comparative) treatment effectiveness. Still, this paper yielded some insights into the 
characteristics of patients visiting centers for integrative mental health, their 
diagnoses and their satisfaction with integrative psychiatry (Hoenders et al., 2013). 
 
 
Integrative research focus 
 
Mental health research needs to span both the natural and social sciences (Van Os, 
2012; De Jong, 2013). Evidence based on RCTs has an important place, but to adopt 
only concepts from one body of knowledge is to neglect contributions that other well-
established methodologies can make (Slade & Priebe, 2001). In other words: besides 
an integrated treatment approach, a truly integrative research focus is also needed.  
In this thesis we used different research methods in an effort to answer some 
of the research questions related to integrative medicine / psychiatry. Based on 
literature searches, we wrote essays on the conceptual foundation. Taking into 
account the Dutch law, scientific research, jurisprudence and rules of professional 
bodies, we wrote a treatment protocol for the judicious application of complementary 
medicine in conventional mental health care. We assessed the quality and results of 
RCTs on complementary medicine in two reviews. Then we used a single-subject 
study to unravel the interrelatedness of symptoms and treatment variables using 
time-series analysis. Finally, we provided some insights into the characteristics of 
patients visiting centers for integrative mental health, their diagnoses and their 





Research into integrative (mental) health is still in its infancy. Far less than 1% of the 
research budget in the United Kingdom and the United States of America is spent on 
complementary / alternative medicine (Ernst, 2003). The rest is spent on 
conventional medicine. This thesis is a small step towards a more evidence-based 
integrative psychiatry. 
Future research in integrative psychiatry should be integrative in methodology 
and include: 1) pragmatic trials comparing integrative treatment approaches to 
conventional treatments to examine (cost-)effectiveness and safety aspects; 2) 
clinical trials that study patient-tailored multiple-component interventions with both 
quantitative outcome measures (e.g. laboratory tests and validated psychometric 
scales) and qualitative experiences (e.g. subjective perceptions of improved 
functioning, placebo and nocebo effects), in RCTs as well as single-subject time-







technologies to elucidate mechanisms of action; 4) exploration of the impact of 
lifestyle modification (e.g. diet, exercise, stress management) on mental health as 
both preventatives and treatments; 5) studies of the interactions between specific 
pharmaceuticals and complementary or alternative therapies and medicines 
(potentially beneficial synergistic and potentially dangerous adverse or toxic effects; 
Sarris et al., 2013); and last but not least 6) qualitative studies with epistemological 
consideration of the paradigms of widely used Eastern medicine such as TCM, 
Tibetan medicine and Ayurveda. This is an area where more of a systems approach 
is warranted than an approach that looks simply at the individual therapies of whole 
systems (e.g. acupuncture, herbal medicines, massage, etc). This kind of research 
holds the potential to yield important new insights for expanding the biomedical 
paradigm – with major implications for medical care and human health (Bodeker, 





In this thesis we differentiated integrative medicine, as a new concept of health care, 
from conventional medicine / psychiatry, arguing that it may provide some solutions 
to current challenges in health care. Looking closer one might argue that most 
aspects of integrative psychiatry should just be part of conventional psychiatry. Most 
conventional doctors agree that the therapeutic relationship is central, that we should 
not only look at diseases, but at the whole patient and that focusing on health is as 
important as trying to eradicate symptoms. Only the third principle, the use of non-
conventional medicines, remains controversial. So, is integrative psychiatry really 
different from conventional psychiatry? Is it really necessary to distinguish them? The 
answer is yes and no. 
 Yes, because even though these three principles should be part of 
conventional medicine, they usually are not. Concepts like the biopsychosocial model 
are acknowledged in theory, but rarely practiced fully. Moreover the third principle 
often provokes strong emotional responses and prejudice, which are not evidence-
based and hinder progress. That is why we discussed those responses extensively. 
No, because most clinicians agree that these principles should be part of 
medicine. So, after differentiating at the start of this thesis we now arrive at 
integration once again, hoping that soon most aspects of integrative medicine are 
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Summary in Dutch [Nederlandse samenvatting] 
 
 
Eind jaren negentig werd door een Amerikaans consortium van acht academische 
ziekenhuizen een nieuw concept gelanceerd: Integrale geneeskunde (‘integrative 
medicine’; IM). Integrale geneeskunde (1) stelt de therapeutische relatie tussen 
patiënt en hulpverlener weer centraal, (2) kijkt naar de gehele mens, (3) maakt op 
basis van wetenschappelijk onderzoek gebruik van alle geschikte therapeutische 
benaderingen, zorgprofessionals en disciplines, om zo (4) tot optimale gezondheid 
en optimaal herstel te komen (The Consortium, 2004). Vanaf die tijd is er voor deze 
nieuwe stroming veel interesse getoond vanuit de medische en wetenschappelijke 
wereld. Dit heeft er toe geleid dat er vandaag de dag vijfenvijftig medisch 
academische gezondheidscentra in Noord-Amerika actief lid zijn van het consortium. 
Ook in Europa (vooral Duitsland en Verenigd Koninkrijk), Azië en Australië zijn IM-
initiatieven op het gebied van patiëntenzorg en onderzoek ontstaan. 
Ondanks een toenemende interesse en toepassing van integrale 
geneeskunde blijft deze ontwikkeling binnen de geestelijke gezondheidszorg 
achterlopen, vooral op het gebied van onderzoek. Integrale geneeskunde toegepast 
in de geestelijke gezondheidszorg / psychiatrie wordt ‘integrale psychiatrie’ genoemd. 
Een integrale benadering binnen de (geestelijke) gezondheidszorg lijkt van belang 
omdat het mogelijk oplossingen kan bieden voor de hedendaagse problemen binnen 
de (geestelijke) gezondheidszorg (Sarris et al., 2013). Wereldwijd beslaan 
psychische stoornissen een derde van alle ziektelast onder volwassenen, hetgeen 
niet alleen persoonlijk lijden met zich meebrengt maar ook maatschappelijke 
problemen en hoge kosten. Tevens is gebleken dat, wanneer rekening gehouden 
wordt met publicatiebias, de meest gangbare behandelingen binnen de psychiatrie 
(medicatie en psychotherapie) minder effectief zijn dan eerder werd aangenomen 
(Kirsch et al., 2008; Turner et al., 2008; Cuijpers et al., 2010; Cuijpers et al., 2011). 
Het lijkt erop dat een nieuw paradigma nodig is binnen de geestelijke 
gezondheidszorg (Bracken et al., 2012). Een integrale gezondheidszorg (d.w.z. 
integrale geneeskunde en psychiatrie) biedt zo’n nieuw paradigma. Het hanteert een 
bio-psycho-sociaal-spiritueel model dat gebruik voorstaat van evidence-based 
behandelingen vanuit verschillende geneeskundige tradities. Het spirituele aspect 
verwijst hierbij naar zin- en betekenisgeving en naar existentiele vragen die een rol 
spelen bij (herstel van) ziekte (Koenig, 2000). Naast reguliere interventies 
(bijvoorbeeld psychofarmaca en psychosociale therapieën) maakt de integrale 
gezondheidszorg op zorgvuldige wijze gebruik van evidence-based complementaire 
en alternatieve medicatie en behandelingen en bevordert het tevens een gezonde 
leefstijl (Sarris et al., 2013). 
 
 
Deel I: Theoretische achtergrond 
 
Daar het gebruik van complementaire en alternatieve geneeswijzen (CAG) binnen de 
reguliere gezondheidszorg (impliciet onderdeel van deel 3 van de definitie van IM; zie 
eerste alinea hierboven) het meest controversiële onderdeel van integrale 
geneeskunde is en omdat dit onderwerp in Nederland tot verhitte discussies heeft 
geleid, hebben we besloten om ons onderzoek op dit onderdeel toe te spitsen. De 










onderwerp is voor veel mensen. Dit komt wellicht omdat er sterk aan tegengestelde 
paradigma’s wordt vastgehouden: de meeste voorstanders van CAG hangen het 
paradigma ‘vitalisme / holisme’ aan, terwijl tegenstanders van CAG meestal het 
paradigma ‘mechanisme / reductionisme’ als uitgangspunt hanteren. Deze 
paradigma’s verschillen categorisch en zijn daardoor moeilijk te verenigen. Dit in 
tegenstelling tot de andere verschillen tussen regulier en CAG, die dimensioneel zijn 
(Hoenders et al., 2008). 
Integrale geneeskunde slaat een brug tussen deze twee paradigma’s, omvat 
zowel de reguliere geneeskunde als CAG en benadrukt gezondheid en het herstel 
van de gehele persoon (bio-psycho-sociaal-spiritueel model) binnen een optimale 
therapeutische relatie (Bell et al., 2002). Het succes van de integrale geneeskunde 
kan onder andere verklaard worden door het feit dat integrale geneeskunde aansluit 
bij breder waargenomen tendensen tot integratie binnen de hedendaagse tijdgeest. 
Zowel in religie, filosofie, spiritualiteit als psychotherapie is deze trend te herkennen. 
Het lijkt een reactie op een voorgaande periode waarin juist de nadruk lag op 
differentiatie, een periode waarin geen absolute, onbetwistbare zekerheden werden 
gevonden (Hoenders et al., 2012). 
 
 
Deel II: Toepassing 
 
We hebben onderzoek gedaan naar het gebruik van CAG bij poliklinische patiënten 
in de GGz en ontdekten dat 42% van de bijna 600 ondervraagden CAG had gebruikt 
in het voorafgaande jaar. De meeste van hen rapporteerden positieve effecten, maar 
gaven ook aan dat zij hun CAG gebruik niet hadden besproken met hun reguliere 
arts, vooral uit angst voor een negatieve reactie. Dit lijkt te kunnen verklaren waarom 
de artsen in kwestie het gebruik van CAG door hun patiënten flink bleken te 
onderschatten (Hoenders et al., 2006). Andere onderzoekers rapporteerden 
vergelijkbare resultaten: 43% van patiënten met een angststoornis (Bystritsky et al., 
2012) en 53% van patiënten met een depressie (Wu et al., 2007) gebruikten 
complementaire en alternatieve geneeswijzen (CAG). Deze patiënten gaven aan dat 
de behandelingen hielpen bij het verbeteren van hun lichamelijk, emotioneel, 
cognitief, sociaal en spiritueel functioneren, dat het de ernst van hun klachten 
verminderde en dat het ondersteunend was voor herstel en gezondheid (Russinova 
et al., 2009).  
In ons eigen onderzoek gaven de meeste patiënten aan dat ze graag door hun 
reguliere arts geadviseerd wilden worden over het gebruik van CAG en dat ze graag 
ondersteund zouden willen worden in het maken van keuzes op dit gebied (Hoenders 
et al., 2006). Dit is in overeenstemming met wat het Europese parlement (1997) en 
de Wereld Gezondheid Organisatie (2003) hun leden hebben geadviseerd. Met dit in 
gedachten hebben we een protocol opgesteld voor artsen en patiënten om hen te 
helpen verstandige keuzes te maken wanneer het gaat om het toepassen en 
gebruiken van CAG. We wilden recht doen aan de diverse kenmerken, wensen en 
behoeften van patiënten; hun keuzevrijheid respecteren; zowel reguliere 
behandelingen als CAG aanbieden die bewezen effectief en veilig zijn; beschermen 
tegen kwakzalverij en misbruik; en ons baseren op de Nederlands wet, de 
jurisprudentie van het Medisch Tuchtcollege, de regels van de Koninklijke 
Nederlandsche Maatschappij tot bevordering der Geneeskunst (KNMG) en op 













Deel III: Effectiviteit 
 
Het CAG protocol benadrukt het belang van een evidence-based aanpak. Om de 
wetenschappelijke onderbouwing van CAG verder in kaart te brengen hebben we 
twee (systematische) reviews uitgevoerd naar complementaire medicatie bij ernstige 
psychiatrische aandoeningen.  
In een review naar de effectiviteit van complementaire geneeswijzen bij 
bipolaire stoornissen vonden we meerdere studies van hoge kwaliteit die een positief 
effect aantoonden van de combinatie van voedingssupplementen met reguliere 
stemmingsstabilisatoren of antipsychotica bij bipolaire depressie. Daarnaast lijken 
sommige specifieke aminozuren (BCAA) en magnesium een positief effect te hebben 
bij manie (in kleine studies). Ten aanzien van het effect van omega-3 vetzuren bij 
bipolaire depressie worden wisselende resultaten gevonden. Een positief effect van 
multivitaminen, N-acetylcysteïne en L-tryptofaan wordt in enkele studies gevonden 
(Sarris et al., 2011).  
In een systematisch review naar schizofrenie werd duidelijk dat weinig 
onderzoek van hoge kwaliteit gedaan is om het effect van natuurlijke medicijnen bij 
schizofrenie of andere psychoses in kaart te brengen. Desondanks vonden we 105 
RCT’s met een Jadad score van 3 of hoger. In deze studies wordt bewijs gevonden 
voor verbetering van symptomen wanneer glycine, sarcosine, N-acetylcysteine 
(NAC), bepaalde Chinese en Ayurvedische kruiden, ginkgo biloba of vitamine B6 als 
aanvulling op een antipsychoticum wordt gegeven (dit gold echter niet voor glycine 
als aanvulling op clozapine). Er is geen of onvoldoende bewijs voor een effect van 
omega-3 vetzuren, D-serine, D-alanine, D-cycloserine, vitamine B, vitamine C, 
dehydroepiandrosteron (DHEA), pregnenolone (PREG), estradiol, inositol, gamma-
hydroxybutyrate (GHB) en des-tyr-gamma-endorfine als aanvulling op antipsychotica. 
Omega-3 vetzuren zonder antipsychoticum lijken wel een positief effect te hebben op 
het voorkomen van schizofrenie. In een dubbelblinde RCT met 200 patiënten werd 
een positief effect van Ayurvedische kruiden zonder gebruik van antipsychotica 
aangetoond. Andere middelen die zonder een antipsychoticum werden aangeboden 
(vitamine B3, vitamine C, sarcosine, glycine, protilerine) zijn niet effectief gebleken of 
zijn alleen onderzocht in een enkel of klein onderzoek. Ginkgo biloba en vitamine B6 
lijken bijwerkingen van antipsychotica te verminderen (tardieve dyskinesie en 
akathisie). Het effect van omega-3, melatonine en DHEA op het verminderen van 
bijwerkingen is onvoldoende bewezen. Hoewel de kwaliteit van de geïncludeerde 
studies goed is (dubbelblinde RCT’s met een Jadad-score van 3 of hoger), zijn de 
meeste onderzochte groepen klein, is het tijdspad van de studie of de behandeling 
vaak kort, hebben de studies slechts betrekking op een klein deel van de 
wereldbevolking en dienen de meeste studies te worden gerepliceerd (Hoenders et 
al., in voorbereiding). 
De volgende stap was het onderzoeken van het effect van een integrale 
psychiatrische aanpak in de dagelijkse praktijk. Onderzoek binnen de psychiatrie 
heeft zich de afgelopen 50 jaar vooral gericht op neurobiologische mechanismen en 
psychotherapeutische technieken. Recent onderzoek richt zich ook op het effect van 
leefstijl, mind-body therapieën en het gebruik van natuurlijke medicatie op de 
psychische gezondheid (Sarris, 2011; Walsh, 2011). Tot op heden is er weinig 
praktijkgericht onderzoek verricht naar de werking van een integrale benadering 










zichzelf staande interventies, gemeten op groepsniveau middels RCT’s, waarbij er 
niet gekeken werd naar individuele verschillen (Slade & Priebe, 2011; Molenaar & 
Campbell, 2009). Vooruitgang in onderzoek en praktijk kan worden geboekt wanneer 
de onderzoeksmethodologie het mogelijk maakt om complexe interventies, 
bestaande uit verschillende therapeutische behandelaspecten, gericht op de 
behandeling van klinische populaties in de praktijk te onderzoeken. Dit vraagt om 
een integrale onderzoeksfocus. Ondanks dat dit methodologisch gezien een 
uitdaging is, biedt deze aanpak wel de mogelijkheid om te onderzoeken welk aandeel 
sociale, psychologische, biologische en spirituele factoren hebben in het effect van 
bepaalde behandelcombinaties op unieke patiënten (Sarris et al., 2013).  
Met dit in gedachten hebben wij een N=1 studie gedaan met tijdreeksanalyse 
om de complexe dynamiek van symptomen en behandelaspecten van een 
gecombineerde behandeling gericht op het verbeteren van een angststoornis te 
ontrafelen. We vonden voor de betreffende patiënt dat ontspanningsoefeningen het 
energieniveau verhoogden, en dat op deze manier de angstklachten afnamen. 
Beweging bleek echter juist een negatief effect op de angstklachten te hebben. Ook 
vonden we dat energie en ontspanning elkaar wederzijds positief beïnvloedden; een 
toename in energie vergrootte ook de neiging van de patiënt om zijn 
ontspanningsoefeningen te doen. Ondanks dat de gevonden effecten significant 
waren, beschrijft de studie slechts één persoon en dat maakt het moeilijk om de 
resultaten te generaliseren. Deze studie laat wel goed zien wat de mogelijkheden zijn 
van een individuele analyse van hoogfrequente tijdreeks-gegevens voor het 
onderzoeken van complexe interacties tussen meerdere elkaar onderling 
beïnvloedende factoren binnen een bepaald systeem (Hoenders et al., 2012). 
 Tenslotte onderzochten wij de effecten van behandeling in het Centrum 
Integrale Psychiatrie door gebruik te maken van Routine Outcome Monitoring (ROM). 
We beschrijven de valkuilen die zich voordoen bij het verzamelen, analyseren en 
interpreteren van gegevens bij dit type onderzoek aan de hand van de ROM-data 
van 376 patiënten die behandeld werden in ons centrum voor integrale psychiatrie. 
De steekproef bestond uit 115 mannen en 261 vrouwen met een gemiddelde leeftijd 
van 41,3 jaar (SD = 12,8). Vijftig procent was hoog opgeleid. Mediane ziekteduur was 
11 jaar (IQR = 15). Mediane behandelduur van degenen die de behandeling hadden 
afgerond was 288 dagen (IQR = 356). De groep was zeer heterogeen wat betreft 
diagnose. Stemmingsstoornissen (36%) en angststoornissen (15%) (as 1 van de 
DSM-IV) en borderline (8%) en cluster-C persoonlijkheidsstoornissen (18%) (as 2) 
kwamen het meest voor. Van de patiënten met een voormeting hadden er 206 (55%) 
ook een of meerdere vervolgmetingen ingevuld. Een mixed-model-analyse liet zien 
dat klachten, kwaliteit van leven en autonomie significant verbeterden, en dat de 
mate van verbetering varieerde per subgroep. Effectgroottes varieerden van klein tot 
groot, afhankelijk van uitkomstmaat en subgroep. Kleine variaties in de 
analysestrategie hadden een aanzienlijk effect op de effectgroottes. We 
concludeerden dat de vele problemen die gepaard gaan met een ROM-design en de 
ROM-analyse het onmogelijk maken om valide conclusies te trekken over 
behandeleffecten en verschillen daarin tussen subgroepen. Desondanks laat dit 
artikel iets zien van de eigenschappen en diagnoses van patiënten die zich 
aanmelden bij een integrale zorginstelling en krijgen we zicht op hun tevredenheid 












Een integrale onderzoeksfocus 
 
Onderzoek binnen de geestelijke gezondheidszorg moet zich verbreden naar zowel 
de natuurwetenschappen als de sociale wetenschappen (Van Os, 2012; De Jong, 
2013). Wetenschappelijke onderbouwing op basis van RCT’s is belangrijk, maar door 
alleen deze informatiebron te gebruiken missen we belangrijke aanvullende inzichten 
vanuit andere goed onderbouwde onderzoeksmethoden (Slade & Priebe, 2001). Met 
andere woorden: naast een integrale behandelaanpak is ook een integrale 
onderzoeksaanpak nodig. 
In dit proefschrift beschrijven we verschillende onderzoeksmethoden om 
verschillende onderzoeksvragen die leven binnen de integrale geneeskunde / 
psychiatrie te beantwoorden. Op basis van literatuuronderzoek schreven we essays 
over de theoretische achtergronden. Met de Nederlands wet, jurisprudentie, regels 
van beroepsorganisaties en wetenschappelijk onderzoek in het achterhoofd schreven 
we een behandelprotocol voor het zorgvuldig gebruik van complementaire 
geneeswijzen binnen de reguliere geestelijke gezondheidszorg. In twee reviews 
hebben we de kwaliteit en resultaten van RCT’s naar het gebruik van 
complementaire medicatie in kaart gebracht. Daarnaast hebben we binnen een N=1 
studie met behulp van tijdreeksanalyse de onderlinge verwevenheid van symptomen 
en behandelvariabelen blootgelegd. Tenslotte hebben we door het gebruik van 
Routine Outcome Monitoring een beeld gekregen van eigenschappen en diagnoses 
van patiënten die een integraal centrum voor psychiatrie bezoeken, en van hoe 





Onderzoek naar integrale (geestelijke) gezondheidszorg staat nog in de 
kinderschoenen. Minder dan 1% van het onderzoeksbudget van het Verenigd 
Koninkrijk en de Verenigde Staten wordt aan onderzoek naar complementaire en/of 
alternatieve geneeswijzen besteed (Ernst, 2003). Het overige budget gaat naar 
onderzoek gericht op reguliere geneeswijzen. Dit proefschrift is een kleine stap naar 
een evidence-based integrale psychiatrie.  
Toekomstig onderzoek binnen de integrale psychiatrie zou gebruik moeten 
maken van een integrale methodologie en het zou de volgende elementen moeten 
bevatten: 1) pragmatische studies waarbij integrale behandelingen met reguliere 
behandelingen worden vergeleken om zo (kosten-)effectiviteit en veiligheidsaspecten 
te kunnen onderzoeken; 2) klinische studies met geïndividualiseerde multiple-
component interventies met zowel kwantitatieve uitkomstmaten (laboratoriumtests en 
gevalideerde psychometrische schalen) als kwalitatieve uitkomstmaten (subjectieve 
ervaringen van verbeterd functioneren, placebo- en nocebo-effecten) waarbij naast 
RCT’s ook single-subject time-series designs en experience sampling methoden 
worden gebruikt; 3) gebruik van farmacogenomische, epigenetische, en neuro-
imaging technieken om werkingsmechanismen te verhelderen; 4) onderzoek naar het 
effect van leefstijlveranderingen op geestelijke gezondheid, zowel preventief als als 
onderdeel van behandeling; 5) studies die de interactie tussen bepaalde 
farmaceutica en complementaire of alternatieve behandelingen en medicatie 
onderzoeken (mogelijke gunstige synergetische en mogelijke negatieve of toxische 










werkingsmechanismen van veel gebruikte Oosterse geneeswijzen, zoals TCM 
(traditionele Chinese geneeswijzen), Tibetaanse geneeskunde en Ayurveda. Hierbij 
is meer een systeembenadering nodig dan een aanpak die alleen maar kijkt naar 
individuele onderdelen van hele geneeskundige systemen (zoals acupunctuur, 
kruiden, massage, etc). Dit soort onderzoek heeft de potentie om belangrijke nieuwe 
inzichten te genereren voor het verbreden van het biomedische paradigma – met 
belangrijke implicaties voor de geneeskundige zorg en de menselijke gezondheid 





In dit proefschrift presenteren we integrale geneeskunde/psychiatrie als een nieuw 
concept binnen de gezondheidszorg, onderscheiden we het van reguliere 
geneeskunde / psychiatrie en beargumenteren we dat het mogelijk een oplossing 
biedt voor hedendaagse problemen binnen de gezondheidszorg. Wanneer je er 
langer over nadenkt zou je kunnen stellen dat de meeste aspecten van integrale 
psychiatrie eigenlijk onderdeel (zouden moeten) zijn van reguliere psychiatrie. De 
meeste reguliere artsen delen immers de mening dat de therapeutische relatie 
centraal moet staan, dat we niet alleen moeten kijken naar symptomen maar naar de 
gehele patiënt, en dat de focus ook op gezondheid moet liggen in plaats van (alleen) 
op ziekteverschijnselen. Alleen het derde principe, het gebruik van complementaire / 
alternatieve geneeswijzen, blijft controversieel.  
Dus, verschilt integrale psychiatrie nu echt van reguliere psychiatrie? Is het 
echt nodig om hier een onderscheid in aan te brengen? Het antwoord is ja en nee. 
Ja, want ondanks dat deze principes standaard onderdeel zouden moeten zijn 
van reguliere geneeskunde, blijkt in de praktijk dat ze dit vaak niet zijn. Principes als 
het bio-psycho-sociaal model worden in theorie onderkend maar worden weinig in 
praktijk gebracht. Daarnaast blijken er betreffende het derde principe vaak heftige 
(emotionele) reacties los te komen en sterke vooroordelen te bestaan. De 
meerderheid van deze reacties en vooroordelen worden niet door wetenschappelijk 
onderzoek ondersteund en belemmeren derhalve de vooruitgang in de wetenschap 
en psychiatrie. Om die reden bespreken wij deze reacties en vooroordelen uitgebreid 
in de discussie van dit proefschrift.  
Nee, omdat de meeste clinici het er over eens zijn dat deze principes 
onderdeel zouden moeten zijn van geneeskunde. Dus waar het aan het begin van dit 
proefschrift draaide om differentiatie, zijn we nu opnieuw aangekomen bij integratie: 
wij hopen dat de meeste aspecten van integrale geneeskunde geaccepteerd en 
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weg te gaan. Ik heb dat erg gewaardeerd. 
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geneeswijzen voor schizofrenie? Spreker. Phrenos psychosecongres, Zwolle; 
Nederland). 
 
2013  Lifestyle and self healing capacity: theory and practice. Chairman and 
speaker. 
Conference The doctor and nutrition. Haarlem; The Netherlands. (Leefstijl 
training en zelfhelend vermogen in de zorg: theorie en praktijk. Dagvoorzitter 
en spreker. Congres Arts en voeding, Haarlem; Nederland). 
 
2013  The conceptual foundation, implementation and effectiveness of 
integrative medicine in mental health care. Speaker. 
Farewell conference Joop de Jong, professor of Cultural and International 
Psychiatry, Free University, Amsterdam [De conceptuele basis, implementatie 
en effectiviteit van integrale geneeskunde in de geestelijke gezondheidszorg. 
Spreker. Afscheidscongres voor Joop de Jong, hoogleraar Culturele en 
Internationale Psychiatrie aan de Vrije Universiteit Amsterdam]. 
 
2012  Routine outcome monitoring in an outpatient clinic for integrative mental 
health. Speaker.  
Lentis research conference. Zuidlaren; The Netherlands. (Routine outcome 
monitoring in een polikliniek voor integrale geestelijke gezondheid. Spreker. 
Lentis onderzoekscongres. Zuidlaren; Nederland). 
 
2012 Integrative medicine and psychiatry; theory and practice. Speaker.  
Conference The whole person. Utrecht; The Netherlands. (Integrative 
medicine en psychiatrie; theorie en praktijk. Spreker. Congres Heel de mens. 
Utrecht; Nederland). 
 
2012  Fifth conference on integrative psychiatry; interconnectedness. Chairman 
of the organizing committee and speaker. 
Groningen; The Netherlands. (Vijfde congres Integrale Psychiatrie; 
interconnectedness. Voorzitter organiserend comité en spreker. Groningen; 
Nederland). 
 
2011  The therapeutic relationship. Speaker.  
Farewell conference Dr. C.F.A. Milders, clinical instructor psychiatry, Lentis. 
Groningen; The Netherlands. (De therapeutische relatie. Spreker. 
Afscheidsymposium Milders, A-opleider Lentis. Groningen; Nederland). 
 
2011 Lifestyle training and self healing capacity. Speaker.  
Conference Lifestyle for Healthy Aging. Leeuwarden; The Netherlands. 
(Leefstijltraining en zelfhelend vermogen. Spreker. Congres Lifestyle for 







2010 Western and Traditional Medicine: a comparison of paradigms and 
working methods, and a plea for integration. Speaker. 
International Conference on the modernization of TCM. Chengdu; China. 
(Westerse en traditionele geneeskunde; een vergelijking van paradigma en 
werkmodellen, en een pleidooi voor integratie. Spreker. Internationaal congres 
over de modernisering van TCM. Chengdu; China). 
 
2010 Fourth conference on integrative psychiatry; self-healing capacity. 
Chairman of the organizing committee and speaker. 
 Groningen; The Netherlands. (Vierde congres Integrale Psychiatrie; zelfhelend 
vermogen. Voorzitter organiserend comité en spreker. Groningen; Nederland). 
 
2010   Integrative psychiatry & addiction. Speaker.  
Conference on Addiction. Solutions Healthcare. The Netherlands. 
(Integrale Psychiatrie & verslavingszorg. Spreker. Congres over verslaving, 
Solutions Healthcare, Nederland). 
 
2010  Lifestyle training & self healing capacity, focus on the rhythm of the 
breath. Speaker. 
Conference MCO Folia Orthica. The Netherlands. (Leefstijltraining & 
zelfhelend vermogen, focus op het ritme van de ademhaling. Spreker. 
Congres MCO Folia Orthica, Nederland). 
 
2010 Integrative Psychiatry: pros and cons. Speaker 
Discussion group. Spring conference of the Dutch union for Psychiatry 
(Integrale psychiatrie: voor- en nadelen, discussie groep Voorjaarscongres 
NVvP) 
 
2009  Western and alternative medicine, a comparison of paradigms and 
working methods. Speaker.  
Second European Conference on Integrative medicine. Berlin; Germany. 
(Westerse en alternatieve geneeskunde; een vergelijking van paradigma en 
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The contents of this thesis 
Despite important progress in psychiatry not all patients respond well to available 
treatments. There are also concerns about increasing costs and the quality of the 
therapeutic relationship, which seems threatened by managed care, focus on protocols, 
and a tendency to reductionism, narrowing the view to diseases or symptoms and losing 
sight of the whole person in his or her context. ‘Integrative medicine’ is a new concept 
in health care defined as: ‘the practice of medicine that reaffirms the importance of the 
relationship between practitioner and patient, focuses on the whole person, is informed 
by evidence, and makes use of all appropriate therapeutic approaches, healthcare 
professionals and disciplines to achieve optimal health and healing’. Integrative medicine 
may provide some solutions to the problems raised. However, there is a paucity of 
research on the application of integrative medicine in mental health care (‘integrative 
psychiatry’). We explored the conceptual foundation of integrative psychiatry in the first 
part of this thesis. The second part is about its implementation in Dutch mental health 
care. Taking into account the Dutch law, jurisprudence, rules of professional bodies, 
and scientific research, we wrote a treatment protocol for the judicious application of 
complementary medicine in conventional mental health care. In the third part we assessed 
evidence for the effectiveness of integrative psychiatry and some selected complementary 
medicines and lifestyle changes. In the discussion we respond to criticism and offer 
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